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SUMMARY
The neurokinins (tachykinins) are a group of closely related peptides with a common
C-terminal amino acid sequence of Phe-X-Gly-Leu-Met-NH2 and have been
identified in most mammalian body systems. The mammalian neurokinins include
substance P (SP), neurokinin A (NKA), neurokinin B (NKB) and neuroipeptide
gamma. In the respiratory tract, they are located primarily in C-fibre afferent nerve
fibres in smooth muscle, around mucus glands and blood vessels and in close
association with the epithelial surface. Their endogenous release from these nerve
fibres or their exogenous administration results in smooth muscle contraction,
vasodilation, plasma leakage and oedema, and increased secretion of mucus. Because
of these effects it has been postulated that the neurokinins, along with other
neuropeptides in the airways, such as neuropeptide Y (NPY) and vasoactive intestinal
polypeptide (VIP), may have a role to play in the aetiopathogenesis of airway
inflammation and airway smooth muscle reactivity, and in particular it has been
suggested that they may have a role to play in asthma.
To this end the airway response to the neurokinins has been investigated in great
detail in a number of species, including man, and it would appear that, in terms of
bronchoconstriction, the order of potency for the neurokinins is NKA > SP > NKB,
although there are species differences where SP is less potent than NKB.
With the advent of the use of sheep as an experimental animal in the investigation of
airway pharmacology and physiology, and with the development of sheep models of
human respiratory diseases such as asthma, the aim of this study was to investigate
and characterise the bronchomotor response of sheep to the neurokinins.
The localisation of SP and the additional sensory neuropeptide calcitonin gene-related
peptide was assessed in the airways of normal sheep, using indirect
immunofluorescence histochemistry techniques. The distribution of these peptides
roughly coincided with reports for other species, although the distribution was sparse.
SP and CGRP-immunoreactive nerve fibres were found in airway smooth muscle,
close to blood vessels and mucus glands. The distributions of NPY, vasoactive
intestinal polypeptide (VIP) and enkephalin (ENK) were also assessed. No ENK-
immunoreactive fibres were detected and only occassional weak-staining VIP fibres
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were noted. However, there was a dense network of interlacing nerve fibres
immunoreactive for NPY in airway smooth muscle.
The respiratory reponse to intravenous SP, NKA and NKB was assessed in normal
anasethetised Suffolk-cross female sheep. NKB was found to be ineffective in causing
broncho-constriction, while SP was more potent than NKA. However, in the
peripheral airways SP and NKA were roughly equipotent in causing airway narrowing
(as assessed by changes in dynamic compliance).
The bronchomotor response to inhaled SP and NKA was assessed in sheep (Texel-
cross) with a naturally acquired airway allergy to Ascaris suum antigen (asthma
model). An order of potency for both peptides similar to that for normal sheep was
demonstrated in these asthmatic sheep.
The bronchomotor response to SP was also assessed in different age groups of normal
sheep. The most pronounced bronchoconstriction occured in young sheep, under 12
months of age. In sheep over 12 months the response was markedly attenuated and in
old sheep, aged approximately four years, there was minimal bronchoconstriction and
a dose-dependent apnoea occured.
The pharmacological antagonism of the airway response to SP by the muscarinic
receptor antagonist atropine, the ganglion blocker hexamethonium, nedocromil
sodium, the NK-1 receptor antagonist CP 96,345-1, the neurokinin antagonist
spantide, and the HI receptor antagonist chlorpheniramine was assessed in normal
sheep. Atropine, hexamethonium and CP 96,345-1 significantly antagonised the
effect of SP. The effects of atropine, the Ml receptor antagonist pirenzepine, spantide
and the NK-2 receptor antagonist L-659,874 on the contractile effect of SP on the
isolate sheep trachealis muscle preparation were also assessed. Only atropine and
pirenzepine significantly antagonised the effect of SP with pirenzepine being
approximately 100 times more potent than atropine.
The effect of vagal cooling and vagotomy on the bronchoconstriction caused by SP
was also determined. Vagotomy abolished the response to SP while the response was
reduced in a temperatiure-dependent manner when the right vagus was cooled (after
the left vagus had been sectioned).
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From the results of this study it can be stated that the order of potency for the
bronchomotor effects of neurokinins in sheep is different from that in other species
and this also applies to asthmatic sheep. This, coupled with the age-related alteration
of the response to SP, needs to be considered when using sheep as models for airway
diseases in man. The mechanism of action of SP appears to be largely indirect,
involving a reflex vagal bronchoconstriction mediated through the NK-1 receptor.
There may be an additional indirect mechanism involving modulation of
acetylcholine release form cholinergic nerve endings or modifying neurotransmission
in airway parasympathetic ganglia. The mechanism of action of SP-induced
bronchoconstriction in the sheep shows some similarity to that in the rabbit and pig,
but is different from most other species including man.
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THE AIM
The aims of the project, described in this thesis, are:
1. To investigate the bronchomotor response of normal sheep and sheep with a
naturally acquired airway allergy to Ascaris suum antigen, to the neurokinin peptides,
substance P, neurokinin A and neurokinin B.
2. To investigate the mechanisms involved in the bronchomotor response to the
neurokinins m vivo and in vitro using a variety of pharmacologically active agents.
3. To investigate the the possible involvement of vagal reflex mechanisms in the
control of the bronchomotor response to the neurokinins.
4. To examine the localisation of various neuropeptides in neuronal and non-neuronal
structures within the sheep airway, using immunohistochemical techniques.
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CHAPTER 1. AIRWAY INNERVATION AND THE ROLE OF THE NEUROKININ
PEPTIDES
This section will briefly outline the gross anatomy of the sheep respiratory system
(Nickel et al, 1973), the current understanding of the complex neural control of
mammalian bronchomotor tone and airway calibre, and the role of the classical and
peptide neurotransmitters. With reference to the peptidergic neural systems, particular
attention will be given to the neurokinin (tachykinin) family of peptides and our
understanding of their pharmacology in the respiratory system. Adopting the current
convention, the term neurokinin will be used instead of tachykinin.
1. Gross Anatomy of the Sheep Respiratory System:
The ruminants are obligate nasal breathers and have a relatively long nasal cavity. The
larynx is similar to that described for other species, but the trachea shows interesting
anatomical differences. The sheep trachea consists of 40-60 cartilage rings. These rings
overlap in the cranial portion of the trachea giving a rigid and reasonably non-distendable
structure. In the middle and caudal parts of the trachea the gap between the rings
gradually widens. The tracheal lumen is circular for the entire length of the trachea and
the left tip of each cartilage ring lies dorsal to the right tip. The trachealis muscle is
located on the lumenal surface attached to the two ends of the cartilage ring.
The lungs of sheep, as in all ruminants, consist of the cranial and caudal lobes of left lung
and the divided cranial, middle, caudal and accessory lobes of the right lung, but the
lobes of sheep are poorly delineated. The cranial lobe bronchi leave directly from the
trachea above the tracheal bifurcation, while the bronchi to the other lobes originate from
the two mainstem bronchi, which are the divisions of the trachea at the carina.
Figure 1. Gross anatomy of the sheep thorax. The lungs have been removed to show the principle
structures of the thorax. A-vagosympathetic trunk; B-cranial vena cava; C-heart; D-phrenic nerve;
E & G-vagus nerve; F-oesophagus; H-cervicothoracic ganglion; I-middle cervical ganglion. The
external carotid artery is located immediately medio-ventral to the cervical vagus. The
vagosympathetic trunk seperates into the vagus and sympathetic branches cranial to the middle
cervical ganglion, close to the thoracic inlet.
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Unlike the situation in cattle only the pulmonary arteries accompany the bronchi while
the veins run intersegmental^. The bronchial circulation arises from the broncho-
oesophageal artery and travels along the trachea, dividing at the tracheal bifurcation and
entering the lungs along with the bronchi. There is no bronchial vein and systemic blood
returns to the heart via the pulmonary veins.
The innervation of the sheep respiratory system is described later in this chapter. A
drawing of the gross anatomy of the sheep thorax is shown in Figure 1.
2. Innervation of the airways and lung:
The innervation of the mammalian airways and lung is extremely complex and not
completely understood (Figure 2). The simplistic model of neural control of the airways
involving an excitatory vagal parasympathetic cholinergic system and an inhibitory
sympathetic system is no longer valid (Coburn, 1988). The respiratory system involves at
least three efferent and three afferent neural systems (Richardson, 1988). The majority of
both afferent and efferent nerve fibres are present within the vagosympathetic trunk, but
there is also some input at the spinal level.
2.1. Efferent Innervation:
The efferent components of the neural network includes the classical excitatory
cholinergic and the inhibitory adrenergic systems, and the more recently identified mixed
excitatory and inhibitory non-adrenergic non-cholinergic (NANC) system. While the
excitatory cholinergic system has been demonstrated in all species studied, there are
widespread differences in the type of inhibitory system found and in the localization of
nerve types (Richardson, 1988).
Figure 2. Diagrammatic illustration of the innervation of the respiratorty system and
some of the recognised and putative peptide and non-peptide neurotransmitters
involved. The afferent input from the airways include stretch receptor inputs from
smooth muscle (not shown) and C-fibre afferent inputs from the airway epithelium.
The efferent output includes cholinergic and non-cholinergic non-adrenergic (NANC)
systems, both originating in the medulla, carried in the vagus and innervating airway
parasympathetic ganglia. Post ganglionic nerve fibres innervate airway smooth muscle.
The system is also modulated by adrenergic innervation of parasympathetic ganglia.
ACh-acetylcholine; NA-nor-adrenaline; SP-substance P; CGRP-calcitonin gene-related
peptide; VTP-vasoactive intestinal polypeptide.
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2.1.1. Excitatory Cholinergic System:
The parasympathetic nervous system is the most important neural system innervating the
airways. It is the major system causing bronchoconstriction and is responsible for the
resting bronchomotor tone (Nadel & Barnes, 1984). The system predominantly
innervates the smooth muscle of the larger airways and appears to be absent from the
peripheral airways and the respiratory bronchioles (Barnes et al, 1983). The efferent
motor pathways travel to the lung in the vagus as preganglionic nerve fibres, innervating
the mural parasympathetic ganglia from which short postganglionic nerve fibres emerge
to innervate the smooth muscle. It is because of this inaccessibility of parasympathetic
airway ganglia that little is known of their function (Skoogh, 1986). The parasympathetic
cholinergic neural network is the main excitatory neural system innervating airway
smooth muscle. Cholinergic post-ganglionic nerve fibres release acetylcholine from
nerve terminals which bind to post-synaptic muscarinic cholinoceptors causing smooth
muscle contraction.
Three distinct classes of muscarinic receptors have been identified using specific
pharmacological antagonists and at least five receptor classes have been cloned (Barnes,
1990). The muscarinic receptors have been classed into Ml (neuronal), M2 (cardiac) and
M3 (smooth muscle, secretory) (Doods et al, 1987). The existence of muscarinic receptor
subtypes in airways and lung has been known for several years, but there seems to be
species variability in their localization and expression. The Ml receptor predominates in
human lung tissue, but is primarily localised to submucous glands and the alveolar
septum, and there are smaller numbers of M3 receptors (Mak & Barons, 1989; Barnes,
1990). Human muscarinic receptors are found in central and peripheral airway smooth
muscle, whereas in the ferret they are predominantly localised in the central airways
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(Barnes et al, 1983). In the guinea pig there are very few Ml receptors as assessed by
binding for the Ml antagonist [3 HJpirenzepine (Mak & Barnes, 1989).
In bovine and canine tracheal smooth muscle the major type of receptor has been
reported to be M2 (Roffel et al, 1989; Fernandes et al, 1992), while in man the
predominant receptor mediating smooth muscle contraction is the M3 subtype (Roffel et
al, 1989). However, antagonists with a greater specificity for the M3 receptor were not
assessed in the bovine study and bovine trachealis muscle is believed to have M3
receptors (Roffel et al, 1989). In the rabbit airway it has been shown that the Ml receptor
mediates bronchoconstriction caused by vagal stimulation, but is not present on smooth
muscle (Bloom et al, 1987).
Using data from functional and binding studies it appears that bronchomotor tone can be
modulated by activation of the three muscarinic receptor subtypes (Barnes, 1990; Minette
& Barnes, 1990). Ml receptors are present in ganglia and modulate ganglionic
neurotransmission, since the Ml receptor antagonist pirenzepine has been shown to
inhibit vagally mediated bronchoconstriction at the ganglia level (Beck et al, 1987;
Bloom et al, 1987; Yang & Biggs, 1991). The M2 receptor acts as an autoreceptor, at pre¬
synaptic sites, modulating and inhibiting ACh release from cholinergic nerve endings.
Activation of the M2 receptor has no effect on vagally induced bronchoconstriction and
its presence has been demonstrated in man, the guinea pig, dog and rat (Faulkner et al,
1986; Beck et al, 1987; Ito & Yoshitomi, 1988; Minette & Barnes, 1988; Aas &
Maclagan, 1990; DelMonte et al, 1990; Doleman et al, 1991; Yang & Biggs, 1991). The
M2 receptor has been shown to functionally antagonise isoproterenol-induced airway
relaxation in the dog (Fernandes et al, 1992) and endogenous noradrenaline release from
the guinea pig trachea (Racke et al, 1992). Finally, the M3 receptor is the receptor present
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on smooth muscle (Mak & Barnes, 1990) and controls the smooth muscle contractile
response to ACh. In addition, there are differences in muscarinic receptor types
subserving the other respiratory functions of cholinergic neuro-transmission, including
mucus secretion and pulmonary arterial vasodilation (McCormack et al, 1988; Gater et al,
1989).
Modulation of airway cholinergic neurotransmission by non-cholinergic mechanisms has
also been clearly demonstrated in canine bronchi (Flavahan & Vanhoutte, 1985;
Vanhoutte & Flavahan, 1988). Noradrenaline prejunctionally inhibits the release of
acetylcholine from cholinergic nerve endings, as demonstrated by its ability to inhibit the
contraction of airway smooth muscle caused by vagal stimulation but not that caused by
exogenous acetylcholine (Vermiere & Vanhoutte, 1979). It also depresses
neurotransmission in parasympathetic ganglia, although this has not yet been
demonstrated in airway ganglia (Skogh, 1988). The inhibitory effect of noradrenaline is
mediated through beta adrenoceptors on cholinergic nerve endings and pre-synaptic alpha
and beta adrenoceptors in parasympathetic ganglia (Brown & Caulfield, 1981; Soh,
1988).
Vasoactive intestinal polypeptide (VIP) and nitric oxide (NO), the putative
neurotransmitters of the non-adrenergic non-cholinergic inhibitory system (NANCis),
modulate cholinergic neurotransmission in the ferret and guinea pig trachea and in
isolated human central and peripheral airways (Sekizawa et al, 1988; Belvisi et al, 1991;
Belvisi et al, 1992). In the ferret trachea VIP potentiates the response to electrical field
stimulation at low concentrations (InM) and inhibits at higher concentrations (20mM)
(Sekizawa et al, 1988). The action of VIP is presumed to be pre-synaptic as it does not
affect smooth muscle contraction caused by exogenous ACh, but the exact site of action
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of NO is not yet known (Belvisi et al, 1991).
Pre-ganglionic non-adrenergic inhibitory and putative peptidergic non-cholinergic
excitatory nerves have also been demonstrated in the vagus (Chesrow et al, 1980; Yip et
al, 1981) and peptides might also be involved in modulation of ganglionic
neurotransmission. In the guinea pig gut substance P (SP) and VIP stimulate ACh release
from myenteric neurons by a calcium-dependent mechanism, and in the lung neurokinins
contract airway smooth muscle by facilitating ACh release from postganglionic
parasympathetic nerve endings and by a direct action on the smooth muscle itself (Yau et
al, 1986; Hall et al, 1989). However, this effect of neurokinins is not mediated through
prejunctional M2 receptors, as the facilitatory effect of gallamine, the M2 antagonist, on
neural bronchoconstriction is not affected by depletion of sensory neuropeptides with
capsaicin (DelMonte et al, 1990).
2.1.2. Inhibitory Nor-adrenergic and Non-adrenergic
Non-cholinergic (NANC) Systems:
There has been considerable difficulty in conclusively demonstrating a functional
adrenergic neural network in human airways (Richardson & Beland, 1976; Davis et al,
1982; Nadel & Barnes, 1984; Richardson, 1988), despite the demonstration of inhibitory
beta adrenoceptors in the proximal airways (Doidge & Satchell, 1982). However, several
investigators have demonstrated adrenergic nerves in human airways (Doidge & Satchell,
1982; Partanen et al, 1982; Laitinen et al, 1985a), with the nerve fibres primarily found in
the periphery, in close association with blood vessels, and with sparse innervation of
smooth muscle (Pack & Richardson, 1984). A close anatomical relationship between
parasympathetic ganglia and sympathetic nerves has been demonstrated in human
airways (Partanen et al, 1982). Noradrenaline has also been shown to inhibit cholinergic
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neurotransmission in airway parasympathetic ganglia in the ferret and cat (Baker et al,
1982), suggesting a functional role for the adrenergic system in controlling bronchomotor
tone.
There may also be an association between the noradrenergic system and the neurokinins.
SP has been demonstrated in the superior cervical ganglion of the rat and is found co-
localised with tyrosine hydroxylase, suggesting sympathetic neurons can express both
noradrenaline and SP simultaneously (Bohn et al, 1984). Haruki et al (1983) have
demonstrated that SP-containing neurons in the nodose ganglia can anastamose with the
post-ganglionic sympathetic trunk associated with the superior cervical ganglia, and an
association between SP-containing and catecholamine-containing neurons has been
demonstrated in the CNS (Pickel, 1979). SP, in addition to CGRP, VIP and NPY, has
also been demonstrated in association with catecholamines in laryngeal nerve
paraganglia, which are carotid body-like structures believed to be involved in the hypoxic
ventilatory response (Dahlqvist et al, 1992). Whether or not similar associations exist in
the rest of the respiratory system is not known, but it would appear that noradrenaline,
either circulating or released from sympathetic nerves, could modify neurotransmission
in peptidergic neurons and their nerve fibres. Conversely, SP, NKA and NKB have been
shown to modulate activity in sympathetic neurons and can have a long lasting effect on
the excitability of these cells (Konishi et al, 1992a,b). Of further interest is the sprouting
of SP-containing nerve fibres and an increased SP content found in sympathetic ganglia
after chemical sympathectomy (Benarroch et al, 1992), and the primary role of SP in
sympathetic ganglia may be to interact with adrenergic mechanisms in maintaining
arterial blood pressure. While SP could affect all preganglionic sympathetic nerve fibres,
morphological studies suggest SP probably only modulates the activity of a small number
of neurons (Pillows et al, 1992).
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Nevertheless, the NANCis system appears to be the most important inhibitory neural
system in man, since functional non-adrenergic relaxation of airway smooth muscle can
be demonstrated (Richardson & Ferguson, 1979, Doidge & Satchell, 1982). The NANCis
system has also been demonstrated in several other species (Diamond & O'Donnell,
1980; Doidge & Satchell, 1982), but there are no definitive reports to date of a NANCis
in sheep airways. In the cat stimulation of the vagus results in an atropine-sensitive
bronchoconstriction followed by prolonged bronchodilation, which is resistant to
adrenoceptor or adrenergic neural blockade (Diamond & O'Donnell, 1980). This NANC
bronchodilation can be reflexly activated by mechanical laryngeal stimulation and is
abolished by hexamethonium, suggesting the NANCis is of vagal reflex origin and
involves preganglionic neurons (Diamond & O'Donnell, 1980; Szarek et al, 1986;
Michoud et al, 1988).
Pre-treatment of guinea pigs with capsaicin, which depletes peptides from sensory
nerves, potentiates NANC bronchodilation and the response to exogenous vasoactive
intestinal polypeptide (VIP) (Stretton et al, 1989b; Stretton et al, 1990b) and this supports
the suggestion that VIP is a putative neurotransmitter for this system (Barnes, 1984;
Laitien et al, 1985; Stretton et al, 1990b). Previously Burnstock (1972) proposed
adenosine triphosphate as the NANCis neurotransmitter in the gastrointestinal tract, but
this is no longer accepted (Diamond & Richardson, 1982). In addition to exogenous VIP
having a direct effect on airway smooth muscle, it also inhibits contractions induced by
field stimulation, but not by exogenous ACh, suggesting a prejunctional inhibition of
ACh release from post-ganglionic cholinergic nerve endings (Sekizawa et al, 1988;
Hakoda & Ito, 1990). However, there is a lack of evidence supporting VIP as the
NANCis neurotransmitter, not least because of a lack of a specific and potent VIP
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antagonist. Strong evidence suggesting nitric oxide (NO) is the endogenous NANC
bronchodilator in man, has recently emerged (Belvisi et al, 1991; Belvisi et al, 1992),
while in the guinea pig NANCis neurotransmission involves both NO and VIP (Belvisi et
al, 1991). Nitric oxide acts by modulating cholinergic bronchoconstriction, but whether
this is due to prejunctional modulation of ACh release or some form of antagonism at the
smooth muscle target site is not known (Belvisi et al, 1991).
While it has been speculated that alteration in the NANCis system may underlie
bronchial hyperreactivity, there is no evidence to support this hypothesis. Ko & Lai
(1988) failed to demonstrate a difference in the intensity of NANCis tracheal relaxation
in normal and ovalbumin sensitised guinea pigs.
2.1.3. The NANC excitatory system (NANCex):
The NANCex system is generally accepted to involve one or more of the sensory
neuropeptides calcitonin gene-related peptide (CGRP), SP or neurokinin A (NKA) as
neurotransmitters (Figure 3). Activation of sensory systems by capsaicin results in release
of CGRP, NKA and SP and the signs typically associated with sensory activation,
including vasodilation and bronchoconstriction (Alving et al, 1991). SP can also be
released from ganglion cells by sensory specific stimuli such as, capsaicin, excess
potassium (50mM) and bradykinin (MacLean et al, 1990). Rebound increases in
neuropeptide Y (NPY), noradrenaline and Cortisol can occur after capsaicin treatment,
resulting in systemic cardiovascular responses of increased blood pressure and
tachycardia.
Non-adrenergic and non-cholinergic bronchoconstriction (NANCex), caused by vagal
stimulation and capsaicin pre-treatment releasing neuropeptides from sensory nerve
A
Figure 3. Schematic illustration of the sensory afferent innervation of the airway and the
possible involvement of these sensory afferents in central and local-mediated axonal reflexes.
Vagal C-fibre afferents terminate between the airway epithelial cells close to the airway
lumenal surface. Stimulation of these endings results in local release of peptides from
collateral nerve fibres close to smooth muscle, blood vessels and airway mucus glands and
local or central modulation of anglionic neurotransmission. A-blood vessel; B-smooth
muscle; C- C-fibre afferent endings and collateral axons; D-airway parasympathetic ganglion;







Figure 4. Diagramatic illustratation of the central projections of thoracic and
abdominal visceral afferents and the source of motor output from the medulla in the
sheep. Visceral afferents travel via the jugular and nodose ganglia to terminate in the
nucleus of the solitary tract (nTS) in the medulla. The motor output of the vagus
arises in the dorso-motor nucleus of the tenth cranial nerve (DMnX) and the nucleus
ambiguus (nA). Motor neuron axons travel predominately the same route as the
afferent fibres, through the nodose (NG) and jugular ganglia, (JG) although
somefibres may travel by other routes. These neurons project axons into the cervical
vagus and synapse on parasympathetic ganglia close to airway smooth muscle.
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fibres, can be inhibited or modulated by neuropeptide Y (NPY), opioids and gamma-
aminobutyric acid (GABA) (Frossard & Barnes, 1987; Belvisi et al, 1988; Belvisi et al,
1989a,b; Giuliani et al, 1989; Stretton et al, 1989a). NPY, the opioids and GABA do not
inhibit bronchoconstriction caused by exogenous SP suggesting blockade of SP release
from vagal NANC nerves. The activity of opioids and GABA are mediated primarily
through mu-opioid receptors and GABAg receptors respectively (Belvisi et al, 1988;
Belvisi et al, 1989a). Furthermore Johansson et al (1989) demonstrated that morphine
also inhibited the cholinergic component of bronchoconstriction induced by electrical
field stimulation, but had no effect on NANCis neurotransmission.
Substance P is found in the vagal sensory nodose and jugular ganglia and in the
termination of vagal sensory afferents in the nucleus of the tractus solitarius (NTS)
(Helke & Eskay, 1985; MacLean et al, 1990) (see Figure 4). SP is also found in spinal
dorsal root ganglia and the dorsal horn of the spinal cord and in the axon terminals of
primary afferent nerve fibres (Otsuka et al, 1976; Cheshire & Black, 1980). The central
termination of capsaicin-sensitive SP vagal afferents is restricted to the lateral part of the
NTS, while a sub-population of capsaicin-resistance SP neurones is found in the medial
part of the NTS. SP is moved towards the periphery, including the thoracic and
abdominal viscera, by axoplasmic transport form the sensory ganglia, and towards the
NTS (Maclean & Lewis, 1984).
2.2. Afferent Innervation and Reflex Control of
Bronchomotor Tone:
There have been several detailed monographs in recent years outlining the current
understanding of the function of vagal afferent innervation in the airways and lung
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(Coleridge & Coleridge, 1977a,b, 1984,1986; Paintal, 1977; Sant'Ambrogio, 1982;
Widdicombe, 1983; Sant'Ambrogio, 1987). There is general agreement that there are
three afferent receptor types, slowly adapting, rapidly adapting and C-fibre receptors, all
of which might be involved in the control of bronchomotor tone. These receptors are
classified on the basis of activity in the nerve fibres they serve.
2.2.1. Lung Afferent Receptor Sub-Types:
Slowly adapting (SAR) and rapidly adapting (RAR) receptors (see Figure 5 a ) are
stretch receptors that alter their activity in response to changes in volume and trans-mural
pressure within the airways and lungs in phase with respiration (Fahim & Jain, 1979).
These stretch receptors are primarily involved in the control of the rate and depth of
respiration by a volume-controlled vagal feed-back mechanism (Trenchard, 1977;
Clement et al, 1981) and their activation primarily results in extension of the end-
expiratory pause (the Hering-Breuer reflex) (Marlot & Duron, 1979). The activity of
SARs and RARs is also increased by hypercapnia (Coleridge et al, 1978).
Bronchoconstriction also increases stretch receptor activity, presumably by mechanical
distortion of the tissue around the receptors (Davenport et al, 1981). However,
Sant'Ambrogio (1987) has recently suggested that stretch receptors are involved in the
control of bronchomotor tone, but there is no evidence that the activation of SARs results
in bronchoconstriction and these are more likely to mediate reflex bronchodilation
(Widdicome & Nadel, 1963a,b). An increase in SAR activity does reflexly decrease
vagal efferent activity and so acts as a negative feed-back mechanism for
bronchoconstriction (Widdicombe & Nadel, 1963b), and they may be important in
countering bronchoconstriction in asthmatic patients by initiating hyperinflation
manoeuvres (Widdicombe, 1983).
Figure 5 a.. Action potentials recorded from a rapidly adapting receptor (RAR) (upper tracing)
and slowly adapting receptor (SAR) (lower tracing) in an adult opposum. The animal was
ventilated passively (records to the left) and with a maintained pressure inflation (records to the
right). Note the activity of both receptors are modulated by respiration. The RAR exhibits an
irregular spiking discharge pattern, which rapidly adapts to a maintained pressure. The SAR has a
more regular and frequent discharge pattern, but shows slow adaptation to sustained
transpulmonary pressure (Ptp) (modified from Farber et al (1983)).
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RAR fibres have similar conduction velocities to SAR fibres (23.3 vs 32.3 m/s; dog) and
are activated by hyperinflation, forced deflation and re-inflation (Sampson & Vidruk,
1975). They show a rapid adaptation of their firing response on stimulation and are
generally quiescent during quiet breathing (Bergeren & Sampson, 1982). A proportion of
RARs are stimulated by histamine and ammonia, but there are interspecies differences in
the reponse to other irritants such as ether and cigarette smoke (Bergeren & Sampson,
1982). Consequently the description of RARs as "irritant receptors" is inaccurate
(Sampson & Vidruk, 1975). Since the RAR receptor responds to a reduction in lung
compliance it is regarded as the principle receptor involved in the initiation of
augmented breaths (Davies & Roumy, 1982).
Histamine causes bronchoconstriction by a combination of vagal reflex, involving
activation of pulmonary RARs, and by a direct effect on airway smooth muscle (Clement
et al, 1981) and this has been supported by vagal cooling studies (Karczewski &
Widdicombe, 1969). However, the ventilatory response (increased minute volume and
frequency) of RARs to histamine in dogs, but not the bronchoconstrictor response, is due
to stimulation of vagal afferent pathways (Bleecker et al, 1976; Cotton et al, 1977).
Furthermore, the stimulation of RAR activity by histamine may be secondary to airway
smooth muscle contraction (Bergren & Sampson, 1982) making it less likely that RARs
are involved in reflex bronchoconstricton. Afferents from pulmonary stretch receptors
also depress activity in preganglionic sympathetic neurons with a concomitant reduction
in systemic arterial pressure (Gerber & Polosa, 1978).
Reflex bronchoconstriction can also be elicited by airway cooling (Jammes et al, 1986)
and while there is evidence that this may be due to activation of C-fibre receptors
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Figure 5b. Recording of the activity of a left vagal filament associated with an airway C-fibre
receptor in a mechanically ventilated dog. Upper tracing A: there is an irregular discharge pattern
in the C-fibre which is not modulated by respiration. Lower tracing B: Activity in the fibre is
increased after inhalation of a 0.4% histamine aerosol. The ventilation pump has been switched off
towards the end of the tracing and the response of the C-fibre ending has continued, showing the
response is not modulated by respiratory movement ECG, electrocardiograph; AP, action
potential; ABP, arterial blood pressure; Pt, tracheal pressure (modified from Coleridge et al
(1978)).
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Sant'Ambrogio (1987) has postulated an additional afferent "cold" receptor to explain
this phenomenon. This effect is primarily a function of the upper airway and in particular
the larynx.
C-fibre receptor afferent nerve fibres (Figure 5b) are unmyelinated and have slower
conduction velocities than SAR and RAR fibres (0.8-2.4ms; dog) and are further
characterised by a sparse and irregular discharge pattern during normal respiration
(Coleridge & Coleridge, 1977a). They are activated by a variety of chemicals including
phenylbiguanide, capsaicin and bradykinin and by hypercapnia (Karczewski &
Widdicombe, 1969; Kaufman et al, 1980; Delpierre et al, 1981; Sant'Ambrogio, 1982;
Green et al, 1984; Coleridge & Coleridge, 1986). They are also activated by
hyperinflation (2-3 times VT / 10-30cmH20) (Kaufman et al, 1982). Their activation by
hypercapnia is immediately followed by bronchoconstriction and as they are not
activated by mechanical distortion of the airway wall they are the more likely candidate
for the afferent component of vagal reflex bronchoconstriction (Delpierre, 1981). Vagal
bronchoconstriction has been shown to involve the activation of C-fibre afferents, since
bronchodilation caused by bilateral sensory vagotomy coincides with cessation of C-fibre
activity (Jammes & Mei, 1979; Russell &Lai-Fook, 1979). Capsaicin, which releases
neuropeptides from sensory afferent nerve endings, when injected into the right heart
causes bronchoconstriction which is abolished by vagotomy or cooling the vagi to
temperatures which block conduction in C-fibre afferent nerve fibres (Coleridge et al,
1982).
Activation of bronchial and pulmonary C-fibres also results in reflex increase in tracheal
mucous gland secretion and concurrent tracheal contraction (Davis, B et al, 1982; Shultz
et al, 1985). This effect can be demonstrated for both capsaicin and bradykinin.
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The initiation of reflex bronchoconstriction can also be achieved by stimulation of the
upper airways, including the nasal passages and the larynx, and is not exclusively a
function of the intra-pulmonary airways (Boushey et al, 1972; Nadel & Widdicombe,
1962; Sant'Ambrogio, 1987). Laryngeal activation of vagal reflex bronchoconstriction is
also accompanied by coughing (Boushey et al, 1972).
2.2.2. The Pulmonary Chemoreflex (Bezold-Jarisch Reflex):
The pulmonary chemoreflex is a complicated response to stimulation of C-fibre afferent
receptors in the lung and involves a combination of bradycardia, systemic hypotension,
bronchoconstriction and apnoea followed by tachypnoea (Coleridge et al, 1964;
Coleridge & Coleridge, 1984; Green et al, 1984). In experimental situations the reflex is
usually initiated by injection of capsaicin or phenylbiguanide (Figure 6) into the
pulmonary circulation (Karczewski & Widdicombe, 1969; Sant'Ambrogio, 1982; Green
et al, 1984; Coleridge & Coleridge, 1986), although it can also be activated by
endogenous agents such as bradykinin (Kaufman et al, 1980) and prostaglandins
(Coleridge & Coleridge, 1977a, 1986). The exact function of this reflex is not known and
it has been suggested that it is not physiologically significant but merely a
pharmacological curiosity (Coleridge & Coleridge, 1986).
While it is generally agreed that capsaicin activates the pulmonary chemoreflex
(Coleridge et al, 1984) there is also evidence that neuropeptides released from afferent
nerve endings within the lung by capsaicin might also be implicated. In rabbits SP
increases respiratory rate and elicits augmented breaths when injected into the pulmonary
artery, while systemic injection has no effect. Bilateral vagotomy abolishes the response
and SP has been shown to stimulate both irritant and C-fibre receptors of
Figure 6. The effect of intravenous phenylbiguanide (PBG) on respiratory
parameters in anaesthetised sheep. PBG (50ug/kg) is one of the agents routinely
used to initiate the pulmonary chemoreflex. In this tracing PBG has primarily
initiated an apnoeic response and systemic hypotension (not shown), without
the rapid shallow breathing and bronchosonstriction typically described for this
reflex in other species. However, the reflex does show species variation and not
every reported feature of the reflex occurs in all species. P - transpulmonary
pressure; V-respiratory flow; VT - tidal volume; horizontal bar - injection of
PBG.
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bronchopulmonary origin (Prabhakar et al, 1987). SP, 5-hydroxytryptamine and
bradykinin also have been shown to stimulate A and C-fibre endings in the contractile
tissues of the abdominal viscera (Lew & Longhurst, 1986).
Attempts have been made to sub-divide the lung C-fibre receptors on the basis of their
circulatory accessibility and response to various chemicals. In the dog there appears to be
pulmonary receptors accessible from the pulmonary side of the circulation and activated
only by capsaicin, and bronchial receptors accessible from the arterial side and stimulated
by capsaicin, phenylbiguanide and bradykinin (Coleridge & Coleridge, 1977a; Coleridge
et al, 1978; Kaufman et al, 1980). These pulmonary receptors are synonymous with
Paintal's J-receptors (Paintal, 1969). However, there are numerous well-recognised
species differences in the response to these chemicals, and it is difficult to state with
certainty that two classes of receptors are present in all species (Coleridge & Coleridge,
1986). Nevertheless, while injection of agents into the bronchial circulation will increase
C-fibre activity, it is injection into the pulmonary circulation which consistently causes
the pulmonary chemoreflex (Coleridge & Coleridge, 1986).
Investigation of vagal afferent activity and the effects of exogenous pharmacological
agents can be assessed using vagal blockade techniques (Franz & Iggo, 1968; Derksen et
al, 1981; Sant'Ambrogio et al, 1984). Vagal cooling techniques enable reversible
blockade of vagal activity and to a certain extent preferential blockade of myelinated and
unmyelinated nerve fibres. Differential blockade of the different myelinated nerve fibres
from slowly adapting and rapidly adapting receptors is not possible, however it is
possible to block most conduction in the myelinated nerve fibres leaving the majority of
the unmyelinated C-fibre afferents intact. The range of temperature sensitivity for nerve
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fibres has been assessed primarily in the dog and cat and there is no information on the
sheep. In general temperatures between 8 and 2097 will block most vagal myelinated
nerve fibres (Paintal, 1967) and temperatures below 797 are required to block
unmyelinated fibres. Nevertheless there is probably an overlap in the temperature
sensitivity of the different fibre types and it has been shown that conduction in all fibres
declines at temperatures below normal body temperature (Franz & Iggo, 1968).
There is conflicting evidence as to the role of afferent receptors in the airways and lung
and the control of bronchomotor tone (SanfAmbrogio, 1987). While all types of
receptors are involved to some extent in the reflex control of bronchomotor tone their
activation does not necessarily imply they cause bronchoconstriction (Coleridge &
Coleridge, 1986). As mentioned previously, the increased activity of stretch receptors
found during bronchoconstriction is probably due to the mechanical distortion of the
muscle around the receptor rather than an increase in receptor activity initiating smooth
muscle contraction (Fischer et al, 1983), making C-fibre afferent receptors the likely
candidate for reflex bronchoconstriction, originating in the intra-pulmonary airways.
2.3. Carotid Sinus Baroreceptors:
Carotid sinus baroreceptors also modulate bronchomotor tone. Altering carotid sinus
pressure either up or down from its normal resting pressure decreases and increases
tracheal tension respectively (Schultz et al, 1987). This reflex change can be abolished by
cooling the carotid sinus nerve to 097, cutting the laryngeal nerves or pre-treating with
atropine, indicating it involves a cholinergic vagal pathway. This change in tracheal
tension is comparable to that occuring with activation of C-fibre receptors (Coleridge &
Coleridge, 1986).
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2.4. Innervation of the Mammalian Lung with Particular
Reference to the Sheep:
The innervation of the sheep airways and lung, described to date, is very similar to that
described for other species. The central projections of vagal afferents and origin of vagal
efferents in terms of the general innervation of the viscera in the sheep have been
described in detail. The dorsal motor nucleus of the vagus and the nucleus ambiguus in
the medulla are the main sites for the vagal motor neurones, but detail of projection of
nerve fibres from these nuclei to the viscera, including the respiratory tract, is not known
(Wild et al, 1991). In other species there is a distinct viscerotrophic organisation of
efferent output from the motor nuclei to the supra-diaphragmatic and abdominal viscera,
but in relation to the heart and lungs viscerotrophic integration might not be as specific as
for other organs (Bieger & Hopkins, 1987; Fox & Powley, 1985; Harding & Leek, 1971;
Katz & Karten, 1985; Kerr, 1969).
The sensory innervation of the lung is predominantly contained within the afferent vagal
projections. Afferent fibres travel in the cervical vagus to the nodose ganglia. Fibres then
form the solitary tract, enter the medulla and terminate in the nucleus of the solitary tract
(Wild et al, 1991) (Figure 4). The intrinsic cholinergic (motor) innervation of the sheep
airways and lung has been mapped in detail by Smith & Taylor (1971), but information
on adrenergic, NANC and general peptide innervation is lacking. However, Sheller and
Brigham (1982) have demonstrated a functional cholinergic excitatory and adrenergic
inhibitory innervation in sheep trachea and bronchi and have suggested that there may be
a NANCis system also present. SP, CGRP, and to a lesser extent, VIP, have been
demonstrated in sheep airway nerves (Mariassy et al, 1990; this is presented in Appendix
I), but overall the neuronal expression of peptides is relatively weak compared to other
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species. In contrast there is a dense NPY-containing nerve fibre network in sheep airway
smooth muscle (see Appendix I), and as NPY is often co-localised with nor-adrenaline,
there may be an equally extensive functional adrenergic nervous system in sheep
airways.
The cervical vagus and the cervical sympathetic trunk are fused over much of their length
to form the vagosympathetic trunk. The trachea and oesophagus are innervated by the
right vagus and its left recurrent branch, while the lower airways and lung are supplied by
both vagi (Krahl, 1964). In the cholinergic system (Smith & Taylor, 1971), at the airway
level, there are large nerve bundles forming a plexus, containing ganglion cells, in the
extrachondral tissues of the posterior border of the trachea. The system generally
conforms to that described for other species (Elftman, 1943; Honjin, 1956; Larsell,
1922). Nerve fibres course from the extrachondral plexus between the cartilage rings to
form a subchondral plexus. Blood vessels and mucous glands are supplied from both
plexuses while the trachealis muscle is innervated from the subchondral plexus. The
subchondral plexus fibres then terminate in the submucosa, but some fibres penetrate
close to the epithelium and lumenal surface. The bronchi have similar extra- and sub¬
chondral plexuses. The extrachondral plexus is a combination of nerve bundles of the
tracheal extrachondral and the pulmonary plexuses. In the bronchi the mucous glands are
poorly innervated and fibres either terminate close to the perichondrium or in the
submucosa just beneath the epithelium. At the segmental bronchial level nerve bundles
from the extra- and sub-chondral plexuses of the larger airways merge and then branch
where the bronchi divide sending fibres into the smooth muscle. Ganglion cells are found
at these nerve bundle division sites.
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There are marked differences in the cholinergic innervation of the pulmonary
vasculature. The pulmonary arteries have a dense innervation incorporating a superficial
adventitial layer of large nerve fibres overlying a fine inter-lacing network of fibres
adherent to the vessel walls. The pulmonary veins are sparsely innervated, while the
bronchial arteries and veins are well innervated. There are also numerous
communications between the nerve fibres of the intrapulmonary vessels and the
extrachondral bronchial plexus.
2.5. Localization of Neuropeptides in Mammalian Lung:
2.5.1. General Localisation:
With the development of immunohistochemical, radio-immuno assay and
autoradiographic techniques, the localization and visualization of neuropeptides, their
binding sites and receptors became feasible. The immunohistochemical method of Coons
and Kaplan (1950) has been used extensively to visualise antigens present within
neuronal structures. The technique has been extensively modified to include the indirect
peroxidase-antiperoxidase and immunofluorescence techniques. These modifications
greatly improve the specificity of the technique (Pickel, 1979).
SP-like immunoreactivity (SP-Li), and immunoreactivity for a whole range of
neuropeptides, has been demonstrated in most mammalian tissues. In addition
immunoreactivity for a physalaemin-like peptide, which is structurally different from
amphibian physalaemin, has been demonstrated in mammalian respiratory, enteric,
genito-urinary systems and spinal cord (Lazarus et al, 1980, 1982). Because of their role
as neurotransmitters and potential central mediators of nociception, the localisation of the
neurokinins, particularily SP, has been studied in detail in the spinal cord and more
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central parts of the nervous system. SP-Li has been demonstrated in primary afferent
spinal neurones (Harmar & Keen, 1981; Buck et al, 1982).
In the peripheral nervous system SP-li has been demonstrated in the nodose ganglion and
the vagus nerve (Polak & Bloom , 1982; Hayashi et al, 1983; Funakoshi et al, 1989) and
in paravertebral sympathetic ganglia and superior sympathetic ganglia (Bohn et al, 1984;
Del Fiacco et al, 1984). These nerve fibres in the sympathetic ganglia are collateral
branches originating from primary sensory afferents such that activation of these
afferents results in release of SP onto sympathetic postganglionic neurones. Saria et al
(1985) demonstrated that removal of the stellate ganglia, with or without vagotomy,
reduces the amount of SP-Li in guinea pig lung and pulmonary artery, and reduces the
brochoconstrictor response to capsaicin, suggesting the airways have C-fibre afferent
inputs of both spinal and vagal origin.
For several of the neuropeptides there is co-localization with other neuropeptides and
with the classical non-peptide neurotransmitters. SP is co-localised with noradrenaline in
sympathetic ganglia (Bohn et al, 1984) and with CGRP in the sensory trigeminal and
dorsal root ganglia (Lee et al, 1985) and occasionally with galanin (Ju et al, 1987).
However, SP is not present in all CGRP positive cells (Ju et al, 1987). SP is also co-
localised with CGRP in nerve fibres in several other structures, including cerebral
arteries (Wanaka et al, 1986). NPY is found in association with noradrenaline in
adrenergic nerves (Johansson, 1986; Luts & Sundler, 1989).
2.5.2. Localisation in the Respiratory System:
With reference to the respiratory tract and structures associated with respiratory control,
several neuropeptides have been demonstrated, including a physaelaemin-like peptide, in






















































































































































































mammalian species (for review see Lazarus et al, 1982) (Ghatei et al, 1982) (Table 1).
SP-Li and VIP-Li are present in nerve fibres of the carotid body while enkephalin-like
immunoreactivity (Enk-Li) predominates in the glomus cells (Lundberg et al, 1979;
Wharton et al, 1980; Smith et al, 1990). A proportion of these SP/CGRP nerves are
chemoreceptive C-fibres while the remainder innervate blood vessels (Kummer &
Habeck, 1991). This suggests a possible role for neuropeptides in the baroreceptor reflex
and the chemoreceptor hypoxia ventilatory response (Smith et al, 1990). In the
respiratory tract SP is mainly found in nerve fibres coursing through the smooth muscle
and the sub-epithelial layer, while VIP is primarily associated with blood vessels and
seromucous glands in the trachea and with smooth muscle in the bronchi (Polak &
Bloom, 1982; Said, 1982). The distribution of CGRP is similar to SP, with the nerve
fibres travelling in the vagus and being primarily associated with primary sensory
afferent nerve fibres (Cadieux et al, 1986; Luts et al, 1990). Double staining techniques
demonstrate SP co-localised with CGRP in sensory ganglia and nerve fibres in the
airways (Martling et al, 1988). The SP and CGRP fibres originate in the vagal sensory
jugular-nodose ganglionic complex, while the CGRP fibres have an additional source in
the dorsal root ganglia (Springall et al, 1987; Funakoshi et al, 1989; Luts et al, 1990),
although a proportion of SP nerves may originate from airway ganglia (Dey et al, 1991).
In addition Lundberg et al (1983) reported 40% of guinea pig sensory afferents originated
from thoracic spinal ganglia. The main sites for CGRP receptors are in blood vessel
endothelium and vessel and airway smooth muscle, with few present in airway
epithelium and mucous glands (Carstairs, 1987; Mak & Barnes, 1988). There is also
marked co-localisation of SP with CGRP in airway nerve fibres in guinea pig, cat, rat and
man (Martling, 1987; Dey et al, 1990; Luts et al, 1990) and of CGRP with serotonin in
hamster lung (Keith & Ekman, 1988). In sheep SP nerve fibres are found in close
association with CGRP around mucous glands and blood vessels and to a lesser extent in
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airway smooth muscle, while NPY immunoreactive nerves form a dense inter-meshing
network in the tracheal smooth muscle (see Appendix 1).
Muscarinic cholinergic receptors also show a close association with SP-containing
neurones in the basal ganglia, and with NPY and VIP-containing neurones in the superior
cervical ganglion (Ariano & Kenny, 1989; James & Burnstock, 1989). SP nerve fibres
show a close association with brainstem motoneurones innervating the extrinsic muscles
of the larynx (Holtman Jr, 1988)
2.6. The Neurokinins:
2.6.1. Neurokinin Structure and Chemistry:
The neurokinins (tachykinins) are a closely related family of peptides with a common
carboxyl-terminal (C-terminal) amino acid sequence of Phe-X-Gly-Leu-Met-NH2, where
X is the aromatic amino acids Phe and Tyr or the branched aliphatic amino acids Val and
lie. Activity of a neurokinin depends on the integrity of the C-terminal sequence and not
the amino-terminal (N-terminal). However, the N-terminal is important in regulating
(inhibiting) enzymatic degradation (Rogerson et al, 1989), the binding to mast cells and
the central behavioural effects of SP. The neurokinin family can be subdivided into the
mammalian peptides SP, NKA and NKB, the amphibian peptides, kassinin, eledoisin and
physalaemin and the recently identified insect neurokinins, locustatachykinins (Schoofs
et al, 1990a,b) and the structures are shown in Table 2.
The first neurokinin discovered was in an impure protein extract of horse intestine and
brain which had atropine-resistant spasmogenic and hypotensive activity (von Euler &
























































































and this name has stuck with it ever since. In 1949 Erspamer discovered the closely
related neurokinin eledoisin in the salivary glands of the Mediterranean octupus Eledone
Moschata. It was noted that there were close pharmacological similarities between SP
and eledoisin but sufficient differences to suggest they are different compounds. Because
eledoisin was easier to collect and purify its amino acid sequence was the first to be
determined (Erspamer & Anastasi, 1962). Subsequent work by Erspamer's group isolated
and sequenced the peptides physalaemin and phyllomedusin from amphibia (Erspamer et
al, 1964; Anastasi & Erspamer, 1971). Indeed Erspamer and co-workers were able to
predict the C-terminal sequence of the mammalian neurokinin SP on the basis of their
work with invertebrate neurokinins. Due to the rapidity of their effects on intestinal
preparations, compared to the more slowly acting bradykinins, the term "tachykinin" was
used to group these pharmacologically and structurally related peptides together.
The activity of neurokinins depends on the C-terminal fragment, with the C-terminal
heptapeptide of SP being as potent as SP in such diverse assays as guinea pig ileum,
salivation in rats, cat dorsal horn neurons and mouse scratch behaviour (Piercey et al,
1982).
2.6.2. Neurokinin Receptors:
Prior to the development of specific neurokinin antagonists the investigation of
neurokinin receptor subtypes had depended on assaying the various neurokinins and C-
terminal fragment analogs in a variety of in vitro mono-receptor tissue preparations
(Piercey & Einspahr, 1980; Piercey et al, 1982). Furthermore, prior to the identification
of mammalian neurokinins other than SP, the main evidence for multiple neurokinin
receptors was based on the observation of varying degrees of agonist activity for SP and
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the non-mammalian neurokinins physalaemin, eledoisin and kassinin. The rank order of
potencies for the neurokinins have been used historically to classify receptor sub-types.
In the guinea pig ileum physalaemin is more potent than SP, eledoisin and kassinin, while
in the rat vas deferens eledoisin and kassinin are markedly more potent than physalaemin
and SP (Lee et al, 1982). This ranking of potency suggested the existence of two
neurokinin receptors, termed SP-P and SP-E, both of which are activated by SP, but for
which the non-mammalian neurokinins have different levels of affinity (Bailey et al,
1986). For the SP-P receptor physalaemin is the most potent and for the SP-E eledoisin is
the most potent agonist. This classification was supported, using radio-labelled binding
techniques, by the demonstration of a single neurokinin receptor in guinea pig pancreatic
acinar cells with a rank order of potency of physalaemin > SP » eledoisin (Jensen &
Gardner, 1979).
Not until the identification of two novel mammalian neurokinins NKA (neurokinin A,
substance K) and NKB (neurokinin B, neuromedin K) could neurokinin receptor sub¬
types be properly classified on the basis of agonist response (Kangawa et al, 1983;
Kimura et al, 1983; Maggio et al, 1983). Specific mono-receptor assays for these three
neurokinins were also identified and include, the dog carotid artery (SP), the rabbit
pulmonary vein (NKA), the rat portal vein (NKB) and several others (Regoli et al, 1987).
The dog carotid artery preparation relaxes in the presence of neurokinins, while the other
two preparations contract. Using these assay systems it was determined that the
endogenous ligands for the SP-P and SP-E receptors are SP and NKA respectively, while
an additional receptor class (SP-K) was added to accommodate the specific effects of
NKB (Buck et al, 1984). The more recent identification of SP analogs (e.g [Pro2]-SP)
which are more potent and selective ligands for neurokinin receptors than their parent
neurokinins, and the identification of the structure-activity relationships that confer
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receptor selectivity on the different neurokinins, further assists in identifying receptor
sub-classes (Naline et al, 1989; Petitet et al, 1991; Cascieri et al, 1992).
Several name changes for the neurokinin receptors have since occurred, include NK-P,
NK-A and NK-B (Dion et al, 1987; Regoli et al, 1987a,b; Regoli et al, 1988) and NK-1,
NK-2 and NK-3 (SP-P, SP-E and SP-K respectively), with the latter being the current
accepted classification (Petitet et al, 1991). This classification has been confirmed in
binding studies (Buck & Shatzer, 1988), but pharmacological classification still depends
on the development of highly specific neurokinin antagonists for all three receptors.
While numerous peptide antagonist analogs of SP and NKA are available, their low
affinity and specificity for single receptor classes limits their use in receptor classification
(Regoli et al, 1988). However, differences in activity and tissue selectivity with these
peptide antagonists indicates there are different receptor sub-classes (Bailey et al, 1986).
The recent discovery of novel, highly selective non-peptide antagonists of SP (CP-
96,345-1, Pfizer Inc, CT, USA; RP-67580, Rhone-Poulenc Rorer, Vitry-sur-Seine,
France) has enabled confirmation, in pharmacological terms, of the existence of
neurokinin receptor subtypes (Snider et al, 1991). CP-96,345-1 antagonises the
contractile activity of SP in the classical NK-1 monoreceptor preparation and the
sialogogic effect in the anaesthetised rat, but does not inhibit the NK-2 and the NK-3
mediated contractile effects of SP (Hakanson et al, 1991; Snider et al, 1991). The fact
that CP-96,345-1 is binding to NK-1 receptors has been confirmed using radio-labelled
binding techniques in guinea-pig brain (McLean et al, 1991). More recently the existence
of neurokinin receptors and the genes encoding for these receptors has been documented
and confirmed using molecular biology techniques (Sundelin et al, 1992)
In several tissue systems the biological response to neurokinins can be explained by the
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presence of a heterogenous population of receptors, as in the guinea pig ileum (Regoli et
al, 1988) and the guinea pig trachea (Gerard, NP 1987) and hamster urinary bladder
(Dion et al, 1987a) (the hamster urinary bladder has been reported to contain primarily
NK-2 receptors; see Buck & Shatzer, 1988) or alternatively by the lack of selectivity for
specific receptor sites (Petitet et al, 1991). Within one organ system there can also be
differences in the anatomical localisation of different receptor types (Regoli et al, 1988).
NKA preferentially contracts trachealis muscle compared to peripheral lung in guinea pig
and overall is more potent than SP, while SP itself is equipotent in its contraction of
central airway and peripheral lung tissues (Gerard, 1987). However, Coats and Gerard
(1989) have demonstrated, using radio-labelled binding techniques, that a single class of
receptor is present in the guinea pig lung, the receptor is NK-1 and both NKA and SP are
equipotent in their affinity for this receptor.
Further division of the receptor classes has been proposed on the basis of antagonist
activity and species differences. NK-2a and NK-2b receptors are now recognised on the
basis of rank orders of antagonist potency, with the NK-2a being typically represented by
the rabbit pulmonary artery preparation and the the NK-2b by the hamster trachea
preparation (Advenier et al, 1992). Sub-types of NK-1 receptors have been suggested
primarily on the basis of species differences in the activity of the specific NK-1
antagonist CP-96,345-1 and the binding affinities for radiolabeled SP (Appell et al,
1992). The non-peptide antagonist CP-96,345-1 is 10 times less potent in antagonising
the effects of SP on rat jejunum than on guinea pig ileum (Legat et al, 1992).
Furthermore, there may be differences in the NK-1 receptor type depending on its
localisation, with, in the case of smooth muscle, both neuronal and smooth muscle
receptors being present (Legat et al, 1992).
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The studies by Coats and Gerard (1989) were carried out in phosphoramidon and
captopril pre-treated animals and while the different biological activities of the
neurokinins may be explained by receptor heterogeneity, differences in the rate of
metabolism by endogenous peptide enzymes should also be considered in explaining
these differences (Martling et al, 1988). Although the degradation of SP in plasma is
extremely rapid (<10 s) compared to the NKA half-life of 2 min, this might not be the
case in tissue systems, such as the lung and intestine, where the existence of multiple
neurokinin receptors are suggested from agonist activity studies.
2.6.3. Neurokinin Antagonists:
While receptors for the different neurokinins have been identified on the basis of agonist
activity, the specificity of SP, NKA and NKB for the NK-1, NK-2 and NK-3 receptors
respectively is not complete. Consequently differentiation of receptor subtypes depends
on the development and use of specific NK-1, NK-2 and NK-3 antagonists (Table 3).
The first generation of neurokinin antagonists are structurally based on modifications of
the SP amino acid sequence and in particular the C-terminal hexapeptide, which is
required for smooth muscle activity (see Folkers et al, 1981). The substitution of L-amino
acids by D-Arg at position 1, D-Pro at position 2 and D-Trp at position 7 and 9 in SP
produces a series of SP analogs with reduced agonist activity while introducing
antagonistic properties (Engberg et al, 1981; Folkers et al, 1981; Bjorkroth et al, 1982).
The most potent of this first generation series [D-Pro2,D-Trp7,9)-SP antagonises the
contractile effect of SP in guinea pig ileum, taenia coli, oesophagus and rabbit iris
sphincter muscle (Folkers, et al, 1981; Leander et al, 1981; Salt et al, 1982; Kamikawa &
Shimo, 1984) and inflammatory response in the rabbit eye (Holmdahl et al, 1981). [D-







































































































































































































bladder (Leander, et al, 1981) or the pressor response (Bjorkroth et al, 1982) and has
variable effects on SP-induced changes in the central nervous system, providing further
evidence for SP receptor heterogeneity (Engberg, 1981; Salt et al, 1982).
However, several of these analogs demonstate partial agonist activity, particularly at high
doses (De & Ghosh, 1990), limiting their usefulness as pharmacological tools. [D-
Pro2,D-Trp7,9)-SP and [D-Pro2,D-Phe7,D-Trp,9)-SP, in addition to antagonising the
contractile effect of SP in guinea pig ileum, can contract it indirectly, either through an
SP receptor on postganglionic parasympathetic neurones or by releasing histamine from
mast cells (Hawcock et al, 1982; Hakanson et al, 1982; Featherstone, et al, 1986). Several
SP analog antagonists are equipotent with SP in stimulating histamine release from rat
peritoneal and cutanoeus mast cells (Hakanson et al, 1983; Skofitsch et al, 1983)). [D-
Pro4,Lys6,D-trp7,9,10,Phell]-SP even enhances the SP-induced plasma protein
extravasation in rat skin (Couture & Kerouac, 1987).
Modifying [D-Pro2,D-Trp7,9)-SP by including D-Arg and Leu at positions 1 and 11
respectively removes smooth muscle contractile activity (Watson, 1983; Mandahl & Bill,
1984; Rosell et al, 1983). This antagonist is equipotent against both SP and eledoisin in
guinea pig ileum, bladder and vas deferens and rat duodenum and vas deferens. It also
antagonises SP, trigeminal nerve stimulation, capsaicin, prostaglandin El, compound
48/80 and histamine induced contraction of the rabbit iris pupillary sphincter muscle
(Mandahl & Bill, 1984) but is less potent against physalaemin or against SP in the rat
urinary bladder (Rosell et al, 1983) and has no effect on SP or eledoisin induced
contraction of hamster bladder (Watson, 1983).
Further modification of SP resulted in the development of spantide ([D-Argl,D-
29
Trp7,9,Leull]-SP) (Folkers et al, 1984). This heralded an new generation of antagonists
as spantide has approximately 10 fold greater potency than earlier antagonists and greater
specificity for the NK-1 receptor (Buck & Shatzer, 1988). However, spantide still retains
the histamine-releasing activity common to the earlier analogs (Lembeck et al, 1986) and
stimulates release of ACh in guinea pig ileum, causing smooth muscle contraction
(Featherstone et al, 1986). It is also ineffective against SP-induced facilitation of the
nociceptive flexor reflex in the rat (Wiesenfeld-Hallin & Durant, 1987). By introducing
Asn into position 6 instead of Gin the potency of spantide (spantide I) was dramatically
increased 5-10 fold (Ljungqvist et al, 1989), while replacing D-Argl and Lys3 with N-
nicotinoyllysine (D-Lys(Nic)) and 3-(3-pyridyl)alanine (Pal(3)) reduced the neurotoxicity
of spantide (Folkers, et al, 1990). Slight further modification has resulted in the latest
undecapeptide SP antagonist, spantide II, which is approximately 100 times more potent
than the antagonists of the early 1980s (Folkers, et al, 1990).
Spantide I and spantide II share only the D-Trp amino acids at postions 7 and 9. While
spantide II is more potent in blocking the contractile activity of SP in guinea pig taenia
coli and the rabbit eye papillary sphincter muscle it is also less potent in releasing
histamine from mast cells. However, spantide I and II appear to lack specificity and both
will antagonise the contractile effects of NKA in guinea pig taenia coli, while spantide II
antagonises (to a lesser extent) NKB and spantide I antagonises the neurokinin-related
peptide bombesin (Hakanson, et al, 1990). As SP has agonist activity at NK-1, NK-2 and
NK-3 receptors, and as SP antagonists are all modificiations of SP, it is not surprising
that SP-derived antagonists lack specificity for neurokinin receptors.
An additional procedure for producing neurokinin antagonist from the parent SP
molecule has involved synthesising a variety of tripeptides. This strategy was based on
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the assumption that the binding domain of the parent peptide for the receptor involved
only a small portion of the whole peptide (Hagiwara et al, 1992). This has resulted in the
development of several highly potent tripeptide neurokinin antagonists (eg FR-113,680)
that are highly selective for the NK-1 receptor (Morimoto et al, 1992; Murai et al, 1992).
FR-113,680 has been shown to antagonise the effects of SP on guinea pig trachea and the
atropine-resistant contraction of isolated guinea pig bronchi by electrical field stimulation
(Hagiwara et al, 1992; Murai et al, 1992). FR-113,680 is inactive at rat NK-1 receptors
which supports the hypothesis of species-specific NK-1 receptor sub-types (Morimoto et
al, 1992).
The development of peptide NKA antagonists has employed the same rational as the
production of SP antagonists and as with SP amino acid substitution affects the
antagonist potency and the specificity. Substitution of D-Trp at positions 6 and 8, Pyr
(pyoglutamic acid) at 4 and Nle at 10 in the NKA C-terminal heptapetide NKA(4-10)
gives a highly selective, although weak, NK-2 antagonist (Rovero, et al, 1990). Further
introduction of D-Trp9 or PhelO, greatly improves potency, but increases NK-1 and NK-
3 receptor antagonism respectively, while replacement of D-Trp9 with D-Pro in the
nonselective neurokinin antagonist [Arg5,D-Trp7,9, Nlel 1]-SP(5-11) markedly improves
its NK-2 selectivity (McElroy et al, 1992). However, the NKA analog
[Ala5,Aib8,Leul0]-NKA contains no D-Trp substitutes and in guinea pig trachea is a
highly selective antagonist of NKA, having no apparent effect on SP-induced contraction
(Abu Shanab et al, 1990).
Nevertheless, it appears that development of neurokinin antagonists based on simple
manipulation of the parent peptide incorporating D-amino acids is unsatisfactory in
developing highly potent specific antagonists. More recently introduction of bicyclic
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conformational constraints into the neurokinins using such agents as spirolactam has
given highly selective NK-1 and NK-2 antagonists (Ward et al, 1990) and increasingly
interest is focussing on non-peptide neurokinin antagonists. RP 67580 {(3aR,7aR)-7,7-
diphenyl-2-[l-imino-2-(2-methoxyphenyl)ethyl] perhydroisoindol-4-one} is a potent NK-
1 antagonist with no activity at NK-2 or NK-3 receptors (Garret, et al, 1991; Carruette et
al, 1992). CP-96,345-1 (Pfizer Inc, Groton, CT) {(2S,3S)-cis-2-(diphenylmethyl)-N-[(2-
methoxyphenyl)-methyl]-l-azabicyclo[2.2.2]octan-3-amine} is another highly selective
quinuclidine non-peptide NK-1 competitive antagonist, a selective NK-1 ligand and can
distinguish the NK-1 receptors of different species (Snider et al, 1991; McLean, et al,
1991). Rabbit jejunum requires 10 times the concentration of CP-96,345-1 than guinea
pig ileum to block the smooth muscle contractile effect of SP (Legat et al, 1992).
Because of these species differences it has been proposed that one type of NK-1 receptor
is present in the guinea pig, hamster, gerbil, rabbit, cow, and man while a different NK-1
receptor is present in the rat and mouse (Chassing et al, 1992). The type of receptor
present in the sheep has not bee reported. CP 96,345-1 is marginally more potent than
spantide I, when assayed in the rabbit pupillary iris sphincter muscle and guinea pig
taenia coli muscle preparations, but is 5 to 10 times less potent than spantide II
(Hakanson et al, 1991). Both RP-67,580 and CP-96,345-1 have been shown to antagonise
contraction of guinea pig ileum, bladder and trachea with SP and the potent NK-1 agonist
septide (Carruette et al, 1992), while CP-96,345-1 demonstrates additional effects
unrelated to its NK-1 antagonism. In anaesthetised rats it reduces mean blood pressure
and heart rate (Donnerer et al, 1992) by a mechanism not involving the NK-1 receptor,
but probably by Ca2+ channel blockade (Schnidt et al, 1992). Non-peptide antagonists for
the NK-2 receptor have also been developed and include SR-48,968 ((S)-N-methyl-N[4-
acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl]benzamide) which is a
potent competitive antagonist of the NK-2 receptor in rabbits, guinea pigs, man and
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hamsters (Advenier et al, 1992).
2.6.4. The Smooth Muscle Contractile Effect of the
Neurokinins:
The contractile effect of substance P on gut has been known since its discovery by Von
Euler and Gaddum in 1931. However, it was over 40 years before the effect of
neurokinins on airway smooth muscle tone was assessed, despite the knowledge that the
respiratory and gastrointestinal systems shared a common embryological origin.
Impicciatone and Bentaccini (1973) had previously demonstrated that the non-
mammalian neurokinin physalaemin and the closely related tetradecapeptide peptide
bombesin cause dose-dependent bronchoconstriction in guinea pigs. With the
demonstration of SP-like immunoreactivity (SP-Li) in nerves of the respiratory tract of
guinea pigs (Nilsson et al, 1977; Sundler et al, 1977) and in particular the close
association of SP-Li nerve fibres with smooth muscle, blood vessels and epithelium
interest developed in the possible effects of SP on respiratory function (Andersson &
Persson, 1977).
The bronchomotor response to SP, the more recently discovered NKA and NKB and the
non-mammalian neurokinins varies between species. Concentrating on the mammalian
neurokinins, SP contracts guinea pig airway in vitro and causes bronchoconstriction, but
has no effect on bronchomotor tone in the cat (Nilsson et al, 1977; Andersson & Persson,
1977; Lundberg & Saria, 1982; Karlsson & Persson, 1983; Karlsson et al, 1984; Stewart
et al, 1985; Malo et al, 1986; Schreiber et al, 1988; Gatto et al, 1989; Biggs & Ladenius,
1990; Kroll et al, 1990). The response in guinea pigs can be augmented by pre-treatment
with neutral metalloendopeptidase enzyme inhibitors such as L-thiorphan and
phosphoramidon (Gerard, 1987; Shore et al, 1988).
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SP has been reported to cause wheezing and retro-sternal discomfort in man after
subcutaneous injection (Bernstein & Hamill, 1981), but inhalation of SP has little or no
effect on bronchomotor tone in normal human subjects (Clarke et al, 1987; Fuller et al,
1987b; Joos et al, 1987; Jamieson et al, 1989). While conflicting results for the response
to SP in asthmatic patients have been reported from several studies (Fuller et al, 1987b;
Joos et al, 1987; Crimini et al, 1988a, 1988b), these apparent differences in response may
be explained by differences in the severity of asthma in the subjects used. NKA does
cause significant bronchoconstriction in asthmatic patients and in general is a more
potent bronchoconstrictor than SP in man (Joos et al, 1987; Joos et al, 1989a, 1989b).
These differences between normals and asthmatics may be due to differing rates of
peptide degradation by enzymes in the respiratory tract (Jamieson et al, 1989) and there
are greater numbers of SP immunoreactive nerve fibres in the airways of asthmatic
patients compared to normals (Ollerenshaw et al, 1991). In one study SP was actually
shown to cause mild bronchodilation (Evans et al, 1988). In isolated human airways SP
causes a dose-dependent contraction (Palmer et al, 1987), but is less potent than either
histamine or acetylcholine (Lundberg et al, 1983).
SP has also been shown to contract isolated airways in the golden hamster (Ishii &
Shimo, 1985), rabbit (Tanaka & Grunstein, 1986; Armour et al, 1991), rat (Joos et al,
1988), bovine (Corson et al, 1990), Rhesus monkey (Patterson & Harris, 1990) and ferret
(Webber, 1989). SP and NKA are roughly equipotent in contracting ferret trachealis
muscle, but in the presence of L-thiorphan NKA is 5 times more potent.
Eledoisin, NKA and kassinin are more potent than SP and physalaemin in constricting
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guinea pig airways (Hua et al, 1984; Karlsson et al, 1984; Gerard, 1987; Saria et al, 1987)
and rat airways (Joos et al, 1988). While NKB has been reported to be ineffective in
guinea pigs and in man (Hua, 1984; Advenier et al, 1987; Naline et al, 1989), several
investigators found NKA and NKB to be up to 100 and 10 times more potent than SP
respectively in the guinea pig (Advenier et al, 1987; Uchuida et al, 1987; Tschirhart et al,
1989). NKB has been shown to be equipotent with SP in the rat, at least in its effect on
dynamic compliance (Joos et al, 1988). In human isolated lower airways (distal bronchi)
NKA is several orders of magnitude more potent than SP (Advenier et al, 1987; Martling
et al, 1987; Naline et al, 1989; Frossard & Barnes, 1991). Indeed both SP and NKA
preferentially contract peripheral rather than central airways suggesting NANC control of
airways is more important in the periphery (Frossard & Barnes, 1991). The order of
potency suggests the NK-2 receptor predominates in human airways and this has been
further supported using highly selective NK-1, NK-2 and NK-3 agonists (Naline et al,
1989). The airway response also correlates with the relative distribution of both peptides
in the airways (Martling et al, 1987). SP is more prominent in the pulmonary vasculature
than bronchi while the reverse is true for NKA. Furthermore, CGRP, which is often
found co-localised with SP in sensory nerves, is more potent than SP in contracting
human airways (Palmer et al, 1987) but not in guinea pigs (Gatto et al, 1989). However,
in the guinea pig regional differences in the contractile response of airways to both SP
and NKA have not been demonstrated, but the content of SP is markedly greater in the
distal airways compared to the trachea (Manzini et al, 1989a). In direct contrast SP is a
more potent bronchoconstrictor than NKA in pigs (Martling et al, 1990; Haxhiu-
Poskurica et al, 1992).
In the lungs of all species SP appears to be restricted to capsaicin-sensitive C-fibre
afferents. Capsaicin pre-treatment will release SP from these nerves and desensitise the
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individual to the responses normally associated with SP release from airway and lung
afferents (Lundberg & Saria, 1982a, 1983; Lundberg et al, 1983).
2.6.5. Neurokinin Metabolism:
The response to neurokinin peptides is affected by enzymatic degradation and variations
in the degree of enzyme activity may explain the apparent differences in the intensity of
response to different peptides within species and between species (Table 4). Differences
in peptide metabolism may also explain the differences in bronchial responsiveness
between normal and asthmatic human subjects. Substance P and the other neurokinins
can be metabolised by a whole range of enzymes, not all of which are important in
modulating the physiological response to these peptides. Early studies demonstrated that
SP could be metabolised by various proteolytic enzymes in both crude and relatively pure
tissue extracts (Von Euler, 1936; Pernow, 1955; Benuck et al, 1975). Interestingly
Boileau and co-workers (1970) failed to demonstrate appreciable metabolism of SP and
physalaemin on passage through the pulmonary circulation, despite the large amounts of
angiotensin converting enzyme (ACE) in the lung and the association of ACE with SP in
the CNS (McGreer et al, 1979).
The most potent enzyme for the metabolism of SP is endopeptidase-24.11 (EC3.4.24.11;
NEP), a zinc metalloendopeptidase (Matsas et al, 1984). This enzyme is also important in
the metabolism of enkephalins and so is also commonly known as enkephalinase. NEP is
functionally and structurally different from the peptidyl-dipeptidase (EC.3.4.15.1)
angiotensin converting enzyme (ACE) (Matsas et al, 1984; Skidgel et al, 1984). NEP
cleaves SP at positions 6, 7 and 9, while ACE cleaves SP at positions 8 and 9 only
(Skidgel et al, 1984). CGRP is also metabolised by NEP and competes with SP for the













































































































































































(Skidgel et al, 1991). This inhibition of SP degradation by CGRP co-released from
primary afferents may augment the physiological response to SP (Le Greves et al, 1989).
In the lung NEP is located primarily in the airway tissue and is epithelium-derived, being
membrane bound on the surface of all lung cells (Fine et al, 1989; Nadel, 1991), while
ACE predominates in the pulmonary vasculature (Johnson et al, 1985). Presumably NEP
inactivates peptides entering the respiratory tract or released in close proximity to the
respiratory epithelium and ACE can metabolise vasoactive peptides in the pulmonary
circulation. NEP interacts with and modifies the numerous and varied respiratory effects
of the neurokinins (Borson et al, 1986; Borson et al, 1987; Nadel & Borson, 1987;
Umeno et al, 1989) and is important in the physiological response to neurokinins
(Lazarus et al, 1987). The effect of NEP can be modified by denuding the airway
epithelium, as with respiratory infections (Borson et al, 1989), and on exposure to
noxious agents such as cigarette smoke (Dusser et al, 1989).
With particular reference to airway smooth muscle contraction, the bronchomotor
response to SP is augmented by pre-treatment with NEP inhibitors, such as L-thiorphan
and phosphoramidon, in isolated airways of rabbits, guinea pigs ferrets and in human
isolated airways (Nadel & Borson, 1987; Sekizawa et al, 1987; Stimler-Gerard, 1987;
Armour et al, 1991; Frossard & Barnes, 1991; Honda et al, 1991) and in anaesthetised
sheep (Abraham et al, 1991) and guinea pigs (Shore et al, 1988; Thompson & Sheppard,
1988; Shore et al, 1989a; Martins et al, 1990) and piglets (Haxhiu-Poskurica et al, 1992).
The responses to SP and NKA are both augmented by NEP inhibition in guinea pigs
(Gerard 1987; Shore & Drazen, 1989b; Martins et al, 1991), sheep (Abrahams et al,
1991) and man (Frossard & Barnes, 1991) with maintenance of the same order of
potency, but L-thiorphan has no effect on the response to NKA in piglets (Haxhiu-
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Poskurica et al, 1992). The response to NKB is also augmented by L-thiorphan in guinea
pig (Shore & Drazen, 1989b)
Several other enzymes have been suggested to control neurokinin metabolism.
Contrasting reports on the effect of angiotensin converting enzyme (ACE) inhibitors,
such as captopril, on the response to neurokinins have been reported. ACE inhibitors
potentiate the bronchomotor response to intravenous SP in anaesthetised guinea pigs and
is roughly equipotent with L-thiorphan in this effect (Shore et al, 1988; Shore & Drazen,
1989a,b). They have no effect on SP or NKA infused directly into the guinea pig trachea
(Martins et al, 1989; Lotvall et al, 1990), on SP-induced contraction or mucus secretion
in isolated ferret trachea (Borson et al, 1987; Sekizawa et al, 1987), NKA and NKB-
induced bronchoconstriction in guinea pigs (Shore & Drazen, 1989b) or SP-induced
contraction of isolated human bronchus (Honda et al, 1991). However, both captopril and
phosphoramidon potentiate the bronchoconstrictor effect of bradykinin in guinea pigs
(Ichinose & Barnes, 1990). The combination of L-thiorphan and captopril further
augments the bronchoconstriction with SP in guinea pigs (Shore et al, 1989b). The
varying effects of captopril may be explained by the occurence of at least two isozymes
of ACE in the rat brain (striatal) and lung tissue. Lung ACE is ineffective in metabolising
NKA, eledoisin, kassinin and SP 5-11, but cleaves SP and physalaemin (Strittmatter et al,
1985). Furthermore, ACE and bestatin-sensitive aminopeptidase do not metabolise rat
brain SP, but are involved in hydrolysis of SP fragments (Oblin et al, 1989). The
peptidase tonin which attacks phenylalanyl peptide bonds metabolises both angiotensin II
and SP (Chretien et al, 1980) and a post-proline cleaving enzyme that cleaves thyrotropin
releasing hormone has been reported to cleave SP at the Pro4-Gln5 bond (Blumberg et al,
1980). Fetal calf acetyl-cholinesterase also metabolises SP (Chubb et al, 1980), but is
ineffective in rabbits (Armour et al, 1991). In ferret ileum ACE and acetylcholinesterase
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and several other peptidases are also ineffective in metabolising SP (Djokic et al, 1989),
but captopril reduces NPY-like immunoreactivity in guinea pig plasma (Dahlof et al,
1991), which has been demonstrated to modulate SP release from NANC nerves in the
airway (Belvisi et al, 1990b). Human lung tryptase, released from mast cells,
metabolises the bronchodilating neuropeptides VIP and peptide histidine methionine
(PHM) and to a lesser extent CGRP, but has no effect on the neurokinins (Tarn &
Caughcy, 1990). This may augment the airway response to the neurokinins in respiratory
disease.
2.6.6. Mode of Action of the Neurokinins:
The biological actions of the neurokinins are mediated via specific receptors and the
structure of the three neurokinin receptors NK-1, NK-2 and NK-3 have been identified
and the receptor genes have been cloned and sequenced (Sundelin et al, 1992) and their
pharmacological profiles determined (Petitet et al, 1991). The neurokinin receptors are of
the guanosine-nucleotide-binding-regulatory-protein-coupled type (G-coupled) and all
can be activated by the three mammalian neurokinins. While the existence of specific
receptor subtypes for the neurokinins is generally accepted, the exact location of these
receptors, either on the target tissue or structures innervating the target tissue, has not
been completely determined (Coats & Gerard, 1989; Snider et al, 1991). Consequently,
the respiratory effects of the neurokinins may involve both direct and indirect
mechanisms but are all mediated by specific neurokinin receptors.
2.6.6.1. Direct Mechanisms:
The mechanism of action of SP appears to be largely direct in the guinea and man.
However, there are several studies suggesting indirect mechanisms may be involved in
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these species. It is well recognised that in guinea pig ileum SP has two separate
mechanisms of action. SP stimulates release of ACh from cholinergic nerve endings and
this indirect effect of is in addition to its direct effect on ileal smooth muscle (Tietelbaum
et al, 1984; Yau et al, 1986; Kowal et al, 1989). The bronchoconstrictor effect of
exogenous SP and histamine in the guinea pig can be significantly reduced by pre-
treatment with capsaicin, suggesting SP at least requires intact sensory afferents
containing peptides for its maximal effect (Goel & Biggs, 1987; Biggs & Ladenius,
1990).
In human airways exogenously administered neurokinins and CGRP appear to act
directly and are not modified by cholinergic and adrenergic antagonists, histamine HI
and H2 receptor blockers or tetrodotoxin (Lundberg et al, 1983a,b; Palmer et al, 1987).
The majority of human studies, however, have used tissue collected during lung resection
of bronchogenic carcinomas in aged patients and the effects of neurokinins in normal
young adults and infants is not known. In asthmatic patients the response to SP and NKA
is greater than in normal subjects and, more importantly, the response to inhaled NKA
and SP can be significantly inhibited by pre-treatment with nedocromil sodium (Crimini
et al, 1988a,b; Joos et al, 1989a,b) in a similar manner to that occuring in rats (Joos et al,
1988). The mode of action of nedocromil sodium is not completely understood but may
involve a combination of mast cell stabilisation and inhibition of vagal reflex
bronchoconstriction (Dixon et al, 1980; Eady, 1986).
The modulation of the response to SP, NK A and NKB by endogenous epithelium-derived
metabolic enzymes further complicates the issue. Denuding the trachea of epithelium in
guinea pigs and ferrets, or treating with a neutral metallo-endopeptidase inhibitor such as
L-thiorphan, potentiates the contractile effect of NKA more than SP, and the mucus
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secreting effect of SP more than NKA (Tschirhart et al, 1989; Webber, 1989) suggesting
specific NK-2 and NK-1 receptors mediate these responses. Furthermore, we know of
several mechanisms that modify the endogenous release of neurokinins from sensory
afferent nerves in the lung, but most evidence suggests that these mechanisms are not
affected by or modify the response to exogenously administered SP.
NPY suppresses nerve-mediated contraction, presumably caused by neurokinin release
from non-cholinergic nerve endings, of guinea pig airways, but has no effect on
contraction caused by exogenous SP (Grundemar et al, 1990; Stretton et al, 1990a).
Opioids and gamma amino butyric acid (GABA) have also been shown to prejunctionally
inhibit SP release from capsaicin-sensitive primary afferent nerves in rat trachea, through
activation of the u-opioid and GABAg receptors respectively (Belvisi et al, 1989a &
1990; Ray et al, 1991a,b) but as with NPY have no effect on exogenously administered
SP (Belvisi et al, 1989a). However, Khalil & Helme (1990) demonstrated that opioid
receptor antagonists inhibited cutaneous inflammation caused by exogenously
administered SP in the rat. There also appears to be a synergism between adenosine and
the neurokinins in causing bronchoconstriction in rats which is associated with an
increase in circulating histamine levels (Pauwels et al, 1990).
It should also be noted that SP has a direct effect on vascular permeability within the
lung, which can result in airway wall oedema and an associated reduction in bronchial
calibre. This phenomenon may be significant in the pharmacological response to SP, but
is probably more important in the increased resistance to breathing associated with
various airways diseases such as asthma (Belvisi et al, 1989b; Lotvall et al, 1990).
Figure 7. Schematic illustration of the possible mechanisms involved in the neural
modulation of cholinergic neurotransmission to airway smooth muscle and the interaction
between peptidergic and non-peptidergic neural systems. Smooth muscle tone is modulated
by acetylcholine (ACh) released from cholinergic nerve endings activating muscarinic
receptors (Ml,2 & 3) and neuropeptides substance P (SP), neurokinin A (NKA) & calcitonin
gene-related polypeptide (CGRP)) from non-adrenergic non-cholinergic (NANC) nerve
endings activating neurokinin receptors (NK1 & 2). Release of peptides from NANC nerves
is pre-junctionally inhibited by gamma amino butyric acid (GABA), neuropeptide Y (NPY)
and opioids, while released peptide is metabolised by neutral metallo-endopeptidase. NANC
peptides prejunctionally stimulate release of ACh, while vasoactive intestinal polypeptide
(VIP), nitric oxide (NO), and ACh (M2) inhibit its release. SP, nor-adrenaline (NA), NPY,
and ACh (Ml) modulate neurotransmission through parasympathetic airway ganglia. + and -
refers to stimulation or inhibition of the target neurons, or in the case of the receptor types
shown, stimulation or inhibition of smooth muscle contraction.
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2.6.6.2. Indirect Mechanisms:
There are numerous studies supporting the hypothesis of an indirect mechanism of action
for the neurokinins in mammalian airways. While it is generally accepted that the
neurokinins interact with specific receptors, designated NK-1, 2 and 3, the exact location
of these receptors in the airways has not been determined (Barnes, 1989). Furthermore,
there appear to be definite inter-species variations in the mechanisms of action of the
neurokinins in the respiratory system (Joos et al, 1989a; Armour et al, 1991) and there is
even some evidence for indirect mechanisms in both man and guinea pigs.
2.6.6.2.1. Modulation of Cholinergic Neurotransmission:
The most common example of an indirect mechanism for neurokinin-induced
bronchconstriction involves modulation of cholinergic neurotransmission (Figure 7),
either pre-junctionally by stimulating ACh release from cholinergic nerve endings,
activating reflex vagal bronchoconstriction, interfering with neurotransmission at the
parasympathetic airway ganglia level or even modifying the activity of post-synaptic
muscarinic receptors (Grunstein et al, 1984; Tanaka & Grunstein, 1986; Haxhiu-
Poskurica et al, 1992).
SP enhances the contractile reponse of tracheal smooth muscle to electrical field
stimulation in the rabbit and this is inhibited by atropine, tetrodotoxin and the SP
antagonist D-Argl,D-Pro2,D-Trp7,9,Leul 1-SP, but SP does not enhance the response to
methacholine itself (Tanaka & Grunstein, 1986). Atropine also inhibits the contractile
effect of SP in rabbit airways (Grunstein et al, 1984). These results, however, have been
recently questioned by Armour et al (1991) who failed to demonstrate an inhibitory effect
of atropine on the contractile response of rabbit isolated trachea and bronchus to SP. In
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the rat atropine, but not vagotomy, reduces the bronchoconstriction caused by eledoisin
and SP (Joos et al, 1988), while in bovine trachealis muscle atropine abolishes the
response to low concentrations of SP, but is less effective when near-maximal
concentrations of SP are used (Corson et al, 1990) indicating SP acts both directly and
indirectly. Similarily in the pig atropine, albeit at quite a high dose (2mg/kg),
significantly reduces tracheal contraction caused by SP and NKA (Haxhiu-Poskurica et
al, 1992). This data suggests that in some species there is a cholinergic component to the
bronchoconstriction caused by the neurokinins probably involving prejunctional
modulation of the release of ACh from cholinergic nerve terminals.
As mentioned earlier, in man, and possibly the guinea pig, the airway response to the
neurokinins appears to be direct, involving interaction between the peptides and post¬
synaptic NK-2 receptors on smooth muscle. However, the bronchoconstriction caused by
capsaicin in man can also be reduced by muscarinic blockade, and while this may suggest
capsaicin activates vagal reflex bronchoconstriction rather than local release of SP (Fuller
et al, 1985), capsaicin may be releasing SP or other neuropeptides from nerve endings
which subsequently activate vagal reflex broncho-constriction. In moderately asthmatic
patients the muscarinic antagonist ipratropium bromide significantly inhibits the
bronchoconstriction caused by inhalation of SP (Crimini et al, 1990) and NKA, in the
presence of the potassium channel blocker 4-aminopyridine, has also been shown to
prejunctionally potentiate cholinergic neurotransmission to the airways in man (Black et
al, 1990).
In the guinea pig SP contracts airway smooth muscle directly. However, Laufer et al
(1985) demonstrated SP, NKA and NKB contracted guinea pig ileum by a combination
of a direct effect on smooth muscle and indirectly by activating a neuronal receptor
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releasing ACh. This neuronal receptor is distinct from the smooth muscle receptor and is
preferentially activated by NKB. SP also enhances the airway contractile response to
both antigen and ACh (Nagai et al, 1990) (this was not demonstrated in a similar study
by Schreiber et al, 1988). This SP-induced enhancement of bronchoconstriction is
abolished by vagotomy and is partially inhibited by the cyclooxygenase inhibitor
indomethacin (Omini et al, 1989). A similar enhancement by bradykinin has also been
noted in the guinea pig. Capsaicin-sensitive sensory nerves are necessary for the toluene
diisocyanate-induced increase in bronchial reactivity to carbachol found in guinea pigs
(Thompson et al, 1987). This suggests sensory neuropeptides also modulate the activity
of post-synaptic muscarinic receptors in guinea pig airway smooth muscle. Atropine, the
HI antihistamine mepyramine, and indomethacin have no effect on SP-induced broncho¬
constriction in guinea pigs (Stewart et al, 1985; Shore & Drazen, 1989a), but
indomethacin inhibits the enhanced response found with repeated challenge with SP,
suggesting cyclooxygenase products of arachidonic acid have some role in the response
to SP. In contrast, inhibitors of lipoxygenase enzymes enhance SP-induced
bronchoconstriction suggesting a lipoxygenase metabolite of arachidonic acid is an
endogenous bronchodilator (Stewart et al, 1985).
SP increases ciliary beat frequency by indirect mechanisms in the dog (Wong et al,
1991). The response is modulated, but not abolished, by indomethacin, the ganglion
blocker hexamethonium, and the muscarinic antagonist ipratropium bromide, suggesting
involvement of a cyclooxygenase-dependent parasympathetic reflex (Wong et al, 1991).
The increase in mucus secretion also caused by SP is a direct effect in the guinea pig
mediated by the NK-1 receptor (Kuo, 1991), while in the cat the secretion of mucus is
entirely abolished by atropine and is not affected by the SP antagonist D-Pro2,D-Trp7,9-
SP (Shimura et al, 1991).
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2.6.6.2.2. Inflammatory and Cellular Mediators:
i. The Eicosanoids:
The eicosanoids consist of the leukotriene and prostanoid families of compounds which
are the metabolites of arachidonic acid (AA) and are produced by the lipoxygenase and
cyclo-oxygenase enzymatic pathways respectively (Reaburn, 1990). Arachidonic acid has
been shown to exert both contractile and relaxant effects in the airways (Tschirhart et al,
1987) and metabolites of AA may be involved in the bronchomotor response to SP and
the activity of peptidergic sensory afferent nerves in the airways. Furthermore,
bronchconstrictor prostanoids may act through cholinergic-mediated mechanisms
(Beasley et al, 1987). In the spinal cord non-steroidal anti-inflammatory drugs block the
increased sensitivity to pain associated with activation of neurokinin receptors
(Malmberg & Yaksh, 1992) and this may be further evidence that eicosanoids can affect
peptidergic mechanisms. Moreover, a specific ability of PGE2 to increase the release of
SP for sensory afferent neurons, by increasing calcium conductance, has recently been
demonstrated (Nicol et al, 1992). Although this does not occur with aracidonic acid,
PGF2a or LTB4, arachidonic acid itself has been shown to cause bronchoconstriction in
guinea pigs, and this depends to a large extent on intact sensory afferents, as the response
is reduced by capsaicin pre-treatment (Tschirhart et al, 1987; Manzini et al, 1989b).
While cyclooxygenase inhibitors, such as indomethacin and aspirin, have been shown to
augment the response to SP in some studies, this has not been universally demonstrated
(Mizrahi et al, 1982; Regoli et al, 1984; Stewart et al, 1985). Gerard (1987) found the
contractile effects of SP and NKA are reduced by cyclooxygenase inhibitors in guinea
pig lung parenchymal strips, but not in the central airways. The cyclooxygenase products
of arachidonic acid could not be identified in perfusates from both tissues suggesting SP
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was stimulating eicosanoid production within smooth muscle cells. The contractile
activity of CGRP, which is often co-localised with SP, is not affected by indomethacin.
In intact guinea pigs the increase in pulmonary resistance (RL) and decline in Cdyn
bronchoconstriction caused by SP is not affected by indomethacin, but is potentiated by
the combined cyclooxygenase and lipoxygenase inhibitors (3-amino-l-(m-
trifluoromethyl)phenyl) pyrazoline HC1 and eicosatetraynoic acid (Stewart et al, 1985).
This suggests that the primary effect of activation of arachidonic acid metabolism in the
airways is the production of a lipoxygenase-derived bronchodilator agent rather than a
cyclooxygenase-derived spasmogenic eicosanoid. While indomethacin inhibits cyclo¬
oxygenase activity it also increases lipoxygenase activity (Walker et al, 1980) and a net
balance between eicosanoid bronchodilator and bronchoconstrictor agents might occur.
The curious enhancement of the airway response to SP caused by repeated exposure to
SP reported by Shore & Drazen (1989a) is inhibited by indomethacin, but not the original
SP-induced bronchoconstriction.
ii. Histamine:
Several neuropeptides, including SP, VIP, somatostatin (SOM), have been reported to
stimulate histamine release from mast cells and this may, in part, underlie the
bronchomotor response to these peptides. SP has been shown to release histamine in skin
and the flare and wheal response to SP can be blocked by antihistamines (Foreman et al,
1983; Barnes et al, 1986). However, the ability of SP to cause histamine release is
restricted to rat peritoneal and human skin mast cells (Shanahan et al, 1985; Repke et al,
1987; Lowman et al, 1988 a,b; McLeod et al, 1990) while the other neurokinins NKA,
NKB, eledoisin and physaelamin and bradykinin have no effect. This specificity of SP
reflects the heterogeneity of the mast cell population in mammalian species and between
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species. On the basis of neutral proteinase content, human mast cells can be subdivided
into two groups, T and TC cells (Irani et al, 1986). In the lung the T cell predominates,
accounting for more than 90% of mast cells while the TC mast cell predominates in skin.
Consequently non-immunogenic stimulation of histamine release from human mast cells
by SP, compound 48/40, poly-l-lysine and morphine may be expected to occur more in
the skin than in lung, adenoidal, tonsilar, or colonic tissue (Lowman et al, 1988a).
However, Louis & Radermecker (1991) recently demonstrated histamine release from
human lung mast cells by SP, which was significantly inhibited by nedocromil sodium.
This would suggest that histamine might be involved in the bronchomotor response to
neuropeptides, but the evidence supporting a definitive role for the mast cell in
neurogenic inflammation is still sparse (Casale et al, 1988; Barnes, 1989).
However, inhalation of compound 48/40 by allergic sheep (which in common with SP
degranulates skin mast cells by an unidentified activation-secretion coupling pathway
(Lowman et al, 1988a) results in both early and late-phase bronchoconstriction (Russi et
al, 1984). Furthermore, Pauwels et al (1990) demonstrated a synergism between NKA
and adenosine-induced bronchoconstriction, which was associated with a significant
increase in histamine levels in bronchoalveolar lavage samples, and suggested the
response to NKA and adenosine was due to enhancement of histamine release from mast
cells. Intravenous SP has been shown to raise plasma histamine levels in rats (Sertl et al,
1988), and while it was presumed that the histamine came from lung mast cells this was
not proven. Although the lung mast cell is possibly not involved in the acute
pharmacological response to exogenously administered SP, an interaction between SP,
VIP, CGRP and gastrin releasing petide (GRP) and mast cells is probably important in
the aetiopathogenesis of respiratory inflammation (Goetzl et al, 1990). Nerve fibres
immunoreactive for NKA and CGRP, but not NPY, are found close to lung mast cells,
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suggesting a close relationship between sensory nerves and these cells (Nilsson et al,
1990). More recently Crivellato et al (1991) have demonstrated a close anatomical
association between mast cells and peptide-containing nerve fibres in rat mesentery.
These nerve fibres, which include fibres immunoreactive for SP, VIP, CGRP and SOM,
not only run close to mast cells, but also come in direct contact with the mast cell surface.
Furthermore, Joos et al (1988) have demonstrated the antihistamine and mast cell
stabilising agent ketotifen, but not the classical antihistamine clemastine, reduced the
bronchoconstriction caused by eledoisin in the rat. The activation of other resident cell
types in the lung, such as macrophages, does not appear to be involved in the responses
to SP (Pujol et al, 1989)
It is interesting to note that histamine, along with bradykinin, the nicotinic agonist
dimethylphenyl piperazinium and vagal nerve stimulation, stimulates release of
neurokinins from sensory nerve endings in the lung (Saria et al, 1988a), indicating there
is an inter-action between SP and histamine.
2.6.7. Additional Effects of Neurokinins on Airway Functions:
2.6.7.1. Mucus Secretion and Airway Cilia Function:
Exogenously applied SP increases cilia beat frequency in dogs and stimulates mucus
secretion in the guinea pig and cat (Rogers et al, 1989; Shimura et al, 1991; Kuo et al,
1991; Wong et al, 1991). The increase in ciliary beat frequency involves a
cyclooxygenase-dependent parasympathetic reflex as it is inhibited by hexamethonium,
the muscarinic antagonist ipratropium bromide and indomethacin (Wong et al, 1991).
The release of SP from sensory nerve endings by capsaicin also increases ciliary activity
(Wong et al, 1990) suggesting SP released during lung injury or inflammation is
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important in improving mucociliary clearance. However, in the guinea pig and man the
sensory neuropeptides SP, NKA, NKB and CGRP stimulate goblet cell mucus secretion
via activation of NK-1 receptors (Rogers et al, 1989; Kuo et al, 1991) and in the guinea
pig the response is resistant to atropine and HI and H2 receptor antagonists (Kuo et al,
1991), while in the cat the response is indirect and cholinergic (Shimura et al, 1991).
2.6.7.2. Plasma Leakage and Plasma Extravasation:
The persistence of bronchoconstriction after inhalation of SP, which can be difficult to
reverse by lung hyperinflation, is primarily due to airway wall and alveolar oedema
(Lotvall et al, 1990a). SP and other neurokinins and CGRP are potent vasodilators, and
in addition the neurokinins cause microvascular leakage, with extravasation of protein
and consequent airway wall oedema. This process is important in the aetiopathogenesis
of airway and lung inflammation (Lundberg et al, 1984,1988; Rogers et al, 1988; Saria et
al, 1988b; Sertl et al, 1988; Belvisi et al, 1989b), but leakage of circulating blood cells
does not affect the smooth muscle and vascular effects of SP (Bethel et al, 1988). SP is
the most potent peptide causing microvascular leakage (Rogers et al, 1988).
The increased vascular permeability caused by SP appears to be direct as the location of
the increase in vascular permeability associated with SP coincides with the highest
concentrations of SP (NK-1) receptors (Sertl et al, 1988). The order of potency for the
neurokinins (SP > NKA = NKB) in causing microvascular leakage is different from that
causing bronchoconstriction in the guinea pig suggesting the NK-1 receptor mediates the
vascular response (Rogers et al, 1988). The vascular response to SP is not due to release
of histamine from mast cells in the lung (Sertl et al, 1988).
At dose levels below those necessary to cause bronchoconstriction, neuropeptides,
49
including the neurokinins, VIP, CGRP and NPY, modulate tracheal vascular resistance
and may be important in the physiological control of airway systemic arterial blood flow
(Salonen et al, 1988).
2.6.8. Neuropeptides as neurotransmitters:
The criteria for identifying peptides as neurotransmitters have proved difficult to fulfill.
Particular problems exist in determining if a peptide co-localised with another peptide or
non-peptide, is a classical neurotransmitter, like acetylcholine, or a neuromodulator.
Makhlouf (1988) has recently re-defined the criteria for peptide neuro-transmitters and
most of these criteria have been satisfied for the neurokinins. Peptide synthesis has been
demonstrated in neurons and the target tissues innervated by these neurones has been
identified in most instances. Specific receptors for the neurokinins have been
demonstrated in target cells tissues using pharmacology and molecular biology
techniques. However, the modulatory actions of the various neuropeptides co-localised
with each other, and with classical non-peptide neurotransmitters, have not been
completely separated from their direct actions, and this area needs further investigation.
Fulfilling all these criteria suggest that a peptide is released from nerves and interacts
with an effector organ (Dahlstrand, 1990). In this respect most criteria have been
effectively satisfied and peptides, including the neurokinins, appear to behave as classical
neurotransmitters, but also modulate the activity of other neural elements in the vicinity
of their target sites.
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2.6.9. Neuropeptides and Respiratory Disease:
The characteristic activities of exogenous SP and capsaicin in the lung have suggested a
role for sensory neuropeptides in inflammatory disease, in the lung and elsewhere in the
body (Figure 8). SP and the other neurokinins are believed to be the mediators of the so-
called "neurogenic inflammatory response" (Barnes, 1986; Yoneharaet al, 1990). The
concept of neurogenic inflammation can be used to explain certain aspects of the
pathophysiology of asthma and other inflammatory airway diseases, various forms of
dermatitis, and immunologic and non-immunologic types of arthritis.
The released neuropeptides, as discussed earlier, would affect bronchomotor tone,
increase mucus secretion, improve muco-ciliary clearance of this excess mucus and dilate
the pulmonary vasculature and the micro-capillary bed resulting in microvascular
leakage, plasma extravasation and oedema. In vivo sensory neuropeptides may be
released from collateral sensory afferent nerve endings, as part of a local axonal reflex
activated by mechanical or chemical stimulation of the airway surface (Lundberg &
Saria, 1983a; Lundberg & Saria, 1983; Lundberg et al, 1984; Barnes, 1986; Joos et al,
1989). The denuding of airway surface epithelium during inflammation may expose
sensory C-fibre endings to inflammatory mediators such as bradykinin and histamine
resulting in reflex bronchoconstriction and the reflex release of peptides from collateral
nerve axons (Saria et al, 1988a; Barnes, 1988).
It is because of the description of this elegant model of airway inflammation, and its
possible role in the aetiopathogenesis of airway disease, that the expansion in research in









Figure 8. The theory of axon reflex mechanisms of bronchoreactive diseases, such as asthma, as
outlined by Barnes (Lancet 1: 242-245,1986). Damage to the airway epithelium results in
exposure of intra-epithelial C-fibre afferent endings. These endings are activated by mediators
released from inflammatory cells, resulting in increased vagal afferent activity and stimulation of
collateral C-fibre axons. The latter results in localised release of neuropeptides causing contraction
of smooth muscle, increased mucus secretion and vascular leakage.
"neurogenic inflammation" and its relationship to airway disease continues to inspire
greater research in this area and with the developement of highly specific peptide
agonists and antagonists, new directions in respiratory pharmcology are likely to occur in
the near future.
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CHAPTER 2. GENERAL METHODOLOGY
2.1. Cardiopulmonary Measurement in the
Anaesthetised Sheep:
The general methodology for measuring cardiopulmonary parameters in normal sheep
and the methodology for investigating the contractility of the isolated sheep trachealis
muscle are described in this section. An additional study investigating neurokinins in
sheep with an airway allergy to Ascaris suum antigen used a computerised technique
for measuring respiratory parameters, and the methodology is described in detail in
chapter 4. A further series of experiments investigated the effects of vagal cooling on
the bronchomotor response to substance P, and the methodology is described in detail
in chapter 7.
2.1.1. Animals:
Experiments were carried out in female cross-Suffolk sheep purchased from
commercial sources. The sheep were aged between 4 months and approximately 4
years with a body weight range of 25 to 60 kg. The sheep were housed in purpose-
built animal accomodation and maintained on ad lib hay and water. The sheep were
housed for at least 7 days prior to experiments.
2.1.2. Anaesthesia:
The sheep were restrained in lateral recumbency and anaesthetised with
pentobarbitone (Sagatal, Rhone Merieux Ltd, UK) 25 mg/Kg body weight,
administered intravenously through the right tarsal vein. An in-dwelling teflon over-
the-needle catheter (Jelco 20g, Critikon Inc, USA) was placed in the right cephalic
vein and secured in place and anaesthesia was maintained with a constant infusion of
0.54% pentobarbitone in sterile 0.15M NaCl (Baxter Ltd, UK) adjusted to deliver 2
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mg/Kg/h of pentobarbitone. The sheep were intubated with a 10 mm cuffed
endotracheal tube (Trimline 10.0 Oral, Leyland, UK) which was securely tied in
place, and put in the prone position with the head supported in a sling (Figure 9).
Anaesthetic depth was assessed using standard ocular anaesthesia criteria, including
palpebral and corneal reflexes, pupil size and the deviation of the eye from the central
position (Hossain et al, 1988). Attempts were made to maintain animals between light
and deep planes of anaesthesia, with weak palpebral and corneal reflexes, partially
dilated pupils and the eyes fixed centrally. However, prolonged anaesthesia was found
to cause several problems with the preparation, particularily with the breathing pattern
and the appearance of rhythmic apneoa-tachypnoea episodes. Attempts were made to
avoid such problems, by limiting the duration of experimental procedures.
2.1.3. Respiratory Measurements:
2.1.3.1. Measurement Equipment:
Respiratory parameters, including flow (V), tidal volume (VT), transpulmonary
pressure (P), pulmonary resistance (RL) and dynamic compliance (Cdyn) were
measured using a standard combined pneumotachograph and oesophageal balloon
technique. Transpulmonary pressure was derived from the pressure difference
between the oesophagus (representing pleural pressure) and the airway opening. An
oesophageal balloon was constructed from a condom sealed over the distal 10cm of a
section of rigid polyethylene tubing (internal diameter 4mm) which had a series of
15-20 spirally arranged holes cut in it (Figure 10). The balloon catheter was
positioned in the caudal third of the oesophagus (Figure 1). Position was confirmed
by first passing the balloon into the rumen, where a positive pressure deflection is
found on inspiration, and then slowly withdrawing the balloon until a pressure signal
of opposite sign was obtained. The balloon catheter was then taped to the
endotracheal tube to prevent movement. A similar section of tubing was placed at the
Figure 9. The anaesthetised sheep preparation for the measurement of pulmonary mechanics.
The sheep is positioned in sternal recumbency with the head supported in a sling.
A-endotracheal tube; B-airway catheter; C-pneumotachograph; D-oesophageal balloon
catheter; E-intravenous indwelling catheter and anaesthetic constant infusion line.
Figure 10. The oesophageal balloon catheter system. The catheter (A) consists of a length of semi¬
rigid polyethylene tubing with an internal diameter of mm. The distal 10 cm of the tube has 15-20
spirally arranged holes. The balloon is a latex rubber condom and is sealed over the end of the
tubing (B).
54
entrance to the endotracheal tube through the side port of a three-way connector. Both
catheters were attached to the input ports of a differential pressure transducer
(pressure range; +/-12 cmH20 (UP2, Pioden Controls, Canterbury, UK).
Airflow at the endotracheal tube opening was measured using a pneumotachograph
flow head, with a flow range of 0-100 litres/min (F100L, Mercury Electronics,
Glasgow, UK), connected to a second differential presure transducer (pressure range;
+/-4 cmH20). The pneumotachograph flow head was not heated.
Signals from both pressure and flow transducers were amplified (3552 Pressure Pre¬
amplifier, Devices, UK) and the flow signal was integrated (3655/3630, Devices, UK)
to give tidal volume measurements. Outputs were than recorded on heat sensitive
paper (MX 19 Physiological Recording System, Devices, UK).
2.1.3.2. Equipment Calibration:
Pressure, flow and tidal volume measurements were calibrated before the start of each
experiment. There was good day-to-day consistency in the measurement of
parameters and only minor adjustments had to be made. The pressure transducer was
calibrated with a water manometer constructed in the Faculty of Veterinary Medicine
Engineering Workshop, and expressed in units of cmH20. The pneumotachograph
head was calibrated with a standard temperature and pressure flow meter (SCR2,
Glass Precision Engineering Ltd, UK), calibrated in litres/min, through which air was
driven with a pump (Cape X Mk IB, Frank Austen Ltd, UK). The volume calculated
from the integrated flow output from the pneumotachograph was calibrated with a
large volume syringe (SCI, Mercury Electronics Ltd, UK).
To enable respiratory resistance (RL) and dynamic compliance (Cdyn) to be
calculated from pressure, flow and volume measurements, outputs from both
Figure 11. Diagramatic illustration of the method for measuring respiratory parameters in
anaesthetised sheep. Oesophageal balloon, airway and pneumotachograph pressures were
measured with two matched differential pressure transducers. The transducer outputs were
amplified using a series of Devices preamplifiers, and the flow signal was integrated to give
tidal volume. Flow, tidal volume and transpulmonary pressure were recorded on heat
sensitive paper, from which pulmonary reistance and dynamic compliance were calculated
graphically.
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transducers were phase matched up to 6Hz. Phase matching was carried out according
to the method of Macklem (1975), using a sealed plastic container, a sinusoidal pump
delivering a volume of 14ml/cycle and a two channel storage oscilloscope (5111,
Tektronix Inc, USA) fitted with a dual trace amplifier (5A18N, Tecktronix Inc, USA)
and time base amplifier (5BION,Tecktronix Inc, USA) (Figure 12). The sinusoidal
pump was constructed in the Faculty of Veterinary Medicine Engineering Workshop.
The two ports of the pneumotachograph and the oesophageal balloon and airway
catheter were separately phase matched. With the pneumotachograph closed at one
end, a sinusoidal pressure signal, generated by volume displacement with the
sinusoidal pump, was introduced into the other opening. The output from the
pneumotachographs transducer was passed through one channel of the oscilloscope.
With equally balanced ports and no phase shift in the signals, no flow signal should
be present. Lengthening the tube to the leading port or narrowing the tube using a
clamp would adjust its time constant bringing the ports back into phase. With the
F100L pneumotachograph phase matching was achieved simply by using equal
lengths of the same tubing connected to both ports. Using similar methods the
oesophageal balloon and airway catheter were also phase matched.
The output signals from the pneumotachograph and oesophageal balloon catheter
were then phase matched. With one side of the pneumotachograph sealed, the other
side and the balloon catheter was exposed to a sinusoidal pressure wave in a sealed
container. Transducer output from the pneumotachograph and the oesophageal
balloon were displayed on two channels of the oscilloscope. Phase matching is
indicated by a linear relationship, which does not change with frequency while phase
shift is represented by an open loop (Lissajous Pattern) (Figure 13). Narrowing the
tubing from the leading system again corrects the phase shift and closes the loop on
the oscilloscope. By using transducers of the same manufacture (UP Type, Pioden
Figure 12. Equipment required for phase matching. The output signals of the differential pressure
transducers are phase matched by exposing the measuring equipment to a sinusoidal pressure wave
form. The two ports of the pneumotachograph are balanced first, followed by the oesophageal and
airway catheters. The pneumotachograph and the pressure catheters are then phase matched with
each other to allow measurement of dynamic compliance and pulmonary resistance.
A-pneumotachograph with one port exposed to the sinusoidal pressure wave; B-pressure
container, C-sinusoidal pump; D-TJP type differential pressure transducer.
Figure 13. Phase matching and Lissajous patterns. Oscilloscope tracings of the Lissajous patterns
obtained from the phase matching of the pneumotachograph and oesophageal balloon catheter. A
closed pattern indicates the signals are in phase and can be achieved by changing the diameter or
lengthening the tubing to the differential pressure transducer The Lissajous patterns are displayed
on a two channel storage oscilloscope. A-open Lissajous pattern when the two pieces of
equipment are out of phase. B-closure of the Lissajous pattern after altering the time constant of
the leading equipment.
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Controls Ltd, UK) and tubing of similar length and internal diameter phase matching
of the two systems was achieved. The phase match of the systems were periodically
checked over the duration of the project and adjusted if necessary.
2.1.3.3. Respiratory Mechanics:
There are three mechanical properties of the respiratory system that govern the flow
of gas in and out of the system in response to a change in pressure (Young, 1990).
The pressure required to overcome the resistance of the respiratory system to airflow
consists of the flow resistive pressure, the pressure to overcome elastance and the
inertial pressure (Figure 14). The total resistance to flow is therfore a function of the
airway resistance, the tissue compliance (reciprocal of elastance) and the tissue
inertance.
p = p , + P + P •r r el r rs r in
Figure 14. Airflow pressure formula. The flow of gas in and out of the respiratory
system is governed by the pressure drop within the system, which is a function of the
forces opposing flow. These forces include the elastic (el), resistive (rs) and inertial
forces (in) of the system, and the total pressure required to overcome the resistance to
airflow is therefore the sum of the pressure components of these three factors.
The summed elastic and inertial pressure is called the reactance (Rodarte & Rehder,
1986). The inertance is the force opposing flow acceleration, and during breathing at
normal frequencies is negligible and can be ignored. However, as the respiratory
frequency increases the pressure loss due to inertance increases, decreasing the
reactance and hence the value of compliance that can be derived from the elastic
pressure. At respiratory rates above 1 Hz inertance becomes significant, but only at
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resonant frequency (typically 2-6Hz for larger mammals) does the inertial and elastic
pressures cancel each other making measurement of compliance impossible.
The resistance is primarily a function of the frictional forces between the airway walls
and the gas moving in the airways, although tissue resistance is also present (DuBois,
1966) and the resistive pressure is in phase with flow (Rodarte & Rehder, 1986).
Resistance can be calculated by a variety of means (see later), but in general is taken
as the ratio between pressure and flow at points of isovolume when the elastic
pressure is zero. The compliance is a measurement of the elasticity or rigidity of
airway and lung tissue and the elastic pressure component is in phase with volume
(Rodarte & Rehder, 1986; Young, 1990). At points of zero flow, flow-resistive
pressure is zero and so pressure is a combination of elastic and inertial pressure.
Consequently, compliance is measured when there is no gas flow in the airways. The
static value of compliance is a measure of the pressure required to maintain a volume
of air in the lungs and can be affected by non-airway factors such as pulmonary
vascular volume and resistance and abdominal compression of the thoracic
diaphragm. Dynamic compliance is the relationship of the change in volume and
pressure between points of zero flow (Mead & Whittenberger, 1953) and during
steady breathing can be taken as an indicator of resistance to airflow and patency in
the more peripheral airways (Figure 15).
p = (1/C)V + RV* + IV"
Figure 15. Formula illustrating the relationship between pressure (P), compliance (C),
resistance (R) and inertance (I). The reciprocal of compliance (1/C) is elastance and
relates pressure to volume, while resistance and inertance relate pressure to flow (V')
and flow acceleration (V") respectively.
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While the inertia of the respiratory system is negligible during quiet breathing (Figure
16), the introduction of an endotracheal tube into the airway can affect measured
values of resistance and compliance (Sullivan et al, 1976) (Figure 17). The larger the
tube caliber the lower the linear and non-linear resistance and hence the lower the
error.
X = j(wl - 1/wC) (1)
wl = 1/wC (2)
Figure 16. Formula for the reactance (X) of the respiratory system is shown (1) and is
defined as the sum of the compliance and inertance, which together are often referred
to as the imaginary part of the impedance (Z). j is a complex number (J2 = -1) and w
is 2 pi times the respiratory frequency. The magnitude of I and C will be determined
by the respiratory frequency and as the frequency increases the importance of I in
determining the magnitude of X increases. However, at a respiratory frequency
defined by formula (2) the inertial and elastic pressure cancel and the reactance is
zero. At this resonant frequency total pressure is equal to flow resistive pressure.
The introduction of an endotracheal tube has certain advantages, not least maintaining
airway patency if emergency resusitation is required during an experiment. With
respect to measurement of airway mechanics an endotracheal tube eliminates the
highly variable upper airway resistance component of total resistance, allowing closer
examination of the intrathoracic airways. The upper airways contribution, including
the mouth, glottis and extra-thoracic trachea, accounts for a significant component of
the pressure loss associated with flow (Ingram & Pedley, 1986) and as the glottis is
the major source of upper airway resistance and changes in glottic patency the major
source of airway resistance variability, it is sensible to by-pass this area
(Higenbottom, 1980).
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I = /L/pi r2
Figure 17. The inertial coefficent for an endotracheal tube is shown. I = inertia; L =
endotracheal tube length; / = mass density. Lengthening the tube increases inertia,
while widening decreases inertia.
Change in airflow resistance can alter the pressure-flow characteristics of the
respiratory system. An increase in transpulmonary pressure invariably denotes a
greater increase in expiratory resistance than inspiratory resistance (Campbell, 1958).
During quiet breathing the inspiratory resistance can be 15-20% less than the
expiratory resistance (Ferris et al, 1964). This is due to recruitment of the respiratory
muscle to overcome air-trapping caused by premature closing of the central airways
during early expiration. With very large increases in transpulmonary pressure
expiratory flow may cease altogether (Figure 18) effectively giving infinite resistance,
while there may only be a marginal change in inspiratory resistance.
2.1.3.4. Oesophageal Pressure Measurement:
The most commonly used method for measuring pleural surface pressure is by
estimation from oesophageal pressure using an oesophageal balloon, constructed from
a latex membrane sealed over a length of tubing, connected to a pressure transducer
(Milic-Emili, 1984). Changes in intrathoracic pressure cause similar changes in the
oesophagus (Milic-Emili & Petit, 1959) (Figure 19). The pressure recorded by the
oesophageal balloon tends to be more positive than true pleural pressure and any
difference in the absolute pressure between the oesophageal balloon and the pleural





Figure 18. Respiratory tracing from a normal sheep after intravenous administration of substance P.
This tracing illustrates the different effects of profound bronchoconstriction on inspiratory and
expiratory respiratory mechanics. While there is a marked reduction in inspiratory flow (Vi) and
tidal volume (VTi) the effect is greater on expiratory flow (Ve) and volume (VTe) such that there
is effective cessation of expiratory airflow. With the large increase in transpulmonary pressure (P)
the calculation of expiratory dynamic compliance and resistance is difficult, with values













Figure 19. Simultaneous tracings of oesophageal (upper) and pleural (lower) pressure in an
anaesthetised dog. It can be seen that the oesophageal pressure is more positive than pleural
pressure, but adequately parallels the changes in pleural pressure. When the volume/pressure
characteristics of the oesophageal balloon catheter system are changed, there is an alteration in the
magnitude of the oesophageal pressure measured. This change is caused by altering the volume of
air in the balloon, which not only changes the volume variation/pressure variation of the measuring
equipment but also the oesophageal wall elastance. Maintaining balloon volume at 0.1-0.15 ml/kg
body weight reduces this source of error. (Modified from Milic-Emili & Petit, 1959).
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balloon catheter system (Milic-Emili & Petit, 1959). Furthermore, there seem to be
individual variations in the manner in which oesophageal pressure reflects pleural
pressure and the ability of the oesophageal pressure change to parallel the change in
pleural presure (Cherniack et al, 1955). In order to transmit pressure to the transducer
the balloon must contain air, but this should be limited to a volume that does not
stretch the balloon membrane. Balloon volumes close to 0.1 ml/kg body weight do not
affect oesophageal elastance and are ideal (Petit & Milic-Emili, 1958). Excessive
volumes will affect oesophageal wall mechanics which will further affect balloon
pressure. (Petit & Milic-Emili, 1958).
While the oesophageal balloon technique may be valid there are potential problems in
measuring oesophageal pressure in sheep. The ruminant oesophagus is a very
distensible and thin walled structure and contains striated muscle along its entire
length (Dyce et al, 1987). Its distensibility is necessary to allow eructation and
regurgitation of stomach gas and food contents. The oesophagus obtains its motor
innervation from the vagus. The pharyngeal branch of the vagus continues as the
oesophageal nerve and with the recurrent laryngeal nerve primarily innervates the
cranial portion of the oesophagus. The caudal oesophagus is innervated by the dorsal
oesophageal branch of the vagus nerve.
The inherent elastance of the oesophagus has been shown to affect the pressure
measured in dogs (Cherniack et al, 1955) and in sheep contraction of the caudal
thoracic oesophagus has been demonstrated in both light and deep planes of
anaesthesia (Hossain et al, 1988). Gastro-oesophageal reflux can also occur during
anaesthesia. Furthermore, there is a high pressure zone close to the gastro-
oesophageal junction in sheep oesophagus, and while the pressure in this zone is not
significantly affected by anaesthesia, in deep anaesthesia there can be fluctuations in
the basal tone in this region (Hossain et al, 1988). Consequently there can be
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alterations in the oesophageal pressure measurement at any time in anaesthetised
sheep, without a change in tidal volume or respiratory flow, resulting in marked
variation in the values of RL and Cdyn obtained (Figure 20). To overcome this
problem it is necessary to measure the bronchomotor response to exogenous agents in
terms of the percentage change in RL and Cdyn compared to the values immediately
prior to administration, rather than absolute values.
With respect to investigating the bronchomotor effects of neurokinins in anaesthetised
sheep, the potential effect of the neurokinins on oesophageal tone need to be
considered. Substance P immunoreactive nerve fibres have been identified in the
oesophagus of several species and exogenously administered SP contracts
oesophageal smooth muscle and potentiates the response to electrical field stimulation
(Leander et al, 1982). Furthermore, both VIP and CGRP have been shown to relax the
lower oesophageal sphincter (Rattan et al, 1988; Yamashita et al, 1992). Therefore,
using oesophageal pressure measurement as an indicator of pleural pressure may be
complicated when administering tachykinins. This particular problem was noted in
several animals in this study, where there appeared to be relaxation of the distal
portion of the oesophagus with gastro-oesophageal reflux of stomach contents (Figure
21). With right cephalic vein administration of SP oesophageal relaxation tended to
occur after peak changes in resistance had occured and so did not adversely affect
measurements. However, with administration into the left side of the heart
oesophageal effects occured more rapidly. This will be discussed in more detail in
chapter 3.
Position of the animal is important. In man the pressure measured by an oesophageal
balloon is elevated in the supine position, due to compression of the oesophagus by
mediastinal contents, and a better estimate of pleural pressure is achieved in the












Figure 20. Spontaneous alteration in transpulmonary pressure (P) recorded with an oesophageal
balloon in an anaesthetised sheep. There is a large negative pressure spike at the beginning of the
tracing associated with gastro-oesophageal reflux and a subsequent change in the pressure baseline
and an increase in the pressure recorded. There are minimal changes in inspiratory and expiratory
flow and volume values (Vi, Ve, VTi and VTe respectively). The animal resumed steady
respiration shortly after this episode, but the pressure did not return to the original baseline.
Figure 21. Neurokinin B (NKB) and oesophageal relaxation. This tracing demonstrates the effect
of neurokinin B (NKB) on respiratory parameters in anaesthetised sheep. Three breaths are shown.
At the beginning of the middle breath (arrow) there is a deflection in the transpulmonary pressure
tracing (P) and movement of the pressure baseline consistent with oesophageal relaxation and/or
opening of the gastro-oesophageal junction. The following breath had the lowest flow (V) and tidal
volume (VT) of this run and was probably the breath at which maximal bronchoconstriction had
occured. This NKB effect on oesophageal pressure was reasonably consistent in the four sheep
examined and interfered with the accurate assessment of the bronchomotor effects of NKB.
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sheep were placed in the prone (sternal) position during measurement of oesophageal
pressure and it was noted that lateral recumbency elevated the oesophageal pressure
recorded. Positioning of the oesophageal balloon is also important. In the middle and
caudal parts of the oesophagus the difference between oesophageal pressue and mouth
pressure accurately reflects transpulmonary pressure, but this is not the case if the
oesophageal catheter is positioned more cranially (Mead & Milic-Emili, 1964).
2.1.3.5. Respiratory Parameters:
All inspiratory and expiratory respiratory parameters, including peak flow (V; 1/s),
peak transpulmonary pressure (P; cmH20), tidal volume (VT; ml), pressure at zero
flow and flow at mid inspiratory and mid expiratory tidal points (VTi & VTe) and
flow at isovolume points, and the derived parameters pulmonary resistance (RL;
cmH20/l/s) and dynamic compliance (Cdyn; ml/cmH20), and respiratory rate were
measured graphically.
There were several problems with the tidal volume measurements due to technical
limitations of the MX19 Physiological Recording System and its ability to integrate
flow. The integration hardware of the MX 19 involves a limit switch and an integrator.
The limit switch operates a relay at pre-selected points of the incoming waveform (eg
flow) to pass required segments of the waveform to the integrator. Using the zero
limit mode of the limit switch the integrator will integrate the inspiratory flow curve
(VI), calculating inspiratory tidal volume, and re-zero the pen as flow approachs zero
ready to integrate the expiratory part of the flow curve (VE). However, during quiet
breathing, the rate of change of flow with time is greater for inspiration than
expiration, such that a greater part of the VE curve is close to the flow rate
immediately preceding the end-flow point. The integrator has difficulty in detecting
this "low" flow and fails to adequately integrate the entire flow curve. Consequently
the inspiratory volume is greater than the expiratory volume. When the rate of change
Figure 22. The ability of the Devices integrator to accurately measure the expiratory tidal volume
during rapid breathing is shown. When there is no end-expiratory pause and end expiratory flow is
high the integrator successfully calculates expiratory volume close to inspiratory volume. P -
transpulmonary pressure; Vi and Ve - inspiratory and expiratory flow; VTi and VTe - inspiratory
and expiratory tidal volume. The respiratory rate in this tracing was approximately 60 breaths per
minute.
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of flow is similar for both inspiratory and expiratory curves, such as in tachypnoea
when there is no end-expiratory pause, the inspiratory and expiratory volumes are
similar (Figure 22). To overcome this problem both the inspiratory and expiratory
tidal volume were measured separately and averaged for the entire respiratory cycle.
Cdyn was calculated by dividing the pressure difference at points of zero flow (end-
inspiratory and end-expiratory flow points) by tidal volume (Figure 23). Compliance
was calculated for the inspiratory and expiratory parts of the respiratory cycle and
then averaged to give a Cdyn value for the entire respiratory cycle.
Respiratory resistance was calculated using two methods (Frank, Mead & Ferris,
1957; Wanner & Reinhart, 1978). Using an isovolume method the pressure difference
associated with the mid tidal (50%) point for VTi and VTe was divided by the
associated difference in flow between these isovolume points (RLiso) (Figure 24).
With this method the pressure difference is the flow resistive pressure. In the second
method the resistance for inspiration and expiration were calculated separately and
averaged to give a resistance value for the entire respiratory cycle. The mid-VTi and
VTe points were identified and the corresponding pressure and flow noted. The
pressure signal was corrected for that part of pressure due to tissue elasticity by
subtracting the pressure associated with compliance (pressure difference at points of
zero flow) (Figure 25). The RL value for inspiration and expiration were averaged to
give a RL value for the entire respiratory cycle.
The percentage change in pulmonary resistance, calculated by both methods, to
intravenous substance P (SP) was assessed by linear regression. For 15 separate
measurements there was a close positive correlation between RL and RLiso with an r
value of 0.662 (p<0.01) and a slope of 0.95 (Figure 26). However, the RL values were
more consistent than the RLiso values, with less variance, and had less tendency to
Figure 23. Calculation of dynamic compliance (Cdyn) (ml/cmF^O). Cdyn is calculated by
identifying the points of zero flow and dividing the tidal volume by the difference in transpulmonary
pressure at those zero flow points. Cdyn is conventionally calculated for the inspiratory part of the
respiratory cycle, but can also be estimated for the expiratory part. Inspiratory Cdyn (x-y)/(b-a);
Expiratory Cdyn (x'-y')/(b-ar). An "average" compliance can then be derived for the respiratory
cycle. The tracings in this figure and figures 24 and 25 are read from right to left
Figure 24. Calculation of pulmonary resistance using the isovolume method (RLiso). The pressure
difference (b-a) associated with isovolume points (typically mid-tidal (50%)) for inspiratory (x') and
expiratory (y') volume is calculated and divided by the associated difference in flow between these
isovolume points (x+y). In theory the mid-tidal points should be the same volume for both
inspiration and expiration. In practice, particularily when there is bronchoconstriction, the mid-tidal
point for inspiration may be greater than that for expiration. To overcome this problem alternative
procedures involve picking an equivalent volume point for both parts of the cycle (eg isovolume
point at 25% of VT) or selecting the mid-tidal point independently for inspiration and expiration
ignoring what the respective volumes are. VTe, VTi - expiratory and inspiratory tidal volume;
Ve,Vi - expiratory and inspiratory flow; P - transpulmonary pressure; BP - blood pressure.
Figure 25. Calculation of pulmonary resistance by averaging the resistance values for the
inspiratory and expiratory parts of the respiratory cycle (RL). The mid-tidal points in inspiration
(x') and expiration (y') are identified and the associated flows (x and y) measured. The
transpulmonary pressure change for these flow points are measured (ab and cd) from which is
subtracted the pressure due to tissue elastance (ac). The derived pressures are then divided by their
respective flows to give inspiratory (RLin) and expiratory (RLex) resistance (cmH^O/l/s) as
follows: RLin = (ab-ac)/x ; RLex = (cd-ac)y. RLin and RLex are added and an average RL for
the entire respiratory cycle calculated. VTe, VTi - expiratory and inspiratory tidal volume; Ve, Vi -
expiratory and inspiratory flow; P- transpulmonary pressure; BP - blood pressure.
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vere towards infinity at the maximal response to SP. The changes in RL and RLiso in
response to two doses of SP, administered 20 minutes apart, were assessed in 7 sheep
using the Spearman rank-order correlation test. The mean reduction in the calculated
resistance values between the two doses were 15 and 49% for RL and RLiso
measurements respectively. Furthermore, there was a close correlation between the
resistance values for the two doses calculated by the RL method (r=0.813; p<0.05)
but not with the RLiso method (r=0.098; p=0.7) (Figure 27). Therefore the RL
method of calculating pulmonary resistance was considered to be the more accurate
and reproducible method.
2.1.4. Arterial Blood Pressure Measurement:
A skin incision was made in the medial aspect of the right thigh and by blunt
dissection the femoral artery or an associated branch was identified. The artery was
tied off and an arterial catheter was introduced and tied in place. The skin incision
was either sutured closed with monofilament nylon or using surgical staples. Patency
of the catheter was maintained by periodic flushing with heparinised 0.15M NaCl
(250 iu/ml).
Blood pressure was measured with a presure transducer (4-327 I, Transamerica Deval,
USA) connected to the MX19 physiological recording system. The pressure signal
was used to measure heart rate, diastolic (D), systolic (S) and mean blood pressure
(MBP). Mean blood pressure was calculated as follows; MBP = D + 0.33(S-D).
The blood pressure transducer was calibrated with a mercury manometer (mmHg) at
the beginning of each day's experiments.
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Figure 26. The percentage change in pulmonary resistance calculated by an isovolume
method (RLiso) and a mid-tidal method (RL). Fifteen seperate measurements were used
from six sheep and the correlation between RL and RLiso was examined using the method of
least squares. There is a close positive correlation (r = 0.662; p<0.01) between the
resistance changes determined by the two methods.
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Figure 27. Comparison of the change in pulmonary resistance, calculated by the isovolume (RLiso)
and mid-tidal (RL) methods, after the same dose of substance P (SP) was administered
intravenously twice, 20 minutes apart, in seven sheep. There was a strong positive correlation
(r = 0.813) between the resistance value calculated by the RL method at the two dose times, but
not when the RLiso method was used (r = 0.098) (Spearmann Rank-Order Correlation Test).
Furthermore the mean reduction in calculated resistance values for the two doses was 15 and 49%
for RL and RLiso respectively.
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2.1.5. Intra Cardiac Catheterisation:
The effect of intra-cardiac administration of drugs was assessed in some sheep. After
anaesthesia the sheep was placed in dorsal recumbency and a mid-line cervical
incision made (Figure 28). The underlying muscle and connective tissue was
separated by blunt dissection and the external jugular vein and external carotid artery
identified. Estimate of the length of catheters required were obtained from external
body measurements and the catheters were pre-filled with heparinised saline. The
jugular vein was tied off cranially and a 60cm cardiac catheter, was introduced and
positioned in the right atrium. The position of the catheter was determined by
continuous monitoring of the jugular pressure. Entrance of the catheter into the right
atrium gave a slightly greater pressure fluctuation. The carotid artery was cannulated
in a similar manner, but without tying off. Positioning of the carotid catheter in the
left ventricle was more difficult to achieve but easier to confirm by monitoring pulse
pressure (Figure 29).
2.2. Drug Preparation and administration:
2.2.1. Preparation:
Neuropeptides were supplied in a lyophilised form and were immediately
reconstituted with phosphate buffered saline (PBS), and in the case of neurokinin B
with 10% ammonium hydroxide, on delivery. The peptides were initially diluted to a
concentration of 1 M and stored as 1 ml aliquots in Eppendoff tubes at -4092. on the
day of each experiment the peptides were further diluted to 100 umol/ml and stored
on ice.
All other drugs were made up on the day of each experiment and dissolved in PBS
immediately prior to administration.
Figure 28. Intracardiac catheterisation. Photograph of the surgical exposure of the external jugular
vein and carotid artery and placement of phosphate buffered saline catheters. The vessels have
been ligated proximally and the catheters guided into the right and left sides of the heart by
monitoring pressure in the catheters (see Figure 29). A-trachea; B-vagus nerve; C-carotid artery;
D-jugular vein.
Arterial Blood Pressure Left Ventricular Pressure
Figure 29. Blood pressure tracing from the right external carotid artery demonstrating introduction
of the carotid catheter into the left ventricle. Arterial blood pressure is shown on the left and the
scale markings are 100 and 120mmHg. On introducing the catheter into the left ventricle the end-
diastolic pressure is close to zero (bottom of tracing) with a large increase in systolic pressure
relevant to arterial pressure. The sensitivity for the left ventricular portion of the tracing is half that
of the arterial side.
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2.2.2. Administration:
Drugs were administered by three routes. In conventional studies of the tachykinin
peptides and antagonists administration was via the indwelling catheter in the right
fore leg. In studies looking at the effects of direct intra-cardiac injection of peptides
administration was via a catheter in the external jugular vein positioned in the right
atrium or a catheter in the external carotid artery positioned in the left ventricle. With
intracardiac administration the catheters were pre-loaded with the agent under
investigation and then flushed as required with phosphate buffered saline. In
inhalation studies in sheep with airway allergy to ascaris suum antigen and normal
sheep, agents were administered as nebulised aerosols and the details are outline in
chapter 4.
2.3. The Isolated Sheep Trachealis Muscle Preparation:
Tracheal samples were obtained from female sheep slaughtered at a local abattoir.
The trachea was removed from the sheep within 10 minutes of slaughter and
immediately immersed in "ice-cold" (4°C) oxygenated (95%02/5%C02! Krebs
solution (composition mmol/L; MgS04.7H£), 1.176; KH 41.175; KC1, 4.67;
NaCl, 118; NaHC03, 24; glucose, 11.6; CaCl2.2Hp, 2.52). The tissue was
transported to the laboratory in a sealed and insulated ice-box with an approximate
journey time of 20 minutes. The material was transferred to fresh Krebs solution at
room temperature and continuously oxygenated for 30 minutes. The trachea was
opened along its ventral border and sections were taken roughly equivalent to the
width of a cartilage ring. The trachealis muscle strip was prepared with 10mm of
cartilage attached at each end. One cartilage piece was pierced with a stainless steel
clip and tied to the end of a glass rod with cotton thread. The other cartilage piece was
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attached to a strain gauge transducer (Washington Transducer Type D, Palmer-
Bioscience) in the same manner. The preparation was mounted in a 20ml glass organ
bath containing Krebs solution at 37°C and continuously oxygenated. The transducer
was connected to a Washington pen recorder to allow measurement of isometric
tension (Figure 30). The tension of the strip could be altered using a
micromanipulator. The tissue was allowed to equilibrate for 60 minutes, with the
tension adjusted to approximately 5g, and the Krebs solution was changed every 15
minutes. Once the tissue had equilibrated the tension was set at approximately 2g for
experiments (Eyre, 1969).
Agents to be tested were added directly to the organ bath in volumes not greater than
0.1ml. Agents were either added to the organ bath as single doses (SD), each one
followed by wash-out with Krebs solution, or in a cumulative dose fashion at three
minute intervals, again followed by a wash-out. The contractile response to
1 uM of methacholine chloride was assessed in each tissue. Three consecutive
methacholine responses of similiar magnitude were obtained before a tissue was used
to assess the effect of test agents. The tissue response to test agents were expressed as
a percentage of the response to 1 uM methacholine.
The effect of substance P (SP) on the trachealis muscle preparation was assessed in
the presence of the neutral metalloendopeptidease inhibitor phosphoramidon.
Phosphoramidon (2 uM) was added to the organ bath 2 minutes before the peptide
and had been found in preliminary experiments to augment the contractile effect of
SP and markedly improve the quality of the response.
Kreb's
Reservoir
Figure 30. Measurement of the contractile response of the sheep trachealis muscle
preparation jn vitro . The tissue was mounted in a 20ml organ bath, in a water bath kept at
37°C, attached to a glass rod and a strain gauge pressure transducer. Changes in tension
were recorded on a Washington pen recorder amplifier. The Kreb's solution in the organ bath
could be changed using a reservoir tank and is aerated with a 95%02/5%C0o gas mixture.
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2.4. Statistical Analysis of Data:
The manner in which the data was analysed is outlined in each experimental chapter.
All data are presented as the mean and standard error of the mean (SEM) unless
otherwise stated. Statistical analysis involved the use of the one way analysis of
variance test (ANOVA) and the paired and unpaired t-tests, where appropriate.
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CHAPTER 3. CARDIOPULMONARY RESPONSE TO INTRAVENOUS
NEUROKININ NEUROPEPTIDES
3.1. Introduction:
The tachykinin neuropeptides are potent bronchoconstrictor and vasodilator agents
and their effects have been demonstrated in vivo and in isolated tissue preparations in
a variety of species including cat, rat, guinea pig, man, sheep and several others
(Nilsson et al, 1977; Andersson & Persson, 1977; Lundberg & Saria, 1982a; Joos et
al, 1987; Abrahams et al, 1991), but there are marked differences in the response to
the different members of this family of peptides and variations in the response of
different species.
With respect to the mammalian tachykinins NKA is, in general, the more potent
bronchoconstrictor (Martling et al, 1987). However, in the sheep and pig SP is more
potent than NKA (Martling et al, 1990; Abrahams et al, 1991; Haxhiu-Poskurica et al,
1992). In the guinea pig the bronchoconstrictor order of potency is NKA > NKB >
SP, with NKA being up to 40 times more potent than SP (Uchida et al, 1987; Saria et
al, 1988a), while in man the order of potency is NKA > SP > NKB (Naline et al,
1989).
In contrast to the order of potency for the tachykinins in contracting airway smooth
muscle SP has a more profound effect on diastolic blood pressure in man and
cutaneous vascular resistance and vascular permeability in both man and guinea pig
(Hua et al, 1984; Fuller et al, 1987; Evans et al, 1988), while in the dog NKA is a
more potent dilator of the tracheal vasculature than SP (Salonen et al, 1988).
However, direct application of SP to structures in the CNS causes a rise in blood
pressure and heart rate (Brattstrom & Seidenbecher, 1992) which may involve
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activation of serotonergic neurons (Gradin et al, 1992). In the heart itself SP
modulates the activity of vagal and sympathetic nerves and may be important in
controlling reflex cardiac effects associated with activation of cardiac afferent nerve
endings (Smith et al, 1992).
There may also be variations in the site of action of the tachykinins relevant to
vasodilation and broncho-constriction. SP increases vascular permeability in the
trachea and to a lesser extent at the hilus, but is ineffective in the peripheral lung of
rats (Sertl et al, 1988). In contrast SP and NKA contract smaller peripheral airways
more than the central airways (Frossard & Barnes, 1991) and SP is more potent than
NKA in guinea pig peripheral airways (Gerard, 1987) and capsaicin-induced
responses, including bronchoconstriction and plasma extravasation, are greater in the
lower than upper airways (Manzini et al, 1989a).
SP, NKA, and the additional sensory neuropeptide CGRP, are also potent pulmonary
arterial vasodilators and may be important in the neurogenic control of pulmonary
vascular diameter and vascular smooth muscle tone (Adnot et al, 1991). SP and NKA
are roughly equipotent in their ability to relax serotonin pre-contracted human
pulmonary arteries (Martling et al, 1987).
The aim of this study was to assess the cardiopulmonary effects of intravenous SP,
NKA and NKB in anaesthetised normal sheep.
3.2 Materials and Methods:
Dose-response curves for SP (n=l 1), NKA (n=9) and NKB (n=4) were obtained in 6
to 12 month old Suffolk cross female sheep, using the methods previously described.
In the case of SP and NKA each experiment began with a dose-response curve to
intravenous SP followed one hour later with a similar dose-response curve for NKA.
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In preliminary studies it was found that the airway response to SP and NKA was not
affected by the order in which the two peptides were administered, but as SP is more
rapidly metabolised than NKA (Shore & Drazen, 1989) it was felt that SP should be
administered prior to NKA. Dose-response curves to NKB and NKA were obtained
separately in different sheep. During each dose response curve at least three minutes
elapsed between peptide doses. Where there was marked bronchoconstriction at
higher dose levels the subsequent dose was not administered until transpulmonary
pressure had returned to baseline. After high doses forced lung inflation was
occasionally necessary to return transpulmonary pressure levels to baseline. Cdyn and
RL were measured 20 to 30s after peptide administration as this was when the most
pronounced airway changes occurred. Changes in respiratory parameters usually
began to return to baseline levels 40 to 50s after peptide administration. Respiratory
rate was also measured during this period. Values of Cdyn, RL and respiratory rate
were compared to those occurring immediately prior to each dose.
The respiratory responses to administration of a sub-maximal dose of SP into the
cephalic vein, left ventricle and right atrium, were compared in six sheep, in order to
determine if circulatory accessibility could affect the response to SP. All sheep were
approximately 6-12 moths old, half were close to 6 months (#s 25,26,27) and the
others (#s 32,33,34) close to 12 months. This apparently minor age difference may
have affected the results (see later). Preparation and placement of intracardiac
catheters has been described in chapter 2. However, in one sheep (#25) a catheter
could not be introduced into the right atrium. In addition to the effects of SP on
respiratory parameters, the time to the change in respiratory parameters and to
development of peak bronchoconstriction was also assessed.
Mean blood pressure (MBP) and heart rate (HR) changes were measured for SP (n=7)
and NKA (n=4), but not for NKB, 10 to 15 s after injection. Values were compared to
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those at the beginning of each dose-response curve as changes in MBP and HR, in
contrast to respiratory parameters, did not always return to baseline values between
doses.
Preliminary studies suggested that tachyphylaxis could develop to the bronchomotor
response to SP. It was found that subsequent responses to the SP doses eliciting a
maximal, or close to maximal, bronchoconstriction were markedly attenuated. The
time delay required to reverse tachyphylaxis to SP was investigated in one sheep and
a separate group of four sheep. Repeated doses of SP were administered at 20 minute
intervals four times in the four sheep.
Data are presented as the mean (+/-sem). The significance of any difference between
SP, NKA and NKB and between the peptides and baseline measurements were
determined using one-way analysis of variance or the t-test where appropriate. P<0.05
was taken as significant.
3.3 Results:
The respiratory effects of SP, NKA, and NKB and the cardiovascular effects of SP
and NKA were assessed in anaesthetised sheep. Eight sheep were assessed for both
SP and NKA and four sheep for SP and NKB. No sheep were assessed for both NKA
and NKB. There was no significant difference between baseline values of RL and
Cdyn in the sheep, prior to administration of SP, NKA or NKB (Table 5). All three
peptides caused a dose-dependent reduction in Cdyn with an order of potency of SP >
NKA > NKB (Figure 31). The maximal change in Cdyn with SP (-81% +/-4.8) and
NKA (-30% +/-7.1) occured at the highest dose level of 5 umol/kg, while the response
to NKB (-17.5% +/-4.78) reached a plateau at 1 umol/Kg. In direct contrast, SP had a
marked effect on RL, with a maximal change of +1020% (+/-154), while NKA (+35%





























































































Figure 31. Percentage decrease in dynamic compliance (Cdyn) after intravenous
administraion of substance P (SP) (n=l 1), neurokinin A (NKA) (n=9) and neurokinin B
(NKB) (n=4) (0.1-5 pmol/kg).
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between SP and NKA and NKB was statistically significantly different at doses of
0.5 umol/Kg or greater (P<0.05) (Figure 32).
Measuring the effect of NKB on bronchomotor tone was difficult as NKB appeared to
cause oesophageal relaxation. In certain instances there was a drop in transpulmonary
pressure just prior to the decline in flow and tidal volume that signals the onset of
bronchoconstriction. This change in transpulmonary pressure did not coincide with
the changes in flow and volume, and so was not due to suppression of respiratory
drive.
There were consistent differences in the response to SP administered by the three
different routes. The change in Cdyn and RL and the increase in peak transpulmonary
pressure were similar for the cephalic and right atrial routes and were consistently,
although not significantly, different from the left ventricular route (Table 6). The
changes in VI, VE and VT were roughly similar for the three routes. The time to onset
(To) of the respiratory response and the time to maximal bronchoconstriction (Tmax)
was shortest for the right atrial route (Figure 33), although the times were not
consistent. In two sheep from the younger group of animals (#s 26,27) in which right
atrial injection was possible, the response started within 2s of administration. In the
older sheep (#s 32,34,35) the bronchomotor response to SP was less than in the
younger animals and the onset of response was more rapid for left ventricular (8s +/-
2) than right atrial (11.8s +/-0.57) administration as was the time to maximal
bronchoconstriction (17.9s +/-0.17 vs 26.5s +/-2.74) (Table 7).
There was a dose-dependent reduction in respiratory rate with SP and NKA, but not
with NKB, and this was significantly different from baseline values at doses of 0.7
umol/Kg or greater (P<0.05) (Figure 34). NKA had a more marked effect on
respiratory rate than SP but the difference was not significant.
Figure 32. Percentage increase in pulmonary resistance after intravenous administration of












































































































Figure 33. The time (seconds) to the onset (To) of the respiratory response and the time to
maximal bronchoconstriction (Tmax) after administration of substance P (SP) via the right cephalic
vein (CV), the right atrium (RA) and the left ventricle (LV) in normal sheep (n=6). While the
response times were faster with right atrial injection, and approached significance (t-test; p=0.07)
the times were not consistent and there were differences between individuals that could be




















































































































Figure 34. The effect of substance P (0.1-5 jimol/kg) (SP, n=10), neurokinin A (NKA; n=7) and
neurokinin B (NKB; n=4) on respiratory rate in anaesthetised sheep. Both SP and NKA had similar
effects on respiratory rate which were statistically significantly different from baseline (ANOVA;
** P<0.01). NKB had no effect on basal respiratory rate.
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SP caused a dose-dependent reduction in MBP while NKA caused a marginal
increase (Figure 35). With both peptides, changes in MBP were due to changes in
both systolic and diastolic pressures (Figure 36). The change in MBP with SP was
significantly different from baseline at doses of 1 umol/Kg or greater.
In the tachyphylaxis study the effect of a near to maximal dose of SP (0.3umol/kg)
was assessed sequentially at zero, 5, 25, 30, and 50 minutes (two five minutes and two
20 minute intervals) in one sheep (#19) and repeated doses of SP at 20 minute
intervals were assessed in four sheep. In sheep #19 there was marked reduction in the
response to SP when only five minutes were allowed between doses, but no
attenuation with the 20 minute intervals (Table 8). In the four sheep group there was
minor reduction (88% of the first dose) in Cdyn with the second dose, but the
subsequent 3rd and 4th doses were greater than the first. All the RL readings were
greater than the first, but this was not statistically significant (Figure 38). This study
suggested the optimal inter-dose interval for sub-maximal doses of SP is
approximately 20 minutes.
3.4. Discussion:
This study demonstrates that SP is a potent bronchoconstrictor agent in the sheep and
has a marked effect on both central (RL) and peripheral (Cdyn) bronchomotor tone.
NKA has some effect on Cdyn and is more potent in this respect than NKB, but both
NKA and NKB have little or no effect on RL. These results compare with inhalation
studies where SP, in allergic sheep pretreated with the neutral endopeptidase inhibitor
thiophan, is a more potent bronchoconstrictor than NKA (Abraham et al, 1991; see
chapter 4). However, the bronchoconstrictor effect of SP in allergic sheep is only
modest and is far less than that achieved with bradykinin. The effect of NKB, or
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Figure 35. The Effect of substance P (SP) and neurokinin A (NKA; n=4) (0.1-5 jimol/kg) on mean
blood pressure (MBP) in anaesthetised sheep. SP caused a dose-dependent reduction in MBP,


















Figure 36. The effect of substance P (SP) on arterial blood pressure (BP, mmHg; upper tracing).
SP caused a decrease in both diastolic (D) and systolic (S) blood pressure approximately 15
seconds after injection into the right cephalic vein. The fall in BP was maximal 29 seconds after
injection and coincided with the peak of bronchoconstriction (not shown) and the change in S/D
was from a pre SP level of 145/120 mmHg to 120/105. After a further 26 seconds BP returned to
pre SP levels. Note the respiratory modulation of the BP tracing. Lower tracing is transpulmonary
pressure.











Table 8. The effect of repeated intravenous substance P (SP) (0.3|imotykg) on dynamic
compliance (Cdyn) and pulmonary resistance (RL) in sheep #19. The SP dose was
administered twice at 5 minutes intervals and twice at 20 minute intervals. At 5 minute
intervals there was complete loss of the response to SP, and this loss was reversed if doses
were spaced 20 minutes apart (see also Figure 38).
Figure 37. Investigation of the tachyphylaxis to the substance P (SP) bronchomotor response. In
preliminary work it had been noted that there was a reduction in the bronchomotor response to SP
if doses were administered close to each other (ie < 5 min apart). Therefore the response to
repeated doses of SP was assessed in anaesthetised sheeep (n=4). Dose-response curves for SP
were obtained and the dose giving approximately 50-80% of the maximal bronchoconstriction was
determined. This dose was then administered four times (1,2,3 & 4) at 20 minute intervals. There
was no significant alteration in the change in dynamic compliance (Cdyn) and pulmonary resistance
(RL) associated with SP, but there was a marginal increase in response over time. It was concluded
that the optimal time interval for repeated administration of sub-maximal doses of SP was around
20 minutes.
75
The bronchoconstrictor order of potency for SP and NKA in sheep contrasts with that
reported in most other species, while the low potency of NKB agrees with other
studies. NKA is more potent than SP in rats (Joos et al, 1988), in guinea-pigs (Hua et
al, 1984; Uchida et al, 1987) and in isolated airway preparations in man (Advenier et
al, 1987; Naline et al, 1989; Frossard & Barnes, 1991). In both asthmatic and normal
humans inhaled and infused SP has variable effects on bronchomotor tone (Joos et al,
1987; Evans et al, 1988; Crimini et al 1988a,b, 1990), while NKA is an effective
bronchoconstrictor agent in asthmatic human subjects (Joos et al, 1987). However, in
young and adult pigs SP is a more potent bronchoconstrictor than NKA (Martling et
al, 1987; Haxhiu-Poskurica et al, 1992). The apparent reduction in oesophageal
pressure with NKB contrasts with the contractile effect of SP demonstrated in guinea-
pigs, cats, and pigs (Leander et al, 1982), and the effect of this oesophageal response
on the transpulmonary pressure measurements achieved with SP and NKA is not
known.
The cardiovascular effects of SP and NKA (NKB was not assessed) could indirectly
affect bronchomotor tone through arterial baroreceptor reflexes. Baroreceptor
activation results in reflex inhibition of respiration and bronchodilation (Grunstein et
al, 1975). The marginal pressor response with NKA may have activated this reflex,
but this is unlikely. While SP is known to activate carotid body and peripheral
chemoreceptors, activation of chemoreceptors by arterial hypoxaemia will cause
bronchoconstriction and this could have augmented the bronchoconstriction caused by
SP. However, blood gas concentrations were not monitored during the experiments.
The effect of the tachykinins on pulmonary vascular tone was also not assessed. The
differential effect of NKA on Cdyn, while suggesting a preferential constriction and
closure of peripheral airways, possibly due to pulmonary vascular congestion and
consequent alveolar collapse, would suggest the Cdyn change with SP is a
combination of pulmonary vascular changes and peripheral airway smooth muscle
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effects. Indeed, SP and CGRP, which are often co-localised in sensory nerves, reduce
the pressor response of the pulmonary artery to infused prostaglandinF2 alpha
(PGF2a) in pigs (Adnot et al, 1991). While SP is a more potent pulmonary arterial
vasodilator than CGRP, the effect is at low (<50pmol/min) infusion rates. However, at
high infusion rates (lOOOpmol/min), in vessels that are not pre-contracted with
PGF2a, SP causes an increase in pulmonary arterial pressure, decrease in systemic
arterial pressure and a concurrent reduction in Cdyn. While these changes are
concomitant, Adnot and co-workers (1991) suggest the change in dynamic
compliance causes the increase in pulmonary vascular resistance. In the rabbit
isolated pulmonary artery preparation (Tanaka & Grunstein, 1985) the effect of SP is
also dependent on the resting arterial tone, causing dilation in pre-contracted vessels
and contraction in relaxed arterial stips. Nevertheless, Frossard & Barnes (1991) have
recently demonstrated that both SP and NKA have a greater contractile effect on
peripheral (non-cartilaginous bronchi) airways compared to central large
(cartilaginous segmental bronchi) airways and there may be a functional difference
between the central and peripheral parts of the respiratory tract.
The reduction in mean blood pressure (MBP) with intravenous SP is in accord with
previous reports from other species including man (Hua et al, 1984; Fuller et al, 1987;
Goel & Biggs, 1987; Joos et al, 1988; Haxhiu-Poskurica et al, 1992) indicating that
SP is a potent vasodilator. However, Bayorh & Feuerstein (1985) have reported a
pressor response with very low doses of SP (0.7-7 nmol/kg) in the pithed rat and
potentiation of the pressor response with sympathetic stimulation. At higher doses
(700nmol/kg) SP tended to inhibit the pressor response to sympathetic stimulation. In
sheep SP is also a more potent vasodilator than NKA which agrees with findings in
man (Evans et al, 1988), rats (Maggi et al, 1985; Couture et al, 1989) and guinea-pigs
(Ezra et al, 1986). Joos et al (1988) have speculated that the reduction in Cdyn with
SP may be secondary to pulmonary vasodilation, but the vasodilator effect of SP on
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pulmonary arteries, as discussed earlier, only occurs in pre-contracted vessels (Tanaka
& Grunstein, 1985; Adnot et al, 1991). NKA can cause mild systemic
vasoconstriction in sheep and, while the effects on pulmonary arteries are not known,
it would appear that the reduction in Cdyn can occur without a concurrent reduction
in blood pressure. Neither peptide had a significant or consistent effect on heart rate.
In preliminary studies tachyphylaxis to the bronchomotor response to SP, but not the
cardio-vascular effects, occured at high doses. By separating doses with an interval of
at least 15 minutes the problem, of tachyphylaxis can be avoided, although this was
not necessary at the lower end of the dose range. In guinea-pigs there is an unusual
enhancement to repeated doses with rapid intravenous administration of SP (Shore &
Drazen, 1989) which is possibly due to cyclooxygenase products of arachidonic acid
metabolism, and Goel and Biggs (1987) did not find tachyphylaxis with SP,
physalaemin or eledoisin in guinea pigs. However, Haxhiu-Poskurica etal (1992),
working with the pig suggest a 10 minute interval between peptide doses and 30
minute pause between dose-response curves for different peptides to avoid problems
of tachyphylaxis.
While SP had a more marked effect on bronchomotor tone when administered into the
systemic venous and pulmonary arterial circulation as compared to the systemic
arterial circulation, the differences were not statistically significant. However, the
possible differences in response between sheep of different ages need to be assessed
further and it could be that in young sheep (see Chapter 5) the increased
bronchomotor response to SP is a function of accessibility to larger numbers of
neurokinin receptors through the pulmonary circulation. Left ventricular
administration of SP still caused a significant bronchoconstriction and it must be
presumed that airway neurokinin receptors can be accessed from both the pulmonary
and systemic circulation. The close anatomical relationship and extensive
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anastomoses between the pulmonary and bronchial circulations make it possible for
agents to come in contact with receptors from either side (SanfAmbrogio &
Sant'Ambrogio, 1982; Butler, 1991).
This circulatory accessibility characteristic of the response to SP is analogous to the
different populations of C-fibre afferent receptors described in the dog and cat
(Coleridge & Coleridge, 1984) that are separately accessible from both the pulmonary
and bronchial circulations. In the rabbit an additional group of pulmonary-bronchial
receptors, accessible from both sides of the circulation, have been described (Russell
& Trenchard, 1979), but there is no information on the C-fibre receptor sub-types in
the sheep respiratory system. The pulmonary C-fibre endings in the dog are
stimulated 0.9-3.Is (mean 2.1s) after injection of capsaicin into the right atrium
(Coleridge & Coleridge, 1977a) which is similar to the onset of changes in respiratory
parameters noted in two sheep in the present study. The bronchial C-fibre endings are
accessible from the pulmonary and systemic circulations, but only after a longer
period after injection (Coleridge & Coleridge, 1984). However, only right atrial
injection of capsaicin causes reflex broncho-constriction in the dog (Russell & Lai-
Fook, 1979) and left ventricular injection has no affect on airway calibre.
Nevertheless, these temporal differences in response to SP by different routes in the
sheep suggest the possible involvement of pulmonary afferent receptors in the
response to SP and should be investigated further.
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CHAPTER 4. SUBSTANCE P AND NEUROKININ A IN ALLERGIC SHEEP
4.1. Introduction:
The bronchomotor effects of SP and other neurokinins have suggested a possible role
for these neuropeptides in the aetiopathogenesis of airway hypersensitivity disorders,
such as asthma in man, and there is considerable interest in the relative effects of the
different neurokinins on hyper-reactive airways in man and animals (Barnes, 1986).
Compared to normal human subjects atopic patients with asthma and rhinitis have
higher concentrations of SP and enkephalin (ENK) in bronchoalveolar lavage
samples, and furthermore there is an increase in SP and ENK after allergen challenge
in atopic individuals (Nieber et al, 1992). In asthmatic human subjects there are
conflicting reports on the effect of inhaled SP on bronchomotor tone (Fuller et al,
1987b; Crimini et al, 1988a) and in general NKA appears to be the more potent
neurokinin (Joos et al, 1987). However, in sheep with an airway allergy to Ascaris
suum antigen SP and NKA appeared to be ineffective in causing bronchoconstriction
(Abraham et al, 1991) and although the response to SP can be enhanced by the neutral
metallo-endopeptidase enzyme inhibitor L-thiorphan the effect of enzyme inhibition
on the relative potencies of SP and NKA was not assessed. SP has been demonstrated
in pulmonary oedema fluid of sheep with experimental adult respiratory distress
syndrome, and generation of the peptide is increased by airway inflammation
(Espiritu et al, 1992). However, SP is found inconsistently in the airways of normal
adult sheep.
The conscious sheep Ascaris suum airway allergy model was developed in the late
1970s by Wanner and co-workers at the Department of Medicine, Mount Sinai
Medical Centre, Miami, USA. The production of this model initially involved
recognising sheep with cutaneous reactivity to ascaris suum antigen and then actively
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sensitizing the airways of these animals to ascaris suum by either biweekly
intramuscular injections for up to 20 weeks (Wanner & Reinhart, 1978) or twice
monthly inhalations of antigen for up to 8 weeks (Wanner et al, 1979). However, this
sensitisation procedure is laborious and it was discovered that a proportion of sheep
already have a naturally acquired airway sensitivity to Ascaris suum and will
bronchoconstrict if they inhale the antigen (WM Abrahams, per. comm.), and they
also have an exaggerated response to carbachol and methacholine compared to
normal sheep. This obviates the need for a sensitisation protocol.
The sheep airway allergy model of asthma has attracted a great deal of interest
because detailed measurements of pulmonary mechanics can be made in the
conscious animal and there are close similarities between this model and human
asthma. Unlike other experimental asthma models the sheep develops lung
hyperinflation in response to antigen (Wanner & Reinhart, 1978; Wanner et al, 1979)
which is a common clinical feature of asthma in man. In addition, some allergic sheep
develop both an early (immediate) and late (6-8 hours post challenge) pulmonary
response to inhaled allergens (Abraham et al, 1983). These early and late phase
responses can both be blocked by nedocromil sodium, but only the late response can
be blocked by methylprednisolone. This again is very similar to the therapeutic
response seen in some asthmatic human subjects. Because of these close functional
similarities between sheep and man it is important to know if the sheep airway asthma
model shows a similar response to the neurokinins as that reported in human subjects.
Therefore, the aim of this study was to assess the relative potencies of inhaled SP and
NKA on pulmonary mechanics in a recognised model of airway allergy in sheep and
to detemine if it was similar to that reported in normal sheep (Chapter 3), in other
animal models of asthma and in human asthma.
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4.2. Materials and Methods:
All work was carried out in the Department of Research Pulmonary Unit at the Mount
Sinai Medical Centre (MSMC), Miami, Florida, USA, in collaboration with Drs. A.
Ahmed and W. Abraham.
4.2.1. Animals:
Texel-cross female sheep (n=5), aged approximately 12 to 18 months, and with a
mean body weight of 22.5 kg were used. All sheep were kept in a purpose built, air-
conditioned, sheep housing unit attached to the laboratory and fed on ad lib hay, water
and a commercial sheep cereal diet. The sheep were not fasted before experiments.
The sheep had a naturally acquired airway allergy to Ascaris suum antigen (Wanner
et al, 1979 ; Abraham et al, 1983, 1991) and hyper-responsiveness to inhaled
carbachol. The bronchomotor response to Ascaris suum antigen was immediate, with
no late phase response, and the sheep were classified as acute responders according to
MSMC laboratory criteria.
4.2.2. Animal Preparation:
Sheep were restrained in the prone position in a purpose built trolley (Figure 39). The
body was supported by a canvas sling and the head was taped onto a metal plate
attached to the trolley, holding it firmly in place. After topical anaesthesia of both
nostrils with 2% lidocaine solution, an oesophageal balloon catheter was introduced
through the right nostril and positioned in the caudal oesophagus. The catheter was
constructed from a 10cm rubber balloon sealed over a semi-rigid polyethylene tube
(2mm internal diameter) with 15 to 20 spirally arranged holes. A semi-rigid tube
(5mm internal diameter) was placed beside the oesophageal catheter to allow removal
of excess secretions using a vacuum pump. The sheep were nasally intubated with a
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Figure 38. Diagramatic illustration of the method for measuring respiratory parameters in
conscious sheep with a naturally acquired airway allergy to Ascaris suum antigen. The sheep
are restrained in a shopping trolley, with the head held firmly on a metal plate with tape. The
oesophageal balloon and airway catheters and the two ports of the heated pneumotachograph
(attached to a nasal endotracheal tube) are connected to two matched differential presure
transducers. The transducer outputs are amplified using Grass preamplifiers and the signal
then passed to an analog-to-digital converter board in an IBM compatible PC. The flow
signal is integrated to give tidal volume. The computer uses a pulmonary mechanics
programme to calculate pulmonary resistance and dynamic compliance from the flow, tidal
volume and pressure signals.
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threading it over a pre-positioned length of rigid polyethylene tubing or by using a
flexible fibreoptic endoscope. A lubricant gel containing lignocaine was applied to the
end of the endotracheal tube to assist placement and to suppress the cough reflex. The
oesophageal balloon and endotracheal tube were then taped to the sheep's head to
prevent movement.
The endotracheal tube was connected to a heated pneumotachograph (Fleisch, Dyna
Science Inc, Pa, USA). The pneumotachograph ports were attached to a differential
pressure transducer (type P-7D, Pace Engineering, Ca, USA) from which flow and
volume (integrated flow) were derived. The oesophageal balloon and a matched
polyethylene catheter, placed towards the tip of the endotracheal tube, were connected
to the ports of another differential pressure transducer (type P-7D, Pace Engineering,
Ca, USA), from which transpulmonary pressure was measured. The signals of
pressure and flow were amplified (type 7P1 pre-amplifier, Grass Instruments, Mass,
USA) and recorded on-line through an analog-to-digital converter board (PDP-11,
Digital Equipment, Maynard, Mass, USA) to an IBM compatible PC. Respiratory
parameters were calculated and analysed using an in-house developed programme
(MECHANIX, Mount Sinai Medical Centre). Pressure, flow and volume
measurements were calibrated at the beginning of each day's experiments. All
transducers, catheters and associated tubing were phase matched and there was no
phase shift between transpulmonary pressure and flow up to a frequency of 9Hz.
4.2.3. Measurement of Respiratory Parameters:
Respiratory paramaters, including respiratory resistance, dynamic compliance, tidal
volume and respiratory rate, were measured. Respiratory resistance (cmH20/l/s) was
calculated on a breath-by-breath basis using a mid-tidal volume method (Wanner &
Reinhart, 1978) dividing the pressure difference at the mid-tidal points for inspiration
and expiration by the associated difference in flow. Dynamic compliance
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(ml/cmH20) was calculated during the inspiratory part of the respiratory cycle by
dividing inspiratory tidal volume by the pressure difference at points of zero flow.
The procedure for measuring respiratory parameters was as follows. Excess rumenal
gases were first removed by compressing the abdomen. A suction tube was inserted
into the endotracheal tube and connected to a vacuum source to remove excess airway
secretions. The suction tube was removed and replaced by the airway catheter which
was attached to one port of the transpulmonary pressure transducer. The oesophageal
balloon catheter was attached to the other port, after inflating with 2ml of air. The
oesophageal suction tube was attached to a continuously running vacuum pump. The
pneumotachograph was attached to the endotracheal tube opening. Data were
collected on a breath-by-breath basis and the mean values of 10 to 20 breaths were
calculated. The MECHANIX programme allowed exclusion of breaths where there
was spontaneous swallowing, or breaths where there was excessively low (less than
0.5cmH2O/l/s) or excessively high (greater than 1 standard deviation from the mean)
resistance values. The results of several runs were combined using a GRAND
MEANS programme to give an overall mean value.
4.2.4. Aerosol Delivery:
Agents were delivered as aerosols via the endotracheal tube. The aerosol was
produced using a disposable medical nebulizer (Raindrop, Puritan-Bennett, Kan,
USA). The nebulizer was driven by compressed air at 20 psi and was connected to a
dosimeter system consisting of a solenoid valve. The nebulizer was connected to a
plastic T piece, one end of which was attached to the inspiratory port of a Harvard
respirator (Harvard Apparatus, Inc., Mass, USA) and the other end to the sheep
endotracheal tube. The pump delivered a tidal volume of 500ml at 20 breaths per
minute, which was tolerated by the sheep and has been shown to have no effect on
subsequent pulmonary mechanics measurements (Allegra et al, 1983). The aerosol
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produced by the Raindrop nebuliser has a mass median diameter of 3.6um (geometric
standard deviation, 1.9) as determined by an Andersen cascade impactor (Andersen
Inc, GA, USA). As the sheep passively allowed the pump to ventilate their lungs,
when disconnected they often did not revert to normal breathing for several minutes.
With respect to drug administration, it was not possible to measure lung mechanics
during the period immediately after cessation of drug administration.
4.2.5. Drug Administration:
The bronchomotor response to inhaled phosphate buffered saline (PBS), the metallo-
endopeptidase inhibitor L-thiorphan, and two different doses of SP and NKA were
assessed over a period of 5 days. Respiratory parameters were measured in the sheep
after inhalation of 20 breaths of PBS and then allowed to rest for at least 30 minutes.
They then inhaled 20 breaths of L-thiorphan (10 uM) and the bronchomotor response
was again assessed 10 minutes later. This was immediately followed on day 1 by 20
breaths of SP or NKA (0.6 mM) and the response measured within 2 minutes of
cessation of inhalation. The same doses of SP or NKA were administered in reverse
order on day 2. After a days rest the procedures were repeated on day 4 and 5 using
40 breath doses of PBS, SP and NKA.
4.2.6. Data Analysis:
The data was analysed by computer and the significance of any change relevant to
PBS control was determined by the paired t-test. p<0.05 was taken as statistically
significant.
4.3. Results:
The respiratory response to inhaled substance P (SP) and neurokinin A (NKA) was
assessed in five sheep at two different doses. Both peptides caused a dose-dependent
increased in bronchomotor tone, but SP was more potent than NKA. The data are
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shown in detail in Tables 9 and 10. Both peptides primarily affected RL rather than
Cdyn. The increase in RL with SP was significantly different from baseline
measurements and the response to inhaled PBS (p<0.01) (Figure 39). The decline in
Cdyn was only significantly different from PBS at the 40 breath dose (p<0.05)
(Figure 41). NKA significantly increased RL from baseline and PBS only at the 40
breath dose level (Figure 40) and had no significant effect on Cdyn (Figure 41).
Inhalation of the metallo-endopeptidase inhibitor L-thiorphan caused a minor, but
insignificant fall in resting bronchomotor tone, although a more marked increase in
Cdyn was note in one sheep (#1227) on two occasions. Neither peptide affected
respiratory rate.
4.4. Discussion:
SP is a more potent bronchoconstrictor than NKA in allergic sheep and this accords
with the findings in normal sheep. The peptides primarily affected RL and had little
effect on Cdyn suggesting their main site of action is in the central airways. This
however might not represent a functional finding, but merely reflects the deposition
of aerosolised peptide in the more central airways during inhalation. In normal sheep
SP is equally effective in reducing Cdyn as increasing RL when given intravenously.
This may be due to improved access to the peripheral airway smooth muscle through
the pulmonary circulation or, as mentioned earlier, due to changes in pulmonary
vascular resistance (Chapter 3).
Abrahams and others (1991) have previously reported the effects of SP and NKA, and
the non-tachykinin peptide bradykinin, on RL in the sheep allergy airway model.
Neither peptide affected RL values significantly, however in the presence of the
metallo-endopeptidase inhibitor L-thiorphan, SP significantly increased RL. The
effect of L-thiorphan pre-treatment on the response to NKA was not assessed.

















































































































































































































































































































































































































































































































































































































B8L PB8 THIOR 208P B8L PB8 THIOR 40SP
Figure 39. The effect of inhalation of 20 and 40 breaths of substance P (20SP & 40SP) on
pulmonary resistance (RL) in allergic sheep (n=5). Compared to baseline (BSL) and 20 or 40
breaths of phosphate buffered saline (PBS), SP caused a significant increase in RL at both doses (t-
test; p<0.01). THIOR-20 breaths of 10~5M L-thiorphan.
Figure 40. The effect of inhalation of 20 and 40 breaths of neurokinin A (20NKA &
40NKA) on pulmonary resistance (RL) in allergic sheep (n=5). Compared to baseline (BSL),
NKA significantly increased RL only at the 40 breath dose (t-test; p<0.05). PBS-20 or 40

















































20NKA 20SP 40NKA 40SP
Figure 41. The effect of inhalation of 20 and 40 breaths of neurokinin A (NKA) and
substance P (SP) on dynamic compliance (Cdyn) and pulmonary resistance (RL), relevant to
phosphate buffered saline control, in allergic sheep (n=5). NKA had no significant effect on
Cdyn at either dose, while SP significantly reduced Cdyn at the 40 breath dose (t-test;
p<0.05). For detail on pulmonary resistance see Figures 39 and 40.
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inhaled carbacol in allergic sheep and Tamura et al (1989) have demonstrated a
similar increase in responsiveness to methacholine after pre-treatment with NKA in
Japanese monkeys. A similar mechanism of enhanced bronchoreactivity has been
demonstrated in guinea pig airways (Hsiue et al, 1992), where capsaicin pre-treatment
enhances the subsequent response to both ACh and NKA. In contrast to SP,
bradykinin produces a significant and long lasting (up to 15 min) bronchoconstriction
in allergic sheep, which is significantly greater than that occurring in normal sheep.
The functional relevance of these differing effects of peptides in sheep airways is not
known. In allergic sheep the epithelial derived metallo-endopeptidase enzyme system
for the degradation of SP appears to be intact, which presumably would limit the role
of endogenously released SP in the bronchospasm and inflammation associated with
airway allergy. Loss of epithelium in airway inflammation might enable SP to act on
airway smooth muscle and the airway micro-vasculature. Of the tachykinins, SP
appears to be the more important for directly affecting bronchomotor tone in allergic
and normal sheep, while NKA may have a role in modifying the activity of other
spasmogenic agents.
The response to tachykinins in human asthma patients and other animal models of
asthma contrasts with allergic sheep and this may reflect a fundamental difference
between sheep and humans. However, in human asthma the relative importance of SP
and NKA in the aetiopathogenesis of the disease has not been decided. Inhaled NKA
is a potent bronchoconstrictor agent in asthmatic adult humans while SP appears to be
ineffective (Fuller et al, 1987; Joos et al, 1987) or causes only mild
bronchoconstriction in asthmatic patients. At infusion rates of 3.3pmol/kg/min SP
even causes significant bronchodilation (Fuller et al, 1987). Pre-treatment with
nedocromil sodium significantly reduces the response to NKA in man (Joos et al,
1989 a,b). However, Crimini et al (1988a,b; 1990) have demonstrated a reduction in
forced expiratory volume in one second (FEV1) with inhaled SP in moderate
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asthmatics, which again can be blocked by nedocromil sodium and the anticholinergic
agent ipratropium bromide, but not by the HI receptor antagonist astemizole. In
studies where SP was ineffective the patients were classified as mild asthmatics and
consequently, although individuals in all studies were asymptomatic, fundamental
differences between mild and moderate asthmatics, such as airway NEP content,
might exist. It is interesting to note that in asthmatic sheep suppression of NEP
activity by L-thiorphan was needed to achieve bronchoconstriction with SP (Abraham
et al, 1991). Furthermore, in piglets, NEP specifically ameliorates the airway response
to SP and appears to have no effect on the NKA response (Haxhiu-Poskurica et al,
1992).
Injected SP also causes bronchoconstriction in experimental guinea-pig asthma
models (Schreiber et al, 1988; Nagai et al, 1990) and has been shown to augment the
bronchomotor response to antigen and acetylcholine in one study (Nagai et al, 1990),
but the comparable effects of NKA have not been reported. In normal guinea-pigs
NKA is consistently more potent than SP. In the guinea-pig asthma model SP infusion
was also found to cause a reduction in respiratory rate, which agrees with the findings
in normal sheep, but there was no change in respiratory rate with SP in asthmatic
sheep.
NKA has been shown to increase airway responsiveness to carbachol in allergic sheep
(Abrahams et al, 1991) and to methacholine in Japanese monkeys (Tamura et al,
1989) and this may underlie its role in the pathogenesis of bronchoreactive illnesses in
man and animals. It would be interesting to know if neuropeptides that have minimal
or variable effects on bronchomotor tone in man, such as SP, could affect
responsiveness to other bronchoreactive agents. While the role of SP in asthma in
man is believed to be minor compared to NKA, there is still an overall increase in the
number and length of nerve fibres immunoreactive for SP in asthmatic subjects
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compared to normals (Ollerenshaw et al, 1991), while there is an absence of the
bronchodilating peptide VIP (Ollerenshaw et al, 1989). Furthermore, an increased
cutaneous reactivity to SP, but not NKA, in asthma patients has been demonstrated
(Iwamoto et al, 1990), and while NKA is probably the more important neurokinin in
man, these findings support attributing a greater importance to SP in human asthma.
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CHAPTER 5. AGE-RELATED RESPIRATORY RESPONSES TO
SUBSTANCE P IN NORMAL SHEEP
5.1. Introduction:
In preliminary studies it was noted that the bronchomotor response to SP was greater
in young sheep in comparison with adults and that occasionally periods of apnoea
after SP administration occurred in some sheep. It was decided to investigate further
the extent of this difference between age groups.
While in most species, including sheep (see Chapter 3), SP is a potent
bronchoconstrictor and vasodilator there is evidence that SP and several other
neuropeptides may be involved in other aspects of respiration. SP, VIP and ENK have
been identified in the carotid bodies and are believed to be involved in baroreceptor
reflexes and in the chemoreceptor hypoxic ventilatory response (Scheibner et al,
1988; Smith et al, 1990). In normal adult man the main effect of exogenously
administered SP is on ventilation and not on bronchomotor tone (Fuller et al, 1987b;
Maxwell et al, 1990), although SP does affect airway smooth muscle in some
asthmatic subjects (Crimini et al, 1988). The bronchomotor and ventilatory responses
to SP also appear to change with age (Tanaka and Grunstein, 1990) and the increase
of the normal physiological hypoxia response coincides with an age-related increase
in carotid body glomus cell SP-like immunoreactivity (Scheibner et al, 1988).
5.2. Materials and Methods:
Experiments were carried out in 11 Suffolk cross and 4 Scottish Blackface female
sheep. The sheep weighed 30-60 Kg and were divided into four age groups; group 1,
4-6 months of age (n=3); group 2, 6-12 months (n=4); group 3, approximately 18
months; group 4 approximately 4 years (n=4). Group 4 were Scottish Blackface as
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these were the only aged sheep available from commercial sources.
All experimental methods, including instrumentation, drug delivery and data analysis,
were as described earlier (Chapter 2), except blood pressure was not measured. The
significance of any difference between groups was determined by comparing the
mean responses at each dose level using one way analysis of variance.
The respiratory effects of rapid intravenous injection of SP (0.01-().5umol/kg, group
1; 0.1-5umol/kg, groups 2,3 and 4) were assessed in each age group. Cdyn and RL
were measured 20-30 seconds after SP injection and respiratory rate was also
calculated during this 10 second period. The presence of apnoeic periods (s) was also
noted and included periods of complete cessation of respiration and/or concurrent
reduction in pressure and flow. Typically apnoea occured 25-30s after SP injection.
5.3. Results:
There was a dose-dependent decrease in Cdyn and increase in RL in all sheep and this
was most pronounced in the youngest age group (Figures 42 and 43). This group also
achieved a greater maximum bronchoconstriction compared to the other groups. The
changes in RL and Cdyn in groups 1 and 2 were significantly different from that in
groups 3 and 4, while the increase in RL in group 1 was significantly different from
that in group 2. Group 3 had a significantly greater decline in Cdyn than group 4.
There was a dose-dependent reduction in respiratory rate in all four groups (Figure
44). Groups 1 through 4 had mean basal respiratory rates of 30, 35 (+/-2.9), 36.2 (+/-
8) and 29 (+/-3.3) breaths per minute respectively and there was no statistically
significant difference in basal respiratory rates between groups. The decrease in
respiratory rate was similar for groups 1 and 4 and was significantly different from


















Figure 42. Percentage change in dynamic compliance (Cdyn) after intravenous
administration of substance P (0.01-5 |imol/kg) in four different age groups of sheep.
Group details are given in the text. The magnitude of the decline in Cdyn is age-related with
the most pronounced change in the youngest sheep (group 1; 4-6mths), and only minimal
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Figure 43. Percentage change in respiratory resistance (RL) after intravenous administration
of substance P (0.01-5 jimol/kg)in four different age groups of normal sheep. Group
details are given in detail in the text. As for the change in Cdyn (Figure 42) the magnitude
of the increase in RL was age-related with the most pronounced change in the youngest
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Figure 44. Percentage change in respiratory rate after intravenous administration of substance
P (SP) (0.01-5 jimol/kg) in four different age groups of normal sheep. Group details are
given in the text. The youngest sheep and the oldest sheep (groups 1 (4-6mths) and 4
( >4yrs) respectively) had the most pronounced reduction in respiratory rate, while the
reduction in respiratory rate was less pronounced in the young adult sheep (groups 2 (6-
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Figure -15. The development of apnoea after intravenous administration of substance P (SP)
(0.01-5 |imol/kg) in four different age groups of sheep. Group details are given in the text.
The two oldest groups (group3 (12-18mths) and 4 (>4yrs)) demonstrated periods of
apnoea after SP administration, which were most consistent in the oldest group (group 4).
At no time did sheep in the youngest group (group 1; 4-6mths) demonstrate apnoea.
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were dose dependent. However, one sheep in group 4 did not develop apnoea, but had
the most pronounced bronchoconstrictor response for that group. At no time did group
1 sheep demonstrate apnoea, and in groups 2 and 3 apnoeic periods were minor or
inconsistent.
5.4. Discussion:
Several studies of the ontogeny of neuropeptide innervation and expression in
different mammalian organ systems and different species have been previously
reported. Ontogenic changes in SP concentrations have been demonstrated in baboon
cerebral cortex (Beal et al, 1988), thoracolumbar spinal sympathetic preganglionic
nuclei in rats (Newton et al, 1988), in several areas of the rat central nervous system
(Diez-Guerra, et al, 1989; Sivam et al, 1991), chicken carotid bodies (Kameda, 1990)
and guinea-pig uterus (Aim et al 1988). In rat lung SP content is constant between 3
and 20 months of age (immature to senescent), but rises rapidly in aged rats (Amenta
et al, 1988). Developmental changes in NPY content and distribution have also been
demonstrated in mouse hypothalamus and adrenal glands (Chua et al, 1991), rat
superior cervical ganglia and perivascular nerve fibres (Dhital et al, 1988; Gurusinghe
et al, 1990) and Rhesus monkey neurohypophysis (McDonald et al, 1988). The ability
of SP to elicit certain types of slow potentials in the rat spinal cord is reduced and
eventually lost during maturation (Gibbs & Kendig, 1992). This suggests the
reduction in response to neuropeptides may be due to a loss of tissue sensitivity rather
than an overall reduction in the level of tissue peptides. The results from rats further
suggest that neuropeptides have an important role in developmental neurobiology.
Immunohistochemical data from man indicates there are fewer peptide-containing,
including SP, nerves in the lung of young adults compared to infants, children and
adolescents (Hislop et al, 1990), while there is an age related increase in NPY-like
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immunoreactivity, particularily in peri-arterial nerve fibres (Allen et al, 1989). SP has
also been demonstrated in human lung neuroendocrine cells (Gallego et al, 1990) with
SP-like immunoreactive cells being more numerous in foetal and infant than in adult
lung. Furthermore, Hislop and co-workers (1990) have noted an age-related increase
in the neural expression of immunoreactivity for the bronchodilating neuropeptide
VIP in human lung and have suggested that alteration in neural peptide content and/or
number of neuropeptide-containing nerve fibres may underlie the age-related change
in asthma symptoms seen in man. While changes in neuropeptide expression in
airway nerves may have a bearing on the bronchomotor response to these peptides, or
their involvement in respiratory disease, the ontogeny of neuropeptides suggests they
have a role in lung development (Johnson et al, 1988; Gallego et al, 1990; Rinaldi et
al, 1991).
In the present study it was demonstrated that SP is a potent bronchoconstrictor in
sheep, that the response decreases with age and that in aged sheep SP causes apnoea.
The effects of breed differences or the possible existence of subclinical respiratory
disease in the aged sheep on the results was not assessed. In organ bath studies with
isolated trachealis muscle preparation a similar lack of contractile response to SP in
aged sheep was found, and the details are given in chapter 6. SP is recognised as a
potent bronchoconstrictor in a variety of species, but it has little effect on
bronchomotor tone in normal adult human subjects where the predominant effect is
to increase ventilation and improve the hypoxic respiratory drive (Fuller and others,
1987b). This increased ventilatory response in man is due to a direct action of SP on
chemoreceptors in the carotid bodies or peripheral chemoreceptors with direct input
to the medullary respiratory centre (Maxwell et al, 1990). The demonstration of
neuropeptides, including SP, in the carotid body and in the carotid body-like laryngeal
paraganglia structures supports the theory that they are involved in the peripheral
control of respiration (Dahlqvist et al, 1992). However, SP is also believed to be
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involved in the pulmonary chemoreflex (Bezold-Jarisch Reflex). This is a complex
reflex involving a combination of bradycardia, systemic hypotension,
bronchoconstriction and apnoea followed by tachypnoea (Coleridge & Coleridge,
1984; Green et al, 1984). In experimental situations the pulmonary chemoreflex is
usually activated by agents such as phenylbiguanide, capsaicin, bradykinin and
several of the eicosanoids (Karczewski & Widdicombe, 1969; Kaufmann et al, 1980;
Coleridge & Coleridge, 1986). Activation of pulmonary C-fibre afferents by both SP
and capsaicin evokes rapid shallow breathing (Green et al,1984; Prabhakar et al,
1987) and in addition injection of capsaicin as a bolus into the right atrium, but not
the systemic arterial circulation, can also result in apnoea (Green and others, 1984).
Therefore, it is possible that the rapid injection of SP into the systemic venous
circulation may activate this apnoeic part of the pulmonary chemoreflex. This part of
the reflex may be easier to activate in adult sheep than in lambs and may constitute
the primary response of the adult airway to SP. It has been shown that direct
application of SP to the central nervous system stimulates respiration. However, adult
human sufferers of sleep apnoea syndrome have elevated SP levels in their cerebro¬
spinal fluid (Gislason et al, 1992), and a role for SP in the central and peripheral
control of respiration can be hypothesised.
The change with age of the sheep SP response contrasts with other species as well
as with the reaction of sheep to other spasmogenic agents. Sheep have been shown to
demonstrate an age-related increase in the bronchomotor response to both histamine
and carbachol (Saunders et al, 1984). In rabbits the neuromodulatory action of SP on
cholinergic neurotransmission and control of bronchomotor tone increases with age
(Tanaka and Grunstein, 1990), but this is due to an increase in intrinsic
bronchoreactivity rather than an increase in the contractile response to SP itself. In the
cat carotid body there is an age-related increase in SP-like immunoreactivity
coiniciding with development of the hypoxic ventilatory response (Scheibner et al,
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1988), while there is an age-related decrease in SP-containing nerves in normal
human airways (Hislop et al, 1990). The change in human neuronal expression of
peptides and the sheep bronchomotor response to SP roughly coincides with the onset
of maturity.
The apnoeic response in aged sheep, as mentioned earlier, is probably due to
activation of pulmonary C-fibre afferent nerve endings, and while the functional
significance of these findings is not known, these preliminary results suggest a limited
role for SP in the control of bronchomotor tone in adult sheep. The possibility that SP
may be stimulating lung afferent receptors also needs to be considered with respect to
the bronchomotor response to SP and this subject is discussed in detail in chapter 7.
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CHAPTER 6. PHARMACOLOGICAL ANTAGONISM OF THE
BRONCHOMOTOR EFFECTS OF SUBSTANCE P IN NORMAL SHEEP
AIRWAYS
6.1. Introduction:
The exact mode of action of SP and other neurokinins is not completely understood
and there appear to be definite species differences (Barnes, 1989). In man and guinea
pig the bronchomotor response to SP is believed to be largely direct (Palmer et al,
1987), involving interaction with specific neurokinin receptors on airway smooth
muscle. However, there are numerous studies in other species demonstrating
pharmacological antagonism (using non-neurokinin antagonists) of the
bronchoconstriction caused by the neurokinins, particularily cholinergic mediated
events in the rabbit, rat and pig (Tanaka & Grunstein, 1986; Joos et al, 1988; Hashiu-
Poskurica et al, 1992). Furthermore, the effect of SP in asthmatic human subjects can
be antagonised by nedocromil sodium, sodium cromoglycate or the muscarinic
antagonist atropinic agent ipratroprium bromide (Crimini et al, 1988a,b; Crimini et al,
1990; Joos et al, 1989a,b). The close anatomical association that has been
demonstrated between cholinergic and peptidergic neural elements in various tissues
would suggest a functional interaction (Martone et al, 1992; Schmidt et al, 1992) and
this may also be applicable to the respiratory system. More likely than not, the event
that initiates bronchconstriction with SP involves a specific NK-1 receptor, although
the exact location of this receptor in airways and its association with other neural and
non-neural elements in the airways is not yet completely understood (Barnes, 1991).
The aim of this series of experiments was to evaluate the effects of a variety of
pharmacological agents and specific neurokinin antagonists on the bronchomotor
response to SP in normal sheep.
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6.2. Materials and Methods:
Experiments were carried out in vivo using anaesthetised sheep and in vitro using an
isolated trachealis muscle preparation. The experimental details are outlined in
Chapter 2.
6.2.1. Pharmacological Antagonism of Substance P in
Anaesthetised Sheep:
Experiments were carried out in Suffolk-cross sheep, 6-12 months old, as described
earlier. A dose response curve to intravenous SP was obtained for each sheep so that a
dose giving 50 to 80% (submaximal) of the maximal bronchoconstrictor response
could be determined. The effects of the general muscarinic antagonist atropine, the
ganglion blocker hexamethonium, the HI receptor antagonist chlorpheniramine, the
non-peptide NK-1 antagonist CP-96,345-1 ((+/-)-Cis-3(2-methoxy-benzylamino)-
quinuclidine-4) (Figure 46), the peptide neurokinin antagonist spantide ([D-Arg^D-
Trp7-9,Leu11]SP ) and nedocromil sodium (Figure 46) on the response to a
submaximal dose of SP was assessed. The decision to use a sub-maximal dose of SP
was due to the tachyphylaxis noted with repeated dose-response curves of SP, and the
ability to achieve reasonable repeatability of the response to sub-maximal doses at
suitable dose intervals. Further details are given in chapter 3.
Atropine (lmg/kg), hexamethonium (20mg/kg), chlorpheniramine (2mg/kg), CP-
96,345-1 (0.1 and 0.5mg/kg) and nedocromil sodium (0.1 and lmg/kg) were
administered as a single intravenous bolus injection, while spantide (lOug/kg/min)
was administered slowly using a continuous infusion pump (Re Cy Chrom, LBK-
Produkter, Sweden) connected to the cephalic intravenous catheter. All agents were
administered via the right cephalic vein at least 10 minutes after the last SP dose. The
subsequent SP dose was given 10 minutes after injection, or 10 minutes into the
NEDOCROMIL SODIUM
Figure 46. The chemical structure of the NK-1 antagonist CP 96, 345-1 and the anti-asthma
drug nedocromil sodium.
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spantide infusion, giving an inter-SP dose interval of at least 20 minutes.
Atropine sulphate, hexamethonium bromide, chlorpheniramine maleate and spantide
were purchased as indicated in Appendix II. CP-96,345-1 and nedocromil sodium
were gifts from Pfizer Inc (USA) and Fisons Ltd (UK) respectively. All agents were
dissolved in PBS.
6.2.2. Pharmacological Antagonism of Substance P in the
Isolated Sheep Trachealis Muscle Preparation:
Experiments were carried out using trachealis muscle preparation obtained from
female sheep aged 6-12 months and in a group of sheep aged over 4 years. The dose-
response characteristics of this preparation to SP were investigated as was the
influence of atropine, the M2 receptor antagonist pirenzepine (Research Biochemical
Incorporated, UK) the peptide SP antagonist spantide and the NK-2 antagonist L-
659,874 (Ac-Leu-Met-Gln-Trp-Phe-Gly-NH2) (Cambridge Research Biochemicals
Ltd, UK) on the contractile response to SP.
6.3. Results:
6.3.1. In Vivo Experiments:
The effects of atropine, hexamethonuium, chlorpheniramine, CP-96-345-1,
nedocromil sodium and spantide on the response to SP was assessed in normal
anaesthetised sheep.
6.3.1.1. Atropine and Hexamethonium:
Atropine pre-treatment (n=6) significantly reduced the bronchomotor response to SP
from a control RL/Cdyn value of +575/-70% to +12/-17% (Figure 47). In 2 sheep































Figure 47. The effect of intravenous pretreatment with atropine (Img/kg) on the
percentage change in dynamic compliance (Cdyn) and pulmonary resistance (RL) after
intravenous administration of substance P (SP) (n=6). Pre and Post represent the SP
response before and after atropine. * p<0.05, ** pcO.Ol.
pre-treatment, but the change in RL had been abolished. Atropine itself did not affect
basal bronchomotor tone.
Hexamethonium (n=3) also reduced the SP-induced change in Cdyn and RL to SP
from a control value of -71+/-4 to 43+/-10% for Cdyn (P<0.05) and from 425+/-168
to 44+/-33% for RL (P<0.05) (Figure 48). Hexamethonium also markedly reduced
mean blood pressure from 98+/-10 to 67+/-14mmHg (P<0.05) (Figure 49 ).
6.3.1.2. Histamine HI Receptor Antagonist:
Chlorpheniramine was administered to 6 sheep. In one sheep administration of SP
resulted in apnoea and bronchodilation (RL/Cdyn; -37/+15%), but after
chlorpheniramine pre-treatment mild bronchoconstriction occurred (RL/Cdyn; +70/-
19%). In the 5 other sheep SP caused varying levels of bronchoconstriction (RL +234
+/-135%; Cdyn -39 +/-13%) (Figure 51). Intravenous chlorpheniramine itself caused
a transient rise in bronchomotor tone (RL/Cdyn; +51/-8%) and stimulated respiration
(Figures 50 and 51), and then caused significant augmentation of the response to SP
(RL +477 +/-205%; Cdyn -55 +/-10%) in all 5 sheep (t-test; p<0.05) (Figure 51).
6.3.1.3. Neurokinin Receptor Antagonists:
Intravenously administered CP-96,345-1 at 0.5 mg/kg (n=5) caused an initial transient
rise in RL (+135%) and fall in Cdyn (-60%) in 3 of the 5 sheep, but values returned to
baseline after 2 to 3 minutes (Figure 53). CP-96,345-1 reduced the change in
RL/Cdyn to SP from control values of +204/-43% to +9/+3% and so effectively
abolished the response to SP. The effect of 0.1 mg/kg of CP-96,345-1 was assessed in
a separate group of sheep (n=4). Unlike the higher dose group there was no effect on
basal RL and Cdyn (Figure 51), but it did abolish the response to SP reducing the












































Figure 48. The effect of intravenous pretreatment with hexamethonium bromide
(20mg/kg) on the percentage change in dynamic compliance (Cdyn) and pulmonary
resistance (RL) after intravenous administration of substance P (SP) (n=3). Pre and
Post represent the SP response before and after hexamethonium. *p<0.05.
Figure 49. The effect of hexamethonium on mean blood pressure (n=3). Hexamethonium









Figure 50. The effect of the HI receptor antagonist chlorphenirmine (lmg/kg) on respiratory
parameters in a normal sheep. Chlorpheniramine was injected intravenously over a 60s period
(marker points 1 to 2) and stimulated respiration resulting in an increase in transpulmonarv
pressure (P), inspiratory and expiratory flow (Vi, Ve) and inspiratory and expiratory tidal volume
(VTi, VTe). These parameters returned to baseline within a further 2 to 3 minutes in all sheep. The




Figure 51. The effect of intravenous pretreatment with chlorpheniramine (2mg/kg) on
the percentage change in dynamic compliance (Cdyn) and pulmonary resistance (RL)
after intravenous administration of substance P (SP) (n=5). Pre and post represent the
SP response before and after chlorpheniramine and chlor is the effect of
chlorpheniramine on basal bronchomotor tone. Chloipheniramine caused a transient
bronchoconstrictor effect and then significantly augmented the bronchomotor response













































Figure 52. The effect of the intravenous administration of the NK-1 antagonist CP-
96,345 at two dose levels on basal dynamic compliance (Cdyn) and pulmonary
resistance (RL). The 0. lmg/kg dose had no effect on basal bronchomotor tone, but






































Figure 53. The effect of intravenous pretreatment with the NK-1 antagonist CP-
96,345 (0.5mg/kg) on the percentage change in dynamic compliance (Cdyn) and
pulmonary resistance (RL) after intravenous administration of substance P (SP)
(n=5). Pre and Post represents the SP response before and after CP-96,345, and CP is
the effect of CP-96,345 on basal bronchomotor tone. CP-96,345 caused a transient
bronchoconstriction and then abolished the response to SP.
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Infusion of spantide was carried out in 4 sheep. In one sheep SP caused apnoea of 35s
which was not affected by spantide (36 s). In the other three sheep spantide reduced
the effect of SP on RL (+75 +/-29 to +44 +/-11%) and Cdyn (-30 +/-7 to -26 +/-
0.6%). The effect of spantide on the SP response was not significant (Figure 54).
6.3.1.4. Nedocromil Sodium:
Nedocromil sodium was administered to 4 sheep and had a variable effect on the
response to SP. Nedocromil sodium itself, at 0.1 and 1 mg/kg, caused mild
bronchodilation with RL/Cdyn values of -20/+11 and -37/+13.5 respectively,
although one sheep (#48) had no response (Figure 55). At the lower dose two of the
four sheep showed a subsequent marked increase in the response to SP over the pre-
nedocromil sodium response, while in the other two sheep the response was reduced.
Overall, there was no significant potentiation of the response to SP after this dose of
nedocromil sodium (Paired t-test) At the 1 mg/kg dose where the effect of nedocromil
sodium on RL was appreciably greater, there was only a slight reduction in the
response to SP in three sheep with a more marked reduction in one (Figure 55). The
sheep (#48) whose basal bronchomotor tone was unaffected by nedocromil sodium
had the greatest reduction in response to SP.
6.3.2. In Vitro Experiments:
The response to SP was expressed as the percentage of the response to lumol
methacholine chloride, and drug concentration refers to the final drug concentration in
the organ bath. The tissue began to contract within 20 s of addition of methacholine to
the organ bath, peaked after 5 min and returned to baseline tension 3 min after
washout.
There was certain difficulties with the preparations response to SP. Addition of the














































Figure 54. The effect of intravenous infusion of the neurokinin antagonist spantide
(lOug/kg/min) on the percentage change in dynamic compliance (Cdyn) and pulmonary
resistance (RL) after intravenous administration of substance P (SP) (n=3). Pre and Post
represents the SP response before and after spantide (10 (ig/kg/min for 10 min) and
SPAN the response to spantide itself. Spantide infusion over 10 minutes caused a
transient bronchoconstriction similar in magnitude to the response with SP and then






































Prt 1 NED 1 Po<1 1 NED 2 Pod 2
Figure 55. The effect of intravenous pretreatment with nedocromil sodium on the
percentage change in dynamic compliance (Cdyn) and pulmonary resistance (RL) after
intravenous administration of substance P (SP) (n=4). Pre 1 is the response to SP before
nedocromil sodium, NED 1 and 2 the response to 0.1 and 1 mg/kg nedocromil sodium, and
Post 1 and 2 the response to SP after NED 1 and 2 respectively. The response to
nedocromil sodium itself and its effect on the response to SP were variable (see text).
Nedocromil sodium augmented the increase in RL at the 0.1 mg/kg dose and reduced the

























































































































Figure 57. The contractile effect of substance P (SP) on the sheep trachealis muscle
preparation, expressed as a percentage of the response to 1 pM methacholine.
Concentration-response curves for young sheep (Group 1; n=21) and aged sheep (Group
2; n=12) are shown, as well as a cumulative concentration-response curve in young sheep
(Group 3; n=25). In agreement with the in vivo studies it was found that SP has little effect
on trachealis muscle tone in aged sheep. In the young sheep (6-12mths) the shape of the
concentration-response curve depended on the method in which the SP was applied to the
tissue (see text). When applying each individual concentration of peptide, in a non-










































Figure 58. Demonstration of tachyphylaxis to the contractile response of the sheep trachealis
muscle preparation to substance P (SP) (n=3). The contractile effect is expressed as a
percentage of the response to lp.M methacholine. Two (First & Second) cumulative
concentration-response curves (CRC) for SP were undertaken in each tissue sample one hour
apart. There was a significant decline in the response to SP with the second CRC. On the
basis of these results it was decided to investigate pharmacological antagonism of the SP
response using single SP concentrations giving reproducible responses (typically 0.05|iM).
Paired t-test, significance of difference between the two concentrations; *p<0.05, **p<0.01.
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but with a large number of samples there was no response, even in the presence of
phosphoramidon. The data presented here represents the responses in 70 tissue
samples, but because of the variability of the response, assessment of larger numbers
of antagonists was not possible. This variability did not appear to be due to lack of
efficacy of the peptide used. Where there were runs of unsucessful in vitro
experiments, the peptide was subsequently assayed successfully in the anaesthetised
preparation.
The response to SP began within 60 s of addition to the organ bath, peaked within 6
min and returned to baseline approximately 2 min after washout.
Concentration-response curves (CRC) for SP were obtained using a cumulative
method (n=25) (Figure 56) and a single dose with inter-dose washout method (SD)
(n=21). The former method was also used to assess the trachealis muscle response to
SP in aged sheep (n=12). The SD method produced a standard CRC up to the 0.05uM
concentration, followed by a drop-off in the response to a minimum at O.luM and
subsequent improvement in the response at 0.5uM. The cumulative CRC gave a more
standard response (Figure 57). The response at 0.07, 0.1 and 0.3uM with the
cumulative CRC was significantly greater than with the single dose method (t-test;
p<0.01 & 0.05). The response to SP in trachealis muscle from aged sheep was
minimal and this is in agreement with the results of the in vivo experiments (see
Chapter 5).
The reproducibility of the cumulative CRC was also assessed by undertaking two
CRCs one hour apart (n=3). There was a shift in the second CRC to the right, which
was significant (t-test; p<0.01) at the 0.01 to O.luM concentration levels (Figure 58).
This indicated development of tachyphylaxis to SP occurs in this preparation,
preventing the use of repeated CRCs to assess pharmacological antagonism.
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The reduction in the response with the 0.1 and 0.5uM concentrations were further
investigated in 21 tissue samples. With the SD method the first 0.05uM
concentrations consistently gave a larger response than the 0.5uM (t-test; p=0.06) and
the O.luM (t-test; p<0.01) concentrations in 19 of the 21 tissues (Figure 59a and b).
The response to the second 0.05uM, administered 5 minutes later, was also larger than
the 0.1 (p<0.01) and the 0.5uM (p<0.1) responses. There was also an insignificant
augmentation of the second response to 0.05uM compared to the first. Because of the
tachyphylaxis found with cumulative SP CRCs and the paradoxical reduced response
in the mid-section of the SD CRCs, it was felt that antagonism of the contractile
response to SP could only be assessed by investigating the pharmacological
antagonism of the single ().05uM SP concentration.
The effects of each antagonist on the response to SP were not assessed in tissue from
the same animals. To reduce the variability of response, samples were always
collected from Suffolk-cross female lambs aged 6 to 12 months. Each agent was
assessed using tracheal samples collected from four different animals on the same
day.
Atropine (luM) (n=8) effectively abolished the response to SP (Figure 60), while
atropine and pirenzepine at doses between O.OlpM to luM antagonised the response
to SP in a dose dependent manner (Figure 61). The difference in response to atropine
and pirenzepine was significant at the InM (t-test; p<0.01), the lOnM and O.luM
(p<0.05) dose levels. The concentration of atropine and pirenzepine required to
inhibit the response to SP by 50% (ICgg) was calculated. The ICg0 for pirenzepine and
atropine were 5x10"10 and 5.6xl0"8 M respectively. The NK antagonists spantide
(n=7) and the NK-2 antagonist L-659,874 (n=6) (0.1 to 4uM) were generally
ineffective in antagonising the response to SP, and the reduction in response with L-
Figure 59a. The contractile effect of 0.05(iM and 0.5|iM substance P (SP) on the sheep
trachealis muscle preparation (n=17). The first and second (#1 and #2 respectively) 0.05|iM
concentrations of SP were administered 5 minutes before and after the 0.5|iM concentration.
The 0.5|iM concentration consistently resulted in a smaller response than 0.05|iM and the
contractile response to the second 0.05|iM concentration was significantly augmented





































































Figure 60. The effect of 1 fiM atropine sulphate on the contractile effect of 0.05 jiM
substance P (SP) on the sheep trachealis muscle preparation (n=8). Atropine effectively











































Figure 61. The effect of the muscarinic antagonists atropine (n=4) and pirenzepine (n=8) on
the contractile response to 0.05 p.M substance P (SP) in sheep trachealis muscle. Both
atopine and pirenzepine antagonised the effect of SP in a concentration-dependent manner,
with concentrations giving 50% inhibition of the agonist (IC50) of 5.6 x 10~8 and 5 x 10~10
M respectively, t-test, significance of difference between pirenzepine and atropine; * p<0.05,
** p<0.01.





659,874 at the highest dose was not statistically significant (Figure 62).
6.4. Discussion:
There is widespread evidence that several of the effects of SP in the airways involve
indirect mechanisms, one of which is activation of the cholinergic system. The
secretory action of SP in the airways is cholinergically mediated in the cat (Kua et al,
1991), but not in the guinea-pig (Shimura et al, 1991), and in several species the
bronchomotor response to different classes of neuropeptides appears to involve
cholinergic neurotransmission.
Atropine significantly antagonised the effects of SP in anaesthetised normal sheep and
in isolated trachealis muscle, and while the effect of atropine on SP in allergic sheep
has not been reported, it effectively abolishes bradykinin-induced bronchoconstriction
(Abraham et al, 1991). The effects of bradykinin can also be antagonised by
nedocromil sodium, but is not affected by chlorpheniramine (Abraham et al, 1991).
The ability of atropine to antagonise the actions of unrelated peptides suggests a
common mode of action. The anticholinergic agent ipratropium bromide also protects
against BK and SP-induced bronchoconstriction in asthmatic man (Fuller et al, 1987a;
Crimini et al, 1990), while atropine pre-treatment inhibits the bronchomotor response
to SP in rabbits, dogs, rats and piglets (Tanaka & Grunstein, 1984,1986; Taivan,
1987; Joos et al, 1988; Haxhiu-Poskurica et al, 1992), although Armour and co¬
workers (1991) failed to demonstrate antagonism of SP by atropine in the rabbit. The
contractile effect of SP on bovine tracheal smooth muscle strips can also be blocked
by atropine, but the effect is less marked at near-maximal concentrations, where the
action of SP is mainly direct (Corson et al, 1990). Atropine is ineffective against SP
induced contraction of airways and the tetrodotoxin-sensitive component of
cholinergic bronchoconstriction in guinea pigs (Karlsson et al, 1984; Shore & Drazen,










































Figure 62. The effect of the general neurokinin antagonist spantide (n=7) and the NK-2
antagonist L-659874 (n=6) on the contractile effect of 0.05|iM substance P (SP) on the
sheep trachealis muscle preparation. Neither antagonist, up to a concentration of 4fiM,
significantly affected the response to SP.
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bronchoconstriction (Omini et al, 1989). It is also ineffective against SP-induced
contraction of isolated airways in man (Lundberg et al, 1983). Therefore, exogenously
administered SP, in some species at least, acts indirectly causing bronchoconstriction
by pre-junctional modulation of acetylcholine release from vagal cholinergic nerve
endings. The released ACh in turn would contract smooth muscle or pre-junctionally
inhibit neurotransmission in adjacent sympathetic nerves (Pendry & MacLagan,
1989). In the guinea pig ileum an analogous situation exists, where part of the smooth
muscle contraction with SP, NKA and NKB is due to activation of neurokinin
receptors on intrinsic cholinergic neurones, and these effects can be antagonised by
the NK-1 receptor antagonist CP-96,345-1 (Legat et al, 1992).
The Ml receptor antagonist pirenzepine was more effective than atropine in
antagonising the SP response in the sheep isolated trachealis muscle preparation. The
Ml receptors appear to be present in airway parasympathetic ganglia and modify
ganglionic neurotransmission (Minette & Barnes, 1990). Pirenzepine will antagonise
vagally mediated bronchoconstriction at the ganglia level (Beck et al, 1987; Bloom et
al, 1987; Yang & Biggs, 1991) and probably at the post-ganglioninic post synaptic
level. The marked antagonism of the SP response with pirenzepine in sheep airways
would suggest SP may be acting at the parasympathetic ganglion level rather than
presynaptically on cholinergic nerve endings, and this is supported by the effect of
hexamethonium on the SP response in the anaesthetised sheep. While the receptor
specificity and affinity of pirenzepine, particularily at high concentrations, is
questionable and it is possible that it is also blocking the pre-synaptic M2 receptor
and the smooth muscle M3 receptor (Yu et al, 1992), the low IC50 value found for
pirenzepine (5xlO~10 M) in antagonising SP would suggest involvement of the Ml
receptor. Determining pA2 values for pirenzepine, atropine and using specific M2 and
M3 antagonists would have been preferable, but was not feasible. It is still
conceivable that the Ml receptor mediates cholinergic bronchoconstriction in the
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sheep airway and this needs to be investigated further.
Nedocromil sodium does not affect the spontaneous or BK-induced endogenous
release of SP in rat trachea (Ray et al, 1991b). Nedocromil sodium does inhibit the SP
potentiation of vagal-induced tracheal smooth muscle contraction (preganglionic
effect) in the rabbit and has no effect on the potentiation of post-ganglionic
contraction (Armour et al, 1991). It is possible that SP-induced bronchoconstriction
in the sheep may be due to stimulation of myelinated and/or unmyelinated afferent
fibres in the lung. However, only in one sheep in the present study could antagonism
of SP by systemically administered nedrocomil sodium be shown, and this was the
one animal whose basal bronchomotor tone was unaffected by nedocromil. In the
three other sheep, where nedocromil caused bronchodilation, SP had a similar effect
on RL and Cdyn as in the control situation and possibly would have had a greater
effect if bronchomotor tone had remained close to baseline. This paradoxical effect of
nedocromil and SP in the sheep needs to be investigated further in a larger sample of
animals, and the effects of inhaled nedocromil sodium on systemically administered
and inhaled SP should also be investigated.
The reduction of the bronchoconstrictor response to SP by the ganglion blocker
hexamethonium, although not as marked as with atropine, contrasts with previous
reports in other species. Hexamethonium enhances the SP-induced
bronchoconstriction in the rat (Joos et al, 1988) and guinea-pig (Stewart & Fennessy,
1986; Del Monte et al, 1990) and in the latter case is due to inhibition of sympathetic
innervation to the airways (Stewart & Fennessy, 1986). Hexamethonium enhances the
bronchoconstriction caused by vagal stimulation at frequencies and intensity (15Hz,
0.2ms, 3s, 7-20V) associated with activation of non-cholinergic (substance P) nerves
(Del Monte et al, 1990). This effect of hexamethonium appears to involve release of
neuropeptides as hexamethonium inhibits neural bronchoconstriction in capsaicin-
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treated animals, and also involves activation of beta-adrenoceptors in parasympathetic
ganglia. The results in sheep suggest SP-induced bronchoconstriction involves
ganglionic neurotransmission, and supports the hypothesis that it is of reflex origin
involving activation of pulmonary vagal afferent nerves or modulates efferent
cholinergic output from airway parasympathetic ganglia. The marked hypotensive
effect of hexamethonium, due to sympathetic ganglion blockade, and the general
interference with sympathetic ganglionic neurotransmission might also have an effect
of the bronchomotor response to SP. The reduction in mean blood pressure in the
present study was greater than 20 mmHg, which would affect baroreceptor reflex
activity, but whether this induced reflex changes in bronchomotor tone is not known.
The possibility that histamine mediates the bronchomotor response to SP has been
discussed earlier, and of particular interest is the close anatomical relationship
between peptide-containing nerves and mast cells recently demonstrated in the rat
mesentery (Crivellato et al, 1991). While SP can release histamine from mast cells, by
activation of phospholipase A2 (Mousli et al, 1992), this has only been reported for
rat peritoneal and human skin mast cells (Shanahan et al, 1985; Repke et al, 1987;
Lowman et al, 1988 a,b; McLeod et al, 1990; Mousli et al, 1992) and does not appear
to apply to lung cells. Conversely histamine releases SP from sensory afferent nerve
endings in guinea-pigs (Saria et al, 1987, 1988a) but not in rats (White, 1988).
However, histamine causes bronchoconstriction directly via HI receptors (Saria et al,
1983), possibly indirectly by activation of vagal afferent nerve endings (Dixon et al,
1979, 1980) and bronchodilation through H2 receptors (Ahmed et al, 1980), and
complex interaction does exist between histamine and peptidergic nerves in the
airway. H3 receptor agonists have been shown to pre-junctionally inhibit
neuropeptide release from sensory nerves (Ichinose et al, 1990) and antagonise the
microvascular leakage due to activation of NANC nerves, and histamine acting on H3
receptors inhibits vagally mediated contraction. However, the present study has
106
shown that the HI receptor antagonist chlopheniramine (CH) does not antagonise the
effects of SP in normal sheep, and this agrees with findings in man and guinea-pigs
(Lundberg et al, 1983; Shore & Drazen, 1989), but on the contrary it significantly
augments the response. The response to BK in allergic sheep is also not affected by
CH (Abraham et al, 1991) suggesting the bronchomotor effect of peptides does not
involve histamine. However, in normal sheep there was an inexplicable increase in
the response to SP after CH pre-treatment. The H2 receptor, which mediates
bronchodilation, predominates in normal sheep airways (Eyre, 1973, 1975; Ahmed et
al, 1980), particularily in the smaller airways (Eyre, 1969) and the HI receptor
predominates in allergic sheep (Wanner et al, 1988). Although chlorpheniramine is
not a H2 or H3 antagonist, a possible, though improbable, interaction between
chlorpheniramine and H2 and H3 receptors may underlie this effect.
The peptide SP antagonists were developed by inclusion of the amino acid D-Trp into
the SP structure and the most potent of the original SP antagonists was spantide (also
known as Spantide I), with the substitution of D-Trp at positions 7 and 9 (Folkers et
al, 1984). Spantide I has been reported to be reasonably selective for the NK-1
receptor, whose endogenous ligand is SP, but also has some activity against NK-2
receptor (NKA), with pA2 values of 6.2 and 5.3 respectively (Maggi et al, 1991).
Spantide has no affinity for the NK-3 receptor (NKB). The use of Spantide I has been
limited by this certain lack of specificity for NK-1 and NK-2 receptors and also by its
tendency to degranulate mast cells and its neurotoxicity when administered centrally.
A derivative of spantide, [D-NicLysl, 3-Pal3, D-C12 Phe5, Asn6, D-Trp7,9, Nlell]-
SP, also known as Spantide II (Folkers et al, 1990), is less toxic, does not degranulate
mast cells and is 10 times more potent than spantide I in antagonising SP at NK-1
receptors. However, it is equipotent with spantide I in antagonising NKA (Maggi et
al, 1991) and has no effect on NK-3 receptors. Spantide was ineffective in
antagonising the effects of SP in anaesthetised sheep and in the sheep trachealis
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muscle preparation, which may reflect a lack of specificity for the sheep airway NK-1
receptor. The apparent lack of effect of spantide I in the anaesthetised sheep may be
due to the low doses of antagonist used (lOug/kg/min), but the use of higher doses
was restricted by cost. However, in the organ bath preparation the concentration of
spantide was much greater than the muscarinic antagonists atropine and pirenzepine
required to antagonise the effects of SP significantly. An alternative explanation for
the lack of effect of spantide I, considering the efficacy of CP-96,345-1, may be that
the material was inactive. The novel neurokinin antagonist L-659,874 is a reasonably
selective NK-2 receptor antagonist, but like spantide was ineffective in antagonising
the contractile effect of SP on the trachealis muscle, suggesting the NK-2 receptor
does not mediate the SP response. The investigation of L-659,874 in the anaesthetised
sheep was again restricted by cost.
The quinuclindine agent CP-96,345-1 is a new non-peptide SP antagonist and is
highly specific for the NK-1 receptor (Snider et al, 1991). It has variable effects on
events characterised by activation of NK-2 or NK-3 receptors (Snider et al, 1991;
Carruette et al, 1992; Nagahisa et al, 1992; Xu et al, 1992) and on the effects of both
histamine and bradykinin (Legat et al, 1992; Nagahisa et al, 1992). It is reported to be
a more potent antagonist of SP than spantide I (McLean et al, 1991), but
approximately 10 times less potent than spantide II with pA2 values of 6.8 and 7.6
respectively in the guinea-pig taenia coli (NK-1) preparation (Hakanson et al, 1991).
CP-96,345-1 has been shown to antagonise the action of SP, NKA and NKB in
inducing plasma extravasation in guinea pig skin (Nagahisa et al, 1992) and the
smooth muscle contraction caused by SP and the potent NK-1 agonist septide in
guinea pig trachea (Carruette et al, 1992).The effects of CP-96,345-1 are not all
mediated through the NK-1 receptor and its effects on histamine and bradykinin
probably involve non-specific mechanisms as they are only apparent at very high
doses (Legat et al, 1992). Along with its enantiomer (CP-96,344), which is inactive at
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the NK-1 receptor (Legatet al, 1992), CP-96,345-1 reduces depressor reflexes caused
by stimulation of capsaicin-sensitive peripheral neurones (Griesbacher et al, 1992).
Furthermore, CP-96,345-1 and CP-96,344 both cause a fall in mean blood pressure
and heart rate in anaesthetised rats (Donnerer et al, 1992). The likely explanation for
these cardiac effects is that they are calcium channel blockers (Schmidt et al, 1992).
CP-96,345-1 at 0.1 and 0.5 mg/kg abolished the bronchomotor response to SP in
sheep indicating the response is mediated via the NK-1 receptor. At the higher dose
CP-96,345-1 caused a transient bronchoconstriction in 3 of 5 animals indicating
possible agonist activity at higher doses, or alternatively activation of a different
mechanism. In the present study the effect of CP-96,345-1 on cardiovascular
parameters was not assessed. The fact that CP-96,345-1 only partially inhibits the
smooth muscle contractile effects of stimulation of capsaicin-sensitive nerves (Legat
et al, 1992) but abolishes SP-induced contraction, suggests it is acting only at the NK-
1 receptor.
The results from these different studies suggest that while the bronchomotor effect of
SP involves modulation of cholinergic neurotransmission this is still mediated
through the NK-1 receptor, which may be located pre-junctionally on post-ganglionic
cholinergic nerve endings or on sensory neurons in ganglia. While atropine did not
abolish the response to SP in anaesthetised sheep, the effectiveness of atropine in
antagonising SP suggests there is a paucity of post-synaptic NK-1 receptors,
mediating smooth muscle contraction, in sheep airways and the response to SP in
normal sheep must be regarded as being largely indirect. This is supported by the
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organ bath studies where both the Ml receptor antagonist and the mixed muscarinic
antagonist atropine effectively abolished the response.
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CHAPTER 7. THE EFFECT OF VAGOTOMY AND VAGAL COOLING ON
THE CARDIOPULMONARY RESPONSE TO SP
7.1. Introduction:
Neural afferent nerve impulses from the thoracic viscera are carried in the vago¬
sympathetic trunk. In the sheep the majority of the afferent fibres come from the
thorax viscera, but an important group arise from the reticulo-rumen and other
abdominal viscera (Cottrell & Greenhorn, 1987). In the case of the respiratory system
three types of afferent nerve fibres and receptors have been identified. The slowly
adapting receptor (SAR) is a stretch receptor that responds to changes in the
mechanical structure of the airways and lung tissues during inspiration and expiration
(Fahim & Jain, 1979). SARs are found from the extrathoracic to the intrapulmonary
airways, but are primarily located in the trachea and the larger conducting airways.
Their activity is characterised by slow adaptation of firing rate to a stimulus, such as
airway distension, and this slow adaptation occurs at the beginning and end of the
stimulus period. A large proportion of the receptors are active at functional residual
capacity (FRC) while others are recruited during breathing. The rapidly adapting
receptor (RAR), also known as the irritant receptor, show a rapid adaptation of firing
response to stimuli (Sampson & Vidruk, 1975; Bergeren & Sampson, 1982). The
RARs are affected by changes in lung mechanics in an irregular fashion, but are
usually quiescent at FRC. The response involves an irregular burst of activity during
inflation, which adapts rapidly to the discharge frequency close to the resting level or
becomes quiescent. They can also be preferentially activated by intermittent lung
collapse during deflation (Schultz et al, 1989). RARs are also affected by a variety of
irritant agents and may be the receptors associated with coughing (Coleridge &
Coleridge, 1986) and the generation of the augmented breath (Davies & Roumy,
1982).
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These differences in the discharge pattern of SAR and RAR associated nerve fibres
are usually sufficent to allow their identification in nerve conduction studies. Both the
SAR and RAR nerve fibres are myelinated and therefore have fast conduction
velocities (23 and 32 m/s; dog) (Sampson & Vidruk, 1975).
The last class of respiratory afferent receptors are the C-fibre afferent receptors, also
known as Paintal's J-receptors (Paintal, 1977) and comprise the majority of afferent
nerve fibres originating in the thorax (Agosini et al, 1957). They are not, in general,
modulated by the respiratory pattern, but some (pulmonary) do respond to
hyperinflation with 2-3 times tidal volume. Attempts have been made to sub-divide
C-fibres further on the basis of their accessibilty through the pulmonary and bronchial
circulations, and their responses to capsaicin, phenylbiguanide and bradykinin
(Coleridge & Coleridge, 1984). Pulmonary C-fibres are preferentially stimulated
when agents are administered through the pulmonary circulation (right atrium), while
bronchial C-fibres are activated by bronchial arterial administration (Coleridge &
Coleridge, 1986). Because of the widespread anastomoses between the two
circulations this sub-division is not readily accepted by some investigators (Martling,
1987). The C-fibre afferents have slow conduction velocities (0.8-2.4m/s in the dog;
Coleridge & Coleridge, 1977) being unmyelinated, and are consequently different
from SARs and RARs. In normal circumstances they are quiescent, with only
irregular and sparse impulse traffic in nerve fibres in spontaneously breathing
animals. In experimental situations activation is usually achieved by chemical
stimulation with capsaicin, phenylbiguanide or bradykinin.
Despite the fact that C-fibres make up the largest number of afferent nerve fibres in
mammalian lung, the function of these receptors is still unknown. They are involved
in the reflex stimulation of mucus secretion in the dog trachea (Schultz et al, 1989)
and in the reflex contraction that follows tracheal relaxation induced by lung inflation
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(Roberts et al, 1988). The activation of C-fibres by chemicals, such as
phenylbiguanide and capsaicin, elicits a chemo-reflex which involves a combination
of apnoea and/or, tachypnoea, bradycardia, mucus secretion and coughing,
hypotension and bronchoconstriction, although not necessarily in all species
(Karczewski & Widdicombe, 1969; Coleridge & Coleridge, 1984). Furthermore, it is
not known if this reflex is physiologically important and it may merely be a response
to potent noxious chemicals. They are also believed to be the main site of sensory
neuropeptide neurotransmitters in the airways and lung (Polak & Bloom, 1982;
Cadieux et al, 1986).
Selective blockade of afferent nerve fibres in the vagus can be achieved using two
techniques, vagal cooling (Figure 63) and anodal block (SanfAmbrogio et al, 1984).
Vagal cooling results in reversible blockade of nervous transmission by progressively
slowing nerve impulse conduction (Figure 64). When certain temperature levels are
achieved conduction ceases, or becomes minimal. Blockade is due to lengthening the
period of absolute refractoriness of nerve fibres. The use of the term "selective
blockade" is only applicable when we talk about myelinated versus unmyelinated
nerve fibres. In the case of myelinated nerve fibres, associated with SARs and RARs,
blocking temperature is largely independent of conduction velocity. Both types of
myelinated fibres are blocked at similar temperatures and so their activity cannot be
separated. Myelinated nerves, in general, are blocked between 20 and 8° C, leaving
most unmyelinated fibres unaffected (Franz & Iggo, 1968). It is interesting to note
that a proportion of unmyelinated C-fibres is blocked at temperatures usually
associated with blockade of myelinated nerves (Paintal, 1967) and it is possible that a
proportion of C-fibres become myelinated once the vagus has left the thorax. The
majority of unmyelinated afferent fibres continue to conduct at 8°C, and the
numbers progressively decrease as the temperature drops. Between 3 and 0° C
impulse conduction can be abolished in most cases, although temperatures below 0°
SECONDS
Figure 63 (upper and lower). Illustrations demonstrating two techniques for cooling the
vagus nerve. In Paintal's preparation (upper) an immersion cooling technique is used where
the nerve is suiTounded by the coolant in a pool separated from the other tissues which are
in paraffin pools. In Franz and Iggos' preparation (lower) the nerve is contained within a
brass cooling probe and the effects of agar gel and oil on the temperature difference
between the nerve bundle surface thermistor (T) and another thermistor at the core or
opposite surface (P) is shown (A3 and C). With the agar gel bathed preparation (A) the
maximum difference between the surface and core temperature was 1.7°C, while in B and C
a difference of more than 7°C was found during cooling. This agar gel preparation, with the
nerve contained in the groove of a brass cooling probe was used in the current experiments,
(modified from: Paintal, 1965; Franz & Iggo, 1968).
A 8 12 16 20 24 28 32 36
Temperature foC]
Figure 64. The effect of vagal cooling on the conduction velocity in a nerve fibre. Conduction was
optimal at normal body temperature and was eventually blocked at 8.6°C. This figure shows the
close correlation between temperature and nerve conduction and also the hysteresis between the
effects of cooling and re-warming, (modified from Paintal, 1965).
113
may be required in some instances. However, freezing blockade is usually not
required and will cause irreversible nerve damage. The reversibility of the procedure
is dependent on the temperature used and the duration of cooling (SanfAmbrogio et
al, 1984).
Since it was demonstrated in Chapter 6 that atropine, pirenzepine and hexamethonium
modified the bronchomotor response to SP, and augmented breaths were observed in
some sheep after SP administration, the aim of this study was to investigate the
possible role of afferent innervation in the bronchomotor response to SP.
7.2. Material and Methods:
7.2.1. Augmented Breaths:
The presence of augmented breaths (ABs), after intravenous injection of SP had been
noted previously in some sheep, and consequently the incidence of ABs was assessed
in all sheep studied during the course of this project. ABs are easily recognised as a
double inspiration on respiratory tracings and have an associated increased flow, tidal
volume and transpulmonary pressure relevant to the breaths immediately before and
after the AB (Figure 65). The ABs were assessed in terms of their peak inspiratory
and expiratory flow, tidal volume, transpulmonary pressure and time from injection of
SP. The response was assessed after injection of 0.3 umol and 0.5 umol/kg SP and the
significance of changes determined by the t-test.
7.2.2. Vagal Cooling and Vagotomy Studies:
Suffolk cross female sheep, aged 6-12 months, were anaesthetised and prepared for
cardiopulmonary measurements as described previously. The cervical vagi were
isolated and exposed as follows. The sheep were placed in dorsal recumbency and an
1S 20s
Figure 65. Augmented breath (AB) after intravenous substance P (SP) administration in a normal
sheep. There is a single augmented breath, with increased transpulmonary pressure (P), flow (V)
and tidal volume (VT), following a series of normal breaths. With flow the AB has increased the
peak inspiratory component and has not affected expiratory flow.
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8cm incision was made in the ventral cervical mid-line, equidistant from the caudal
edge of the larynx and the thoracic inlet. Using blunt dissection, the right and left
external jugular veins and carotid arteries were identified and separated from
surrounding structures. The right and left vagi were identified adherent to the dorso-
medial aspect of the carotid arteries and isolated by blunt dissection. Umbilical tape,
soaked in 0.15M NaCl, was passed around each vagus for later identification. The
wound incision was closed with temporary surgical clip staples and the sheep placed
in the prone position.
A dose response curve for intravenous SP was carried out to establish an appropiate
dose which would give a bronchoconstrictor response between 50 and 80% of
maximum. The cervical incision was re-opened and the left vagus was identified. The
nerve was blocked with 0.25-0.5ml of lOmg/ml lignocaine hydrochloride (Xylocaine
1%, Astra Pharmaceuticals Ltd, UK) injected directly into the nerve and the response
to intravenous SP assessed. The nerve was then cut through the blocked section of
nerve. The right nerve was identified and placed on a brass cooling probe (Figure 66).
The nerve was sealed onto the probe with a 4% solution of agar (BDH Laboratory
Supplies, UK) in 0.15M NaCl, which was at 37-40 0 C. The temperature around the
probe was maintained at close to 37 0 C using direct heat from a lamp. The
temperature of the nerve was monitored with an electrical thermistor embedded in the
probe head which was attached to a volt meter (Micronta Digital Multimeter (Intertan
Australia Ltd), Tandy Ltd, UK). The volt meter output was twice calibrated over the
temperature range of 0°to 40 <C on the day of each experiment before the probe was
attached to the nerve, and at the end of each experiment. The thermistor demonstrated
excellent linearity primarily in the lower part of the temperature range (0-20^2) and
with no variability in output throughout an entire day's experiments.
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The nerve temperature was controlled by passing a coolant liquid through two tubes
connected to the probe. The coolant (ethylene glycol) was pre-cooled in a reservoir
tank (Colora Low Temperature Bath, Colora Messtechnik GmBH, Germany) to 10 C
below the required temperature at the probe head to allow for heat loss in the tubing.
The coolant was passed through the tubing with a pump which allowed the nerve to
be cooled reasonably rapidly. However, the lower the temperature required the longer
the delay in achieving that temperature. An additional pump tank (Colora Ultra
Thermostat Bath, Colora Messtechnik GmBH, Germany) containing water at 37° C,
was connected to the thermode tubing through a two-way valve to enable nerve
temperature to be returned rapidly to normal (approximately 20 s).
The coolant was used to cool the right vagus to 10, 7 and 3 0 C, and the effect on the
cardiopulmonary response to intravenous SP and to phenylbiguanide (PBG) (50ug/kg)
was assessed. PBG was administered after SP once baseline V, VT and P levels had
been achieved. Preliminary studies suggested that SP would not affect the
cardiopulmonary response to PBG. Between each of the three temperatures the nerve
temperature was returned to normal using the heated bath. At least 20m elapsed
between each SP dose to allow for reversal of tachyphylaxis (see Chapter 3). Finally
the effect of blockade of the right vagus with lignocaine and subsequent sectioning on
the response to SP was assessed. In other experiments bilateral vagotomy without
prior cooling of the right vagus was also carried out. Because of the problems of
tachyphylaxis to SP and the problems associated with prolonged anaesthesia
discussed earlier, the effect of cooling itself on the subsequent response to SP at
normal temperatures was not assessed, except in sheep #42. In this animal cooling did
not appreciably affect the response to SP when the nerve was re-warmed.
Figure 66. The cooling probe used to cool the isolated cervical vagus nerve in anaesthetised
sheep. The nerve sits in the brass cooling channel (A) in a pool of agar gel. The coolant, at a
pre-determined temperature, is pumped to the cooling probe head through the tubing (B) and




7.3.1. Analysis of Augmented Breath Activity:
The respiratory tracings of 40 sheep ranging in age from 4mths to over 4yrs were
assessed for ABs. ABs were found consistently in 10 animals. Of these 10 sheep, 9
were aged 6-12mths and one was less than 6mths. ABs were not found in sheep aged
12-18mths or over 4yrs where bronchoconstriction was minimal or the response to SP
involved apnoea (Chapter 5). The mean (+/-sem) time from injection of SP to the AB
was 9.9 (0.69) and 11.4s (0.83) for 0.5 and 0.7 umol doses respectively, and to
maximal bronchoconstriction (Bm) was 28.4 (1.37) and 28'.3s (1.95). While the mean
time to Bm was similar at 0.5 and 0.7 umol doses, there was no correlation between
the time to appearance of the AB and time to Bm (Figure 67).
The AB consistently involved an increase in Vi, Ve, VTi, VTe and P and the
percentage changes relevant to the previous breath are shown in Figures 68, 69 and
70. The increase in P was significantly different from baseline at the 0.5 umol
(p<0.05) and the 0.7umol (p<0.01) dose levels (Figure 71), while the change in Vt
was significant only at the 0.5umol dose (p<0.01).
There was no significant difference between the change in respiratory parameters
with the 0.5 and 0.7umol doses of SP, but the percentage change in Vi was
significantly different from Ve at the 0.5umol dose (p<0.05).
7.3.2. Vagal Cooling and Vagotomy:
Anaesthesia of the left vagus resulted in minor changes in the breathing pattern with
increased inspiratory and expiratory flow times, characteristic of blockade of afferent
input from stretch receptors. However, there was no significant change in tidal


























Figure 67. The time (seconds) to the appearance of augmented breaths (T), and the time to
maximum bronchoconstriction (Tmax), after intravenously administered substance P (SP), at
two different dose levels of 0.5 and 0.7 (imol/kg, in normal sheep (n=10). There was no




























Figure 68. Expiratory (Ve) and inspiratory (Vi) flow immediately before (Pre AB) and
during (AB) augmented breaths elicited by intravenous SP (0.5 |amol/kg) in normal sheep




























Figure 69. Expiratory (VTe) and inspiratory (VTi) tidal volume immediately before (Pre
AB) and during (AB) augmented breaths elicited by intravenous substance P (SP) (0.5
(imol/kg) in normal sheep (n=10). There is an increase in VTe and VTi during the
augmented breath. The change in tidal volume was statistically significant (paired t-test;
p<0.05)
Figure 70. Transpulmonary pressure (P) immediately before (Pre AB) and during (AB)
augmented breaths elicited by substance P (SP) (0.5 (imol/kg) in normal sheep (n=10). There


































Figure 71. The differences in the magnitude of the augmented breath with intravenous SP in
normal sheep (n=10) at 0.5jrmol/Kg and 0.7(imol/Kg. The percentage change in expiratory
flow (Ve), inspiratory and expiratory tidal volume (VTi & VTe) and transpulmonary pressure
(P) was greater at the 0.7uM dose than the 0.5uM dose, t-test, significance of difference
from baseline; *p<0.05, **p<0.01.
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input was present in the right vagus for the breathing pattern to remain close to
normal. In some individuals a normal breathing pattern resumed several minutes after
left vagal blockade. Left vagal blockade had no statistically significant (paired t-test)
effect on the bronchomotor response to SP or PBG.
The effect of vagal cooling on respiratory patterns and parameters are illustrated
graphically in Figure 72 and representative tracings from individual animals are also
shown (Figures 73, 74 & 75). There was temperature dependent increases in peak
inspiratory flow, transpulmonary pressure and tidal volume and a decrease in
respiratory rate. While cooling to 10 0 C gave respiratory changes consistent with
blockade of myelinated fibres from stretch receptors (Figure 73), further changes
occured in the respiratory parameters at lower temperatures (Figure 72). Furthermore,
cooling to below 10 0 C in some sheep resulted in paradoxical changes in respiration
characterised by an increased respiratory rate (Figures 74 & 75).
SP (0.7-1 .Oumol/kg; n=7) increased RL (+150% +/-29.3) and decreased Cdyn (-43%
+/-4.7) at normal temperature. Vagal cooling resulted in a temperature dependent
reduction in the bronchomotor response to SP with the most marked reduction at 3° C
(RL +6% +/-3.36; Cdyn -8.2% +/-4.24) (Figure 76). At 7 0 C the change in RL was
greater than at 3 0 C (+20% +/-8.11), but Cdyn was similar (-8.6% +/-4.5). Stretch
receptor input, as assessed by increased inspiratory and expiratory times, and
increased tidal volumes and transpulmonary pressure, was abolished at temperatures
below 14 0 C. At 10 0 C two sheep showed a reduction in the Cdyn response to SP
and 3 to the RL response. After chemical (lignocaine) or surgical vagotomy (n=7) the
bronchomotor response to SP was effectively abolished with RL/Cdyn of +4.3/-2.43%
compared to pre-vagotomy values of +318/-56% (Figure 77). There was no
statistically significant difference between the effects of cooling to 3 0 C and
vagotomy on the response to SP.
Figure 72. The effect of vagal cooling on respiratory parameters compared to normal temperature.
There is a temperature dependent increase in peak inspiratory flow (V), transpulmonary pressure
(P) and tidal volume (VT) and a decrease in respiratory rate (RR). This is consistent with blockade
of conduction in myelinated fibres from stretch receptors, although further changes occured at
temperatures consistent with blockade of C-fibre afferent conduction (<10°C).
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Figure 73. The effect of vagal cooling to 10°C on respiratory parameters of normal sheep.
Transpulmonary pressure (upper tracing), respiratory airflow (middle tracing) and tidal volume
(lower tracing). At 10°C (solid bar) there is a reduction in the respiratory rate and increase in the
amplitude of the flow, pressure and volume tracings. This is presumably due to a reduction in
stretch receptor input to the respiratory centres in the brainsetm and medulla. Cooling to this
temperature does not always give this type of change and paradoxical alterations in respiratory
parameters can occur. Examples of this effect are shown in Figures 74 and 75.
Figure 74. The effect of vagal cooling to 7°C on respiratory parameters of normal sheep,
respiratory airflow (upper tracing), tidal volume (middle tracing) and transpulmonary pressure
(lower tracing). It can be seen that at 15°C there is a reduction in stretch receptor input with
resultant increase in flow, volume and pressure, but as vagal temperature approachs 7°C there is
paradoxical increase in respiratory rate with a reduction in volume and pressure. The effect of
phenylbiguanide (PBG) is also shown in this tracing. This paradoxical change in respiratory pattern
did not occur in all sheep when the vagus was cooled to below 10°C.
Figure 75. The effect of vagal cooling to 3°C on respiratory parameters of normal sheep.
Respiratory airflow (upper tracing), tidal volume (middle tracing) and transpulmonary pressure
(lower tracing). In this tracing there is a similar change in parameters at 15°C to that occuring in
figure 74 and there is again a paradoxical increase in respiratory rate. However, at temperatures
below 7°C breathing is more regular and the amplitudes of the pressure, flow and tidal volume
tracings are greater than at normal temperature.Cooling to 7 or 3°C results in similar quantitative





















































Figure 76. The effect of vagal temperature on the bronchomotor response (percentage
change in dynamic compliance (Cdyn) and pulmonary resistance (RL)) to substance P (SP) in
normal sheep. The reduction in the response to SP at 10°C was not significantly different
from the response at normal temperature (TN). The responses at 7 and 3°C were similar and


















































Figure 77 The effect of bilateral vagotomy on the bronchomotor response (reduction in
dynamic compliance (Cdyn) and increase in pulmonary resistance (RL)) to substance P (SP)
in normal sheep (n=7). Vagotomy has effectively abolished the response to SP.
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Figure 78. Effect of vagal cooling on the change in peak inspiratory flow (V) caused by
intravenous injection of 50(1g/Kg phenylbiguanide (PBG) in normal sheep (n=7-l 1). At
normal temperature (TN) PBG caused a 57% reduction in V from 0.335 (Pre) to 0.144 1/s,
with a transient subsequent rise in V to 0.35 1/s (Post). Vagal cooling caused a significant
reduction in the change found with PBG at 7 and 3°C (t-test; p<0.01), but not at 10°C.
There was also a temperature-dependent increase in mean basal flow consistent with





























Figure 79. Effect of vagal cooling on the change in tidal volume caused by phenylbiguanide
(PBG). Detail is as for figure 77. At normal temperature PBG caused a reduction of 52% in
tidal volume, vagal cooling significantly reduced the change in tidal volume at 7 and 3°C
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Figure 80. Effect of vagal cooling on the change in transpulmonary pressure (P) caused by
phenylbiguanide (PBG). Detail is as for figure 77. At normal temperature PBG caused a 56%
reduction in transpulmonary pressure. Vagal cooling significandy reduced the change in P at
7 and 3°C (t-test; p<0.05 and 0.01 respectively), but not at 10°C.
TN 10 7 3
Vagal temperature
Figure 81. Effect of vagal cooling on the change in respiratory rate (RR) caused by
phenylbiguanide. Detail as for Figure 77. At normal temperature PBG caused a 33%
reduction in RR. While vagal cooling to 7 and 3°C reduced the change in RR by 12 and 5%
respectvely this was not significandy different from the response at normal temperature or
10°C.
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The effect of PBG (n=l 1) on ventilation, including flow (V), tidal volume (VT),
transpulmonary pressure (P) and respiratory rate (RR), but not on RL and Cdyn, was
assessed (Figure 78, 79, 80 and 81). PBG, at normal temperature, caused a transient
reduction in all respiratory parameters and the onset and reversal of these changes
were rapid. In all sheep the response occurred within 10s of injection into the cephalic
vein, and began with an augmented breath followed by variable periods of apnoea (4-
12s). When normal breathing resumed there was a transient rise in V, VT and P, but
respiratory rate returned to the pre-PBG levels. In no animal did PBG induce
tachypnoea. PBG reduced V, VT and P by 57, 52 and 56% respectively from baseline
at normal temperature. At 10 0 C the response to PBG was broadly similar,while at 7
and 3 0 C the response was significantly reduced (p<0.01). The major difference
betwen 7 and 3 0 C was in the pressure change (-38 vs -25%). Vagotomy had no
further effect on the response to PBG.
7.4. Discussion:
The appearance of augmented breaths after SP injection has been reported previously
in rabbits (Prabhakar et al, 1987). An augmented breath is characterised by a deep
inspiration consequent on an increase in inspiratory motor output to the diaphragm
(van Lunteren et al, 1986) and may occur spontaneously during normal breathing or
be stimulated by respiratory manoeuvres, various chemicals and hypoxia and
hypercapnia (Glogowaska et al, 1972; Davies & Roumy, 1982; Coleridge &
Coleridge, 1986; Berkenbosch et al, 1988; Marshall & Metcalfe, 1989). The precise
mechanism for generation of ABs has not been determined yet, but appears to involve
a variety of vagal and chemoreceptor inputs from the lung (Glogowska et al, 1972).
During normal breathing the AB is activated in response to low lung compliance and
its physiological function is to reverse the fall in compliance and end-expiratory lung
volume associated with quiet breathing (Reynolds & Hilgeson, 1965; Szereda-
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Przestaszewska et al, 1976; Coleridge & Coleridge, 1986). In addition, spontaneous
ABs have been shown to increase the alveolar concentration of active forms of
surfactant (Oyarzun et al, 1991). Even in asthmatic attacks in guinea pigs ABs appear
in response to pulmonary compression caused by ventilation inequalities (Delmore &
Roller, 1977).
This association of ABs with lung compression and deflation strongly suggest that
ABs are generated by activation of pulmonary deflation receptors (rapidly
adapting/irritant receptors) (Sellick & Widdicombe, 1970; Delmore & Roller, 1977)
and there are direct recordings from lung irritant receptors illustrating this association.
Phenylbiguanide, which is reported to stimulate C-fibre endings also elicits ABs, and
as for histamine, is probably also stimulating RARs (Winning & Widdicombe, 1976;
Coleridge & Coleridge, 1986). However, it is possible that stimulation of several
different vagal afferent receptor types, either alone or in combination with enhanced
chemoreceptor activity, may be involved in the generation of ABs (Glogowska et al,
1972; Marshall & Metcalfe, 1989). While the appearance of augmented breaths can
be prevented by bilateral vagotomy (Marshall & Metcalfe, 1988; Szereda-
Przestaszewska et al, 1992), re-appearance of ABs some time after vagotomy has
been demonstrated in the rat and cat (Cherniak et al, 1981; Marshall & Metcalfe,
1988). Post-vagotomy ABs appear only in a small proportion of animals and are
activated primarily by hypoxia and hypercapnia, possibly by affecting central control
of somato-motor output to the respiratory muscles (Szereda-Przestaszewska et al,
1976).
Prabhakar et al (1987) have demonstrated that SP (lOOng/Rg) can elicit ABs in
anaesthetised rabbits after right atrial injection, but not after intra-aortic injection. The
time to appearance of the AB was not consistent with stimulation of central structures
or carotid chemoreceptors, and since the response was abolished by bilateral
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vagotomy, this suggested sensory receptors accessible from the pulmonary circulation
were involved. Furthermore, they demonstrated that SP stimulated activity in both
rapidly adapting and C-fibre receptors suggesting both receptor types might be
involved in the generation of ABs. Any role for carotid bodies in ABs might be in
prolongation of the expiratory time rather than generation of the AB itself (Bowes et
al, 1983).
While ABs occured only in 10 sheep and there was no definite association with
maximal bronchoconstriction, the data suggests SP can stimulate pulmonary afferent
receptors, which may in turn be involved in control of bronchomotor tone. The effects
of vagotomy and vagal cooling on the bronchomotor response to SP tends to support
this finding. However, the effect of SP, and other tachykinins, on bronchomotor tone
in the guinea pig and rat cannot be abolished by vagotomy (Goel & Biggs, 1987; Joos
et al, 1988). It is interesting to note that no ABs occurred in sheep over 12 months of
age (n=9), and whether or not this is associated with the ontogenic change in the
bronchomotor response (Chapter 5) is not known.
The degree of selectivity of vagal cooling in blocking myelinated and unmyelinated
nerve fibres is questionable, as there is undoubtedly a wide temperature sensitivity
range for both type of fibres (Franz & Iggo, 1968). However, at temperatures below
approximately 10^3 the majority of the myelinated fibres cease to conduct while
conduction in the majority of unmyelinated C-fibers, and the unmyelinated efferent
fibres, remains intact (Paintal, 1967; Sant'Ambrogio et al, 1984). The data from sheep
strongly support the hypothesis that the response to SP involves a vagal reflex and on
the basis of the cooling data the primary afferent input appears to be from the C-fibre
afferents. However, as can be seen from Figure 72, cooling to below 10 0 C still
induced changes in respiratory parameters consistent with blockade of additional
myelinated fibres from stretch receptors, and it could be presumed that sufficent
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numbers of these fibres were conducting at 7 0 C to be involved in the reflex response
to SP.
Phenylbiguanide was used in this study, as a known stimulator of C-fibre afferent
receptor activity, to assist in validating the response to vagal cooling. PBG elicits the
Bezold-Jarisch reflex through activation of 5-HT3 receptors and its cardiopulmonary
effects of bradycardia and tachypnoea or apnoea is predominantly vagally-mediated
(Evans et al, 1990). However, a proportion of the response to PBG is not vagally
mediated and possibly involves activation of central 5-HT1A receptors (Bogle &
Ramage, 1989). While PBG has been reported to decrease conductance (reciprocal of
resistance), Cdyn and tidal volume and increase the respiratory rate in rabbits (lOOug
PBG; 1.5-3.0 Kg body weight) (Karczewski & Widdicombe, 1969) its effect on
bronchomotor tone in sheep was not assessed. However, a more recent study failed to
reduce conductance (reciprocal of resistance) with PBG (128ug/kg) although it did
cause a consistent dose-dependent reduction in Cdyn (Armstrong et al, 1990). Cooling
of the vagi to 8-10t significantly reduced the bronchomotor response to PBG and
the changes in breathing pattern, while vagotomy effectively abolished the response
(Karczewski & Widdicombe, 1969). A similar effect was achieved with vagal cooling
and vagotomy in sheep, suggesting the technique was reasonably effective in
differentially blocking unmyelinated nerve fibre activity, but it is not possible to say if
C-fibre ending stimulation, per se, results in bronchoconstriction.
SP and other sensory neuropeptides such as CGRP have been localised in
unmyelinated C-afferent nerve fibres and are generally regarded as the putative
neurotransmitters in these nerves. While endogenous SP is believed to be involved in,
for example, afferent nociceptive neurotransmission, the effect of exogenous SP on
C-fibre activity has only recently been investigated. In several types of rat dorsal horn
preparations SP, NKA and CGRP enhance C-evoked firing in dorsal horn nociceptive
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neurons, but have no effect on A-evoked (myelinated fibres) or on spontaneous
activity (Nussbaumer et al, 1989; Kellstein et al, 1990). These C-evoked responses
can be blocked by the SP antagonists [D-Pro2 ,D-Trp7,9] -SP and spantide, and the
opiates, galanin, somatostatin and gamma-aminobutyric acid (GABA).
More likely than not in the spinal cord, the effect of SP is due to postsynaptic
facilitation of the effects of agents such as L-glutamate rather than presynaptic
modulation of neurotransmitter release from the C-fibres. As yet there is little direct
evidence that exogenously applied SP itself increases intrinsic C-afferent fibre
activity (see review by Maggi & Meli, 1988), but in specialised rabbit retinal ganglion
cells (sensory neurons) SP increases both evoked and spontaneous discharges
(Zalutsky & Miller, 1990) possibly through putative autoreceptors (Spigelman & Puil,
1991). It would also appear that C-fibre stimulation facilitates nociception centrally
and that this involves release of SP (Wiesenfeld-Hallin et al, 1990). Maggi & Meli
(1988) have speculated that a possible target for sensory neuropeptides are the
sensory nerves themselves and there is indirect evidence that tachykinins, including
SP, activate sensory afferents from abdominal visceral organs (Lew & Longhurst,
1985; Maggi et al, 1986, 1987). If this is the case, the putative receptor, at least in the
urinary bladder, would appear to be NK-2 (Maggi et al, 1987). Activation of visceral
sensory afferents by SP and NKA could additionally release neurokinin peptides
centrally according to the mechanism described by Wiesenfeld-Hallin et al (1990) and
affect vagal efferent outflow to the airways. Haxhiu et al (1989) have demonstrated
that SP can act on structures in the ventral medulla to increase cholinergic output
(antagonised by atropine) to the trachealis muscle causing bronchoconstriction. An
indirect mode of action for the tachykinins is further supported by the findings that
the cardiovascular depressor effect of tachykinins involves a vagal reflex (Bezold-
Jarisch reflex), activated indirectly through NK-3 receptors in capsaicin-insensitive
sensory fibres (Couture et al, 1989). Moreover, it has been shown that SP can
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modulate the activity of vagal and sympathetic innervation of the heart and may be
important in controlling reflex cardiac effects associated with activation of cardiac
afferent nerve endings (Smith et al, 1992).
Whether similar mechanisms apply to pulmonary vagal C-fibre afferents,
parasympathetic ganglia and the central ramifications of pulmonary vagal afferents is
not known. However, there is ample evidence that in the airway sensory afferents
function in much the same way as spinal afferents. Neurokinin release from non-
adrenergic non-cholinergic excitatory nerve fibres (NANCis) can be antagonised by
GABA, NPY and selective u-opoid receptor agonists such as [D-Ala2, NMePhe4,
Gly5]ENK (Belvisi et al, 1990; Stretton et al, 1990a; Ray et al, 1991a,b).
Furthermore, in guinea-pig airways exogenously administered SP and histamine
require intact capsaicin-sensitive sensory afferents for at least part of their action
(Biggs & Ladenius, 1990). Since histamine causes reflex bronchoconstriction possibly
by activating rapidly adapting receptors (Karczewski & Widdicombe, 1969;
Armstrong et al, 1990) it is possible that SP operates through this mechanism.
However, at temperatures that block the majority of RAR fibre conduction (10 0 C)
the bronchomotor response to SP in sheep is largely intact, and complete abolition of
the response is only achieved at 3 0 C or after vagotomy. Sodium cromoglycate
effectively blocks activation of C-fibre afferent endings by capsaicin in dog lung
(Dixon et al, 1980) and the bronchoconstrictor effect of inhaled SP and NKA patients
with mild to moderate asthma can be abolished by pre-treatment with the closely-
related agent nedocromil sodium (Crimini et al, 1988a,b; Joos et al, 1989 a,b). The
effect of nedocromil sodium on the bronchomotor response to SP in anaesthetised
sheep was, however, equivocal (Chapter 6).
Determining whether or not SP affects afferent nerve fibre terminals, particularily C-
fibre endings, in the sheep lung to cause reflex bronchoconstriction will require
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recording activity in single afferent nerve fibres, as chemical manipulation of nerve
fibre activity and vagal cooling alone are not sufficent. However, there are difficulties
in interpreting the results of such experiments. The ability of a variety of agents, such
as histamine, to increase vagal afferent input may be due to mechanical distortion of
the area around receptors caused by direct contraction of smooth muscle (Sano et al,
1992). Demonstrating that the bronchomotor response with any agent is abolished by
vagotomy is stronger proof that the mechanism has a reflex origin. The data from this
study in sheep suggests there is a potential role for this reflex mechanism in the
bronchomotor response to exogenously administered SP in the sheep.
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CHAPTER 8. GENERAL DISCUSSION, FURTHER WORK AND CONCLUSIONS
8.1. General Discussion:
This study was developed to investigate the bronchomotor response of the sheep to
exogenously administered neuorkinin peptides. Since the late 1970s there has been
extensive interest in the potential role of these peptides in the pathological responses
to airway diseases, including bronchoconstriction, airway oedema, mucus secretion
and recruitment and activation of inflammatory cells. In general, the most important
neurokinin in the airways of species examined to date seems to be NKA, suggesting
the NK-2 receptor predominates in mammalian airways. With the increased use of the
sheep as an experimental animal for investigating respiratory function, and more
importantly, with the development of various sheep models of human respiratory
conditions (Abraham et al, 1983; Wanner et al, 1979,1988) it was necessary to
determine if the sheep demonstrated a similar sensitivity to the neurokinins as had
been reported for other species.
The data from this study demonstrates that the order of potency for the bronchomotor
response to the neurokinins in sheep is fundamentally different from that reported for
other species, and the sheep response is similar to that recently reported for pigs
(Haxhiu-Poskurica et al, 1992). While the lack of response with NKB roughly agrees
with reports for other species (Advenier et al, 1987; Naline et al, 1989), SP is a
significantly more potent contractor of airway smooth muscle than NKA. The fact
that a similar order of potency is found in asthmatic sheep is of further importance
considering its extensive use as a model of asthma in man.
With the increasing availability of specific neurokinin receptor antagonists the
pharmacology of the neurokinins in the airways has come under closer scrutiny. In the
126
majority of studies the effects of neurokinins have been shown to be direct, involving
interaction with neurokinin receptors on target organs (Petitet et al, 1991). In the
respiratory tract the current consensus is that the neurokinins contract airway smooth
muscle through activation of the NK-1 and NK-2 receptors on the muscle cells
(Barnes 1991). However, there is evidence that an indirect component may be
involved in some species and, in particular, several of the airway effects of the
neurokinins may involve modulation of acetylcholine release from cholinergic nerve
endings (Tanaka & Grunstein, 1984, 1986; Joos et al, 1988; Haxhiu-Poskurica, 1992).
The results of the present study in sheep suggest the bronchomotor response to SP is
largely indirect, and again this is roughly in agreement with reports in the pig and
rabbit. Moreover, in sheep the response appears to involve a vagal reflex, and apart
from demonstration of vagally-mediated SP-induced augmented breaths in rabbits,
neurokinin-induced vagal reflex bronchoconstriction has not been demonstrated
previously in other species.
8.2. Experimental Problems:
There were several problems found with the experimental techniques throughout this
study.
With the anaesthetised preparation the problems with tachyphylaxis to SP and
prolonged anaesthesia have been outlined. These limited the scope of experimental
design that could be undertaken, in particular, the production of repeatable dose-
response curves. In addition the problems with prolonged anaesthesia and
tachyphylaxis prevented the repeated checking of the recovery of the bronchomotor
response after re-warming the vagus nerve to normal body temperature. The
continuous demonstration of the reversibility of the vagal cooling technique would
have satisfactorily validated the results. However, by limiting the number of SP doses
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administered the potential problems with tachyphylaxis and extended anaesthesia
could be reduced.
The main problems that occurred with this project and the most disappointing part of
the study involved the organ bath studies. The difficulty in obtaining consistent
responses of trachealis muscle preparations to
substance P limited the extent to which its pharmacology in the sheep airway could be
assessed. The tissue samples that failed to contract with SP all contracted with
methacholine, and as mentioned in Chapter 6, the substance P used was active in the
live animal preparations. Samples were obtained from a local abattoir and precautions
were taken to sample only sheep under 12 months of age (except when looking at the
response of samples from old sheep), but it is possible that samples were
inadvertently obtained from "older lambs".
A proportion of the immunostaining results were disappointing, as a sub-epithelial
and intra-epithelial SP and CGRP-immunoreactive sensory nerve network was not
demonstrated, and the density of nerves immunoreactive for these peptides was low.
However, the demonstration of a rich supply of NPY-immunoreactive nerve fibres in
smooth muscle was encouraging.
With the sheep asthma model there were no opportunities to assess the effects of
various pharmacological antagonists or the response to intravenously administered
SP. The technique itself was limited in its sensitivity as quite often the changes in RL
and Cdyn could only be measured several minutes after drug administration, due to
breath-holding and oesophageal regurgitation. It is possible that the peak
bronchoconstriction was not measured in some animals because of this delay.
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8.3. Further Work Required:
The mechanism of action of SP in causing bronchoconstriction in sheep requires
additional investigation. The vagal reflex bronchoconstriction found with
exogenously administered SP is a novel mechanism of action for a neurokinin
peptide. Recording the activity of single afferent vagal nerve fibres in the presence of
SP would assist in clarifying this issue. Although demonstrating activation of vagal
afferent nerve fibre receptors by SP would not in itself prove a vagal reflex mode of
action for SP as contraction of smooth muscle itself would increase afferent nerve
fibre activity. However, preliminary studies are currently being planned to
investigate the effects of neuropeptides on vagal afferents, and these studies will
initially assess the effects of neurokinins on the activity of rapidly adapting receptors
in rat lung.
The in vitro assessment of the contractile response to SP on the trachealis muscle
could be investigated further. However, the variability in the response to SP found,
and the tachyphylaxis that occurs, makes investigation in this preparation difficult.
Determining whether or not the effect of SP involves neural or muscular receptors
could be assessed using electrical field stimulation techniques and monitoring the
effects of SP in the presence of neurotoxins, such as tetrodotoxin. As a clearly distinct
neuronal receptor, mediating smooth muscle contraction, has been identified in guinea
pig ileum (Laufer et al, 1985), this may explain the effect of muscarinic antagonists
on the bronchomotor response to SP in sheep.
The ontogenic changes in the bronchomotor response to SP is a further novel finding
and again work is in progress to investigate the ontogenic changes in peptide
expression in the airways of sheep. The demonstration of developmental changes in
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the response to spasmogenic neuropeptides, particularly in close association with the
onset of sexual maturity, may have important implications in our understanding of the
developmental changes seen with bronchoreactive diseases, such as asthma, in man
(Hislop et al, 1990). More recently Berto and co-workers (1993), in a longitudinal
study looking at young adult patients who had had childhood asthma and whose
symptoms had ameliorated with age, found an improvement in their FEV values to a
level similar to that found in the general population. It would be of additional interest
to characterise the expression of neuropeptides in neural and non-neural elements of
allergic asthmatic sheep.
8.4. Conclusions:
From the results of this study it can be concluded that the order of potency for the
bronchomotor effects of neurokinins in sheep is different from that in most other
species, and this order of potency also applies to asthmatic sheep. There is also an
age-related alteration of the response to SP which roughly coincides with the onset of
sexual maturity. Considering the increased use of sheep as experimental animals in
respiratory physiology and pharmacology and the development of several types of
sheep models of human respiratory diseases, these differences between the species
need to be considered.
The mechanism of action of SP appears to be largely indirect, involving a reflex vagal
bronchoconstriction mediated through the NK-1 receptor. There may be an additional
indirect mechanism involving modulation of acetylcholine release from cholinergic
nerve endings or modifying neurotransmission in airway parasympathetic ganglia.
The mechanism of action of SP-induced bronchoconstriction in the sheep shows some
similarity to that reported for the rabbit and pig, but is different from most other
species, including man, where the mechanism is believed to be direct.
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APPENDIX 1. PEPTIDE IMMUNOHISTOCHEMISTRY IN THE SHEEP
AIRWAY AND LUNG
1. Introduction:
The investigation of the pharmacology and physiology of neuropeptides in most organ
systems has tended to be undertaken prior to the demonstration of those particular
peptides in the system being examined. Before beginning the study investigating
neurokinins and their effect on sheep bronchomotor tone, there had been no investigation
of neuropeptides and their localisation within the sheep respiratory system. To date only
a single minor study has looked at the localisation of SP in sheep airways (Mariassy et al,
1990). Therefore, the aim of the present study was to investigate the localisation of
various neuropeptides in the sheep airway and lung and to obtain qualitative information
on the relative importance of these peptides in the innervation of airway smooth muscle.
As there have been numerous reports on the histochemical characteristics of
neuropeptides and their ubiquitous distribution in mammalian airways, it was presumed
they would also be present in the sheep respiratory system.
Since the development of immunohistochemical techniques (Coons & Kaplan; 1950)
numerous neuropeptides have been demonstrated in mammalian airways and lung tissue
(Lundberg et al, 1984; Hislop et al, 1990), and in associated non-respiratory structures
such as the carotid body (Lundberg et al, 1979). These peptides have been localised in
both neuronal and non-neuronal structures in the respiratory system and in the extra¬
pulmonary neuronal networks innervating this system.
In the respiratory tract SP and VIP are found in autonomic nerves of the airway walls
(Polak & Bloom, 1982). SP in particular is found in association with airway smooth
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muscle and the airway epithelium, while VIP is usually found in nerve fibres close to
blood vessels and mucus glands. SP has also been demonstrated in solitary
neuroendocrine epithelial cells and neuroepithelial bodies in human lungs, with the
greatest number of immunoreactive cells in foetuses and infants (Gallego et al, 1990).
Within identified neural structures SP is found predominately in the vagal sensory jugular
and nodose ganglia and in the vagus nerve itself (Hayashi et al, 1983). It tends to be co-
localised with calcitonin gene-related peptide (CGRP) in sensory nerve fibres (Lee et al,
1985; Ju et al, 1987), particularily those located in the sub-epithelial layer in the airway
mucosa (Luts & Sundler, 1989; Dey et al, 1990), and together they are the predominant
sensory neuropeptides in the respiratory system. While CGRP immunoreactive nerve
fibres are found in airway smooth muscle, they also have a close association with small
bloodvessels (Carstairs, 1987).
SP and CGRP are putative neurotransmitters for the afferent innervation of the
respiratory system (Cadieux et al, 1986). The vagus is the main source of SP and CGRP
detected in the lung, but a proportion of the total peptide found originates from dorsal
root (sensory) ganglia sources (Saria et al, 1985; Springall et al, 1987). The main
pulmonary sites for these sensory neuropeptides are in the central larger airways and
associated blood vessels and to a lesser extent in the smaller airways and alveoli (Mak &
Barnes, 1988).
Outside the respiratory system neuropeptides have been demonstrated in other structures
that are involved in the control or modulation of respiration. In the carotid body large
numbers of enkephalin (ENK) immunoreactive cell bodies and nerve fibres are found,
while vasoactive intestinal polypeptide (VIP) and to a lesser extent substance P (SP) are
found only in nerve fibres (Lundberg et al, 1979; Wharton et al, 1980; Smith et al, 1990).
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SP and VIP have also been localised in sensory afferent neurons within sensory ganglia,
dorsal root ganglia and the dorsal spinal cord (Harman & Keen, 1981; Buck et al, 1982).
SP immunoreactive vagal fibres have been traced to the nucleus tractus solitarius, the
dorsal motor nucleus of the vagus and the nucleus ambiguus in the medulla, showing
central SP-peptidergic structures are involved in control of visceral function (Funakoshi
et al, 1989).
An association between SP-containing and catecholamine-containing neurons has also
been demonstrated in the CNS (Pickel, 1979), but whether or not a similar situation exists
in the respiratory system is not known. However, it has proved difficult conclusively to
demonstrate functional sympathetic innervation of the mammalian respiratory. Lastly,
neuropeptide Y (NPY) has been co-localised with nor-adrenaline and has also been found
in post-ganglionic parasympathetic nerves innervating the larynx (Johansson, 1986;
Domeij et al, 1991).
2. Materials and Methods:
2.1. Tissue Fixation:
Tissue was obtained from sheep aged 6 to 12 months at a local abattoir. Material was
removed within 10 minute of slaughter. Sections of trachea, two to three cartilage
segments wide, a 10 mm wide section of the right apical lobe bronchus and three to four
10-20 mm wide sections of the right apical lung lobe were collected and immediately
placed in a solution of saturated (15%) picric acid, formaldehyde (40%) and 0.2M
phosphate buffered saline (PBS) (Zamboni's fixative) which had been kept at 492.
Tissue was kept in fixative for 24 hours, then washed three times, 5 minutes each time, in
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0.1M phosphate buffered saline and stored in 0.1M PBS and 0.05% azide at 4(t until
processed for immunostaining.
2.2. Tissue Sectioning:
The tissue was sectioned into suitable sized blocks and frozen onto corks on cryostat
chucks in isopentane cooled with liquid nitrogen. The tissue was immersed in isopentane
for a maximum of 2 minutes and placed in the cryostat cabinet to allow tissue
temperature to equilibrate with the cabinet temperature (-26^2). lOum thick sections
were cut and placed on gelatin-alum coated glass slides. A sufficent number of slides for
the peptide immunostaining (3-5), negative controls, haematoxylin and eosin staining
were cut for each tissue. The slides were then placed in a mositure chamber box to
prevent the tissue from drying out. Tissue morphology was assessed, at the time of
cryostating, by rapid staining of representative sections with toluene blue. Only sections
of good morphological quality were used for immunostaining.
2.3. Immunostaining:
Several sources of primary antibodies were used. Primary antibody was either recieved as
gifts or purchased from commercial sources and the details are given in Table 1.
Antibodies against antigens for substance P (SP), calcitonin gene-related peptide
(CGRP), vasoactive intestinal polypeptide (VIP) and met-enkephalin (met-ENK) were
assessed. All primary antibodies had been raised in rabbits. The primary antibody was
diluted, according to the manufacturers/suppliers instructions, with 0.1M PBS (neat
antibody) and divided into 5ul aliquots and stored in 1ml Eppindorf tubes at -40^2. Prior
to immunostaining neat primary antibody was diluted to a 1:10 dilution with 0.1M PBS
















































































































































100-X and 10% normal sheep serum, to the working dilution 30 minutes prior to
application to the tissue.
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The slides were pre-incubated in neat normal sheep serum for 30 minutes at room
temperature to help reduce background staining. After washing once with 0.1M PBS,
three to five tissue sections from the trachea, lobar bronchus and peripheral lung was
covered with each of the primary antibodies. The optimal dilution for each antibody was
determined in preliminary experiments (see Table 1). Volumes of between 40 and 60ul
were required to cover the sections. Sections were returned to the moisture chamber
boxes and left to incubate for 20 to 24 hours at room temperature. Except for SP, pre-
adsorption controls were not carried out for all antibodies in sheep tissue. SP antibodies
were incubated at room temperature for 30 minutes with 10, 50 and lOOumol SP before
application to the tissue, and then processed in the normal manner. However, pre-
absorption controls for the primary antibodies had been carried out for SP, CGRP and
VIP in dog skin (Hartland & Corcoran, pers. comm.) and for SP, CGRP, NPY, VIP and
ENK in horse jejunum (Pearson & Woodman, pers. comm.), and demonstrated the
antibodies to be highly specific for their respective antigens. Negative controls included
tissues incubated with antibody diluent, 0.1M PBS and secondary antibody only and the
diluents with secondary antibody.
After incubation the slides were washed three times, for five minutes each time, in 0.1M
PBS. The slides were air- dried and then covered with a secondary anti-rabbit fluorescein
isothiocyanate (FITC)-labelled antibody raised in goats (Capped, NC, USA) diluted to
1:10 with 0.5% Triton 100-X PBS. The secondary antibody was left in contact with the
tissue for 90 minutes and washed off, again three times for five minutes each time in
0.1M PBS. The slides were air-dried and mounted in buffered glycerine and covered with
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glass slides. The slides were examined immediately and photographed if necessary.
Otherwise the slides were stored in cardboard trays at -4093, to preserve FITC
flourescence, until they could be examined.
2.4. Assessment of Immunostaining:
Slides were examined for peptide-like immunoreactivity using an Olympus microscope
(BH2, Olympus Optical Company, UK) fitted with a reflected light fluorescent
attachment (BH2-2RFL) and an IF 490 excitation filter (wavelength 400-490nm) suitable
for FITC studies. Slides were qualitatively assessed for the degree of background staining
and the level of auto-fluorescence. Immunoreactive nerve fibres were photographed with
an automatic exposure photomicrographic system (PM-10AK, Olympus).
Preliminary experiments had shown that fixing in ice-cold Zambonis fixative, pre-
treatment of slides with normal sheep serum and addition of normal sheep serum to the
primary antibody and the surfactant detergent Triton-100X to PBS used to dilute both the
primary and secondary antibodies all improved the quality of tissue fixation and reduced
the amount of background staining.
3. Results:
As it cannot be assumed that the primary antibodies are recognising specific peptide
antigens the term peptide-like immunoreactivity (-Li) is used as convention.
Using the techniques outlined above, the level of background fluorecence was acceptable
and did not interfere with identification of peptide containing structures. However,
tracheal tissue contains large amounts of collagen which autofluoresces under ultra-violet
light and can cause some problems with interpretation (Figures 1, 2 & 4 as examples).
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Nerve fibres imunoreactive for NPY, CGRP, SP and VIP, but not ENK were found in
sheep airways. The major site of immunoreactivity was in the trachea, with, apart from
some VIP-Li in lobar bronchus, no detectable immunoreactive nerves in the smaller
airways or peripheral lung.
In the trachea NPY-Li fibres were the most numerous with a dense inter-connecting
network of fibres in the trachealis smooth muscle (Figure 1). There was also some NPY
fibres around seromucous glands in the submucosa (Figures 2 & 3), but no evidence of
NPY in the airway epithelium or the lamina propria. CGRP-Li was primarily found in
single nerve fibres and nerve bundles in close associated with blood vessels (Figure 4)
and as fine single nerve fibres in adjacent connective tissue (Figure 5). SP-Li fibres were
found in similar location to CGRP fibres but distinct nerve bundles were not identified
(Figure 8 & 9). SP-Li was also found close to glands in the submucosa (Figure 10).
Smooth muscle fibres were sparse for both these sensory neuropeptides, although
occassional distinct single immunoreactive fibres were noted between smooth muscle
bundles (Figures 6, 7) or at the junction between smooth muscle and connective tissue
(Figures 8, 9 & 11). No SP or CGRP-Li was detected in the epithelial layer. VIP-Li was
found only in the smooth muscle layer of one lobar bronchus section and in epithelial
neuroendocrine cells in one tracheal section. Met-ENK-Li was not detected in any of the
sections.
4. Discussion:
Of the neuropeptides studied, the predominant neuropeptide in sheep airway smooth
muscle appears to be NPY. NPY is often co-localised with noradrenaline in airway
smooth muscle (Johansson, 1986; Luts and Sundler, 1989; Soneaet al, 1991a) and
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modulates neurotransmission in NANCex neurons, being important in suppressing nerve-
mediated contraction (Belvisi et al, 1989a; Grundmar et al, 1990; Stretton et al, 1990b).
The demonstration of an intense NPY-Li neural network suggests the sheep airway
smooth muscle may have a functional sympathetic innervation and this needs further
investigation.
Although there were more CGRP then SP-Li nerve fibres, the sparse nature of both in the
airway smooth muscle would suggest a minor role for these peptides in broncho-
constriction. However, airway smooth muscle cells are connected together by gap
junctions and smooth muscle activation does not require direct innervation of individual
muscle cells (Daniel, 1988). A sparse neural network may still be sufficent to cause
marked contraction of smooth muscle bundles. In most species studied CGRP appears to
be the more commonly respresented sensory neuropeptide (Sonea et al, 1991b) and this
appears to also apply to the sheep. In general SP in airways has been found co-localised
with CGRP, but there is an additional population of CGRP neurons that do not contain
SP (Lee et al, 1985; Ju et al, 1987; Luts & Sundler, 1989). The failure to demonstrate
sub-epithelial SP and CGRP containing nerve fibres in the sheep contrasts with other
species. In the horse CGRP-Li fibres, and to a lesser extent SP-Li fibres, form a dense
arborising network close to the basement membrane and fibres penetrate between
epithelial cells to lie close to the airway lumen (Sonea et al, 1991b) and a similar
situation is described in other species such as the ferret (Luts & Sundler, 1989) and cat
(Dey et al, 1991). Morphological changes due to poor fixation of the surface structures
may explain this difference found with sheep. Haematoxylin and eosin staining of
respresentative sections, however, demonstrated normal morphological features and it is
ulikely this would explain the diference. It is possible, but very unlikely, that sensory
afferent nerve fibres in the sheep airway do not terminate close to the airway lumenal
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21. Normal Sheep Serum; Scottish Antibody Production Unit, UK
23. Pentobarbitone Sodium (5-ethyl-5-[l-methylbutyl]-2,4,6-
trioxohexahydropyrimidine sodium); CllHl7N230Na; MW 248.3; RMB Animal Health
Ltd, UK
22. 1 -Phenylbiuanide; (C6H5(=NH)NHC(=NH)NH2; MW 177.21; Aldrich Chemical
Company Ltd, UK
24. Phosphoramidon (N-(a-rhamnopyransosyloxy-hydroxy-phosphinyl)-Leu-Trp);
C23H34N10OP; MW 543.5; Sigma Chemical Company Ltd, UK
25. Picric Acid (2,4,6-trinitrophenol); (N02)3C6H2.0H; MW 229.11; BDH Laboratory
Suplies Ltd, UK
26. Pirenzepine Dihydrochloride (5,ll-dihydro-ll-[(4-methyl-l-piperazinyl)acetyl]-6H-
pyridol[2,3-b][l,4]benzodiazepin-6-onedihydrochloride; C19H21N502.2HC1; MW
442.31; Research Biochemicals Inc, USA
27. Potassium Chloride; KC1; MW 74.55; BDH Laboratory Supplies Ltd, UK
28. Potassium Dihyrogen Orthophosphate; KH2P04; MW 136.09; BDH Laboratory
Supplies Ltd, UK
29. Sodium Azide; NaN3; MW 65.01; BDH Laboratory Supplies Ltd, UK
30. Sodium Chloride; NaCl; MW 58.44; BDH Laboratory Suplies Ltd, UK
31. Sodium Dihydrogen Orthophosphate Dihydrate; NaH2P04.2H20; MW 156.01;
BDH Laboratory Supplies, UK
32. Sodium Hydrogen Carbonate; NaHC03; MW 84.01; BDH Laboratory Supplies
Ltd, UK
33. Spantide; [D-Arg^D-Trp?^, Leu1 ^-Substance P; MW 1497.9; Cambridge
Research Biochemicals Ltd, UK
34. Substance P; Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2; MW 1347.8;
Cambridge Research Biochemicals, UK
35. DL-Thiorphan (DL-3-mercapto-2-benzyl-propanoylglycine) C12H15NO3S; MW
253.3; Sigma Chemical Company Ltd, UK
36. Triton X-100; Bdh Laboratory Supplies Ltd
2. PHOSPHATE BUFFERED SALINES (PBS)
2.1. Agent Dilution PBS
Composition is given in mmol/litre
NaCl, 136; KC1,2.68; Na2HP04.2H20, 6.46; KH2P04,1.46
2.2. PBS for Zambonis Fixative (See Appendix I)
Composition is given in mmol/litre
Na2HP04, 61; NaH2P04.2H20, 32.1
t
Figure 1. A section of the trachea incubated with NPY antiserum showing
numberous nerve fibres (arrows) with prominent varicosities throughout the
smooth muscle layer. There is little immunoreactivity in the underlying
connective tissue layer (x200).
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Figure 2. Section ol the trachea including epithelium (E), sub-mucosa mucous
glands (SG) and smooth muscle (SM), incubated with NPY antiserum. There are
sparse NPY-like immunoreactive nerve fibres close to the mucous glands (small
arrows) and in the smooth muscle layer (large arrow). No immunoreactive nerves
are visible in the epithelial layer and lamina propria (x200).
Figure 3. Enlargement of the submucosal mucus gland (SG) area in figure 2,
showing NPY-like immunoreactive nerve fibre (arrow) (x400).
Figure 4. Section of the trachea showing biood vessels in the connective tissue
layer underlying the trachealis muscle layer incubated with CGRP antiserum.
There are several (small arrows) prominent immunoreactive nerve fibres close to
blood vessels and two adjacent nerve bundles (large arrows) (x200).
Figure 5. Enlargement of part of figure 4. In addition to the prominent CGRP-like
imunoreactive nerve fibres around blood vessels (BV), there are less distinct
fibres in the adjacent connective tissue (CT) (arrows) (x400).
Figure 6. Single prominent CGRP-iike immunoreactive nerve fibre and several
less distinct fibres (arrows), in the trachealis smooth muscle layer. The prominent
nerve fibre is located between muscle layers (x200).
Figure 7. Enlargement of the prominent CGRP-like immunoreactive fibre in
figure 6 demonstrating the distinct varicosities along the fibre length.
Figure 8. A section of the trachea showing smooth muscle (SM) and connective
tissue (CT) incubated with SP antiserum. There are prominent SP-like
immunoreactive nerve fibres in the connective tissue layer (arrows), but no fibres
visible in the smooth muscle layer (x200).
Figure 9. Prominent SP-like immunoreactive nerve fibres in connective tissue
(CT) and close to blood vessels (BY) (x400).
Figure 10. Section of the trachea showing submucosal mucous glands processed
for SP-like immunoreactivity. There is a single faint SP-like immunoreactive
nerve fibre coursing between glands (arrow) (x400).
Figure 11. Section of trachea including smooth muscle (SM) and connective tissue
(CT) incubated with SP antiserum. There are SP-like immunoreactive nerve fibres




Information includes the familar and scientific name of the reagent, it's molecular weight
and manufacturer/supplier.
1. Agar powder (High Gel Strength); BDH Laboratory Supplies Ltd, UK
2. Calcium Chloride; CaCl2; MW 58.44; BDH Laboratory Supplies Ltd UK
3. (+/-)-Chlorpheniramine Maleate; C16H19C1N2.C4H404; MW 390.9 Sigma Chemical
Company Ltd
4. Chrome Alum; Raymond A Lamb, UK
5. CP96,345-1; ({2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1
azabicyclo[2.2.2]octan-3-amine); MW 485.0; Pfizer Inc, USA (gift)
6. Decon 90; Decon Laboratories Ltd, UK
7. Di-sodium Hydrogen Orthophosphate 2-Hydrate; Na2HP04.2H20; MW 177.99;
BDH Laboratory Supplies Ltd, UK
8. Formaldehyde; HCHO; MW 30.03; BDH Laboratory Supplies Ltd
9. Gelatin; BDH Laboratory Supplies
10. D-Glucose; C6H1206; MW 180.16; BDH Laboratory Supplies
II. Heparin Sodium; Leo Laboratories Ltd, UK
12.Hexamethonium Bromide (Hexane-l,6-bis[trimethylammonium bromide];
Cl2H30N2Br2; MW 362.2; Sigma Chemical Company Ltd, UK
13. Isopentane (2-methylbutane); (CH3)2CH.CH2.CH3; MW 72.15; BDH Laboratory
Supplies Ltd, UK
14. L-659874; Ac-Leu-Met-Gln-Trp-Phe-Gly-NH2; MW 822.0; Cambridge Research
Biochemicals, UK
15. Lidocaine Hydrochloride Anhydrous (2-Diethylamino-N-[2,6-
dimethylphenyl]acetamide; lignocaine); C14H22N20.HC1; 270.8; Astra Pharmaceuticals
Ltd, UK
16. Magnesium Sulphate 7-Hydrate; MgS04.7H20; MW 246.47; BDH Laboratory
Supplies Ltd, UK
17. Methacholine Chloride (Acetyl-B-methylcholine chloride); C8H18C1N02; MW
195.7; Sigma Chemical Company Ltd, UK
18. Nedocromil Sodium (Disodium 6,9-dihydro-9-ethyl-4,6-dioxo-10-propyl-4H-
pyrano[3,2-g]quinoline-2,8-dicarboxylate); Cl9Hl5NNa207.1.5H20; MW 442.33;
Fisons PLC, UK (gift)
19. Neurokinin A; His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2; MW 1297.0;
Cambridge Research Biochemicals,UK
20. Neurokinin B; Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2; MW 1210.45;
Cambidge Research Biochemicals, UK
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SUMMARY
The mammalian tachykinin neuropeptides substance P (SP) and neurokinin A (NKA) are
present in the airways of several species and are involved in control of bronchomotor tone. We
investigated the effect of SP and NKA on various respiratory and cardiovascular parameters
in anaesthetized sheep. Dose-dependent decrease in dynamic compliance (Cdyn) and increase in
respiratory resistance (RJ occurred with intravenous administration of SP. The predominant
effect of NKA was on Cdyn with little or no effect on /?,. Consequently SP is a more potent
bronchoconstrictor than NKA in the sheep and affects both central and peripheral airway tone.
The sensitivity to SP and NKA and the order of potency found suggests the NK-1 receptor
predominates in sheep airways. Atropine and the ganglion blocker hexamethonium markedly
reduced the bronchoconstriction caused by SP. SP and NKA were equipotent in causing a
significant reduction in respiratory rate. SP caused a fall in mean blood pressure while NKA
caused mild vasoconstriction. Neither peptide affected heart rate. We concluded that SP is a
more potent bronchoconstrictor than NKA in the sheep and that the mechanism of action is
mainly indirect involving modulation of postganglionic cholinergic nerve endings.
INTRODUCTION
Substance P (SP) and neurokinin A (NKA) are two closely related tachykinin neuropeptides
that have been identified in sensory nerves, particularily C fibre sensory afferents, in the
airways of several mammalian species (Lundberg, Brodin, Hua & Saria, 1984; Frigo,
Barbareschi, Mariscotti, Motta, Felisati, Pignataro & Manghisi, 1989). SP and NKA cause
contraction of airway smooth muscle in vivo (Evans, Dixon, Clarke, Conradson & Barnes,
1988; Shore & Drazen, 1989) and in vitro in a variety of species (Tanaka & Grunstein, 1986;
Advenier, Naline, Drapeau & Regoli, 1987) and it has been suggested that the tachykinin
neuropeptides are involved in airway inflammation and in the pathogenesis of asthma in
man (Barnes, 1986). In addition to causing contraction of airway smooth muscle
they can also activate mast cells and alveolar macrophages (Foreman & Jordan, 1983;
Flartung & Toyka, 1983) and increase vascular permeability and protein leakage in lung
tissue as part of the pulmonary inflammatory response (Hua, Lundberg, Theodorsson-
Norheim & Brodin, 1984; Lundberg et al. 1984).
The bronchoconstrictor mechanism of action of the tachykinin neuropeptides is not
completely understood. SP and NKA can act directly on NK-1 and NK-2 receptors in
airway smooth muscle in guinea-pigs (Gerard, 1987; Kroll, Karlsson, Lundberg & Persson,
1990) and man (Advenier et al. 1987). In rabbits and rats SP-induced bronchoconstriction
is atropine-sensitive, suggesting SP indirectly affects bronchomotor tone by modulating
acetylcholine release from cholinergic nerves in these species (Tanaka & Grunstein, 1986;
Joos, Pauwels & Van Der Straeten, 1988). SP can also cause the release of histamine and
prostaglandins from mast cells and macrophages which could induce contraction of airway
smooth muscle. However, in normal guinea-pig airways histamine is not involved in the
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bronchomotor response to SP (Gerard, 1987; Shore & Drazen, 1989), but endogenous
cyclo-oxygenase-derived metabolites of arachidonic acid mediate the contractile effect of
SP in guinea-pig peripheral airways (Gerard, 1987) and also enhance the response to
repeated SP administration in this species (Shore & Drazen, 1989). The effect of SP on mast
cells and histamine release in sheep is not known.
Recently the sheep has attracted attention as a potential animal model for bronchial
asthma in man (Wanner, Ahmed, Abraham, Phipps & Long, 1988), necessitating a greater
understanding of its respiratory pharmacology and physiology. Abraham, Ahmed, Cortes,
Soler, Farmer, Baugh & Harbeson (1991) have recently reported that inhaled SP and NKA
have little effect on bronchomotor tone in conscious allergic adult sheep, but a response
with SP can be obtained if the sheep are pretreated with the neutral endopeptidase inhibitor
thiorphan. In the present study we have examined the respiratory and cardiovascular effects
of injected SP and NKA in normal sheep and present evidence that SP causes
bronchoconstriction by indirect mechanisms, modulating the activity of cholinergic nerves.
METHODS
Suffolk-cross sheep were obtained from commercial livestock sources. All sheep were female, between
6 and 12 months of age and weighed 3CM-0 kg. The animals were kept in a conventional animal house
for at least 1 week before experiments and fed ad lib. hay and water. Food was withdrawn 24 h before
experiments.
The sheep were anaesthetized with an intravenous injection of pentobarbitone at 25 mg (kg body
weight) '. An in-dwelling catheter was placed in the right cephalic vein and anaesthesia was
maintained with a constant infusion of 0 54% pentobarbitone in 0-15 M-NaCl adjusted to deliver
2 mg kg-1 h 1 of pentobarbitone. The sheep were intubated with a cuffed endotracheal tube and
placed in the prone position with the head supported in a sling. An oesophageal balloon, constructed
from a condom sealed over a length of rigid polyethylene tubing, was positioned in the lower
oesophagus and a similar tube was connected to the opening of the endotracheal tube.
Transpulmonary pressure was measured as the difference between oesophageal and airway pressure
using a differential pressure transducer (UP2, Pioden Controls, Canterbury, Kent). Airflow at the
endotracheal tube opening was measured with a pneumotachograph (F100L, Mercury Electronics,
Glasgow) connected to another differential pressure transducer (UP1, Pioden Controls). Blood
pressure and heart rate were monitored via a femoral artery catheter connected to a pressure
transducer (4-327 I, Transamerica Deval, Pasadena, CA, USA). Signals from all transducers were
amplified and recorded on heat-sensitive paper, and flow signals were integrated to give tidal volume
measurements (MX 19, Devices, Welwyn Garden City, Herts). Respiratory pressure and
pneumotachograph transducers were phase matched to a frequency of 6 Hz.
Inspiratory and expiratory respiratory resistance (Rh; cmHjOf1 s) and dynamic compliance
(Cdyn; mlcmHjCU1) were calculated graphically from pressure, flow and volume measurements
(Frank, Mead & Ferris, 1957). Inspiratory and expiratory values were used to calculate an 'average'
Cdyn and Rh for the entire respiratory cycle. Systolic (S) and diastolic (D) pressure were measured
from which mean blood pressure (MBP) was calculated (MBP = D + (S — D/3)).
Each experiment began with a dose-response curve to intravenous SP (n = 10). In some sheep
(n = 7) this was followed 1 h later with a similar dose-response curve for NKA. With preliminary
studies we found that the airway response to SP and NKA was not affected by the order in which the
two peptides were administered, but as SP is more rapidly metabolized than NKA (Shore & Drazen,
1989) it was felt that SP should be administered prior to NKA. During each dose-response curve at
least 3 min elapsed between peptide doses. Where there was marked bronchoconstriction at higher
dose levels the subsequent dose was not administered until transpulmonary pressure had returned to
baseline levels. Occasionally forced lung inflation was necessary to return transpulmonary pressure
levels to baseline. Cdyn and RL values were measured 20-30 s after peptide administration as this was
when the most pronounced airway changes occurred. Changes in respiratory parameters usually
began to return to baseline levels 40-50 s after peptide administration. Respiratory rate was also
measured during this period. Values of Cdyn, Rh and respiratory rate were compared to those
occurring immediately prior to each dose.
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Fig. 1. Percentage decrease (means i.5.c.M.) in dynamic compliance after intravenous administration of substance
P (□; n = 10) and neurokinin A (♦; n = 7). Significance of difference between SP and NKA, ** P < 0 01.
Mean blood pressure and heart rate (HR) changes were measured for SP (n = 7) and NKA (n = 4)
10 15 s after injection. Values were compared to those at the beginning of each dose response
curve as changes in MBP and IIR, in contrast to respiratory parameters, did not always return to
baseline values between doses.
The effect of atropine (n = 6) and hexamethonium (« = 3) on the response to SP was also
investigated. Sixty minutes were allowed to elapse between the last peptide dose response curve and
cither the atropine or hcxamcthonium studies. A submaximul dose of SP was administered and this was
followed 10 rnin later with an intravenous dose of atropine or hexamcthonium. After a further 10 min
the SP dose was repeated.
Substance P and neurokinin A (Cambridge Research Biochemicals) were dissolved in 0-15 m -NaCl
to a concentration of 10-:i mol ml-1 and stored as 1 ml aliquots in Eppindorp tubes at —40 °C. Prior
to each experiment the peptides were further diluted with 015 m-NaCl to a working concentration of
10-4molml-1 and stored on icc. The peptides were administered intravenously by rapid bolus
injection, in the dose range 10 7—5 x 10° mol (kg body weight)-1. Atropine sulphate and
hexamethonium (Sigma) were dissolved in 015 m-NaCl immediately prior to use and administered
intravenously at 1 and 20 mg (kg body weight)-1 respectively over a period of 1 min.
Data are presented as means (±s.e.m.). The significance of any difference between SP and NKA
and between the peptides and baseline measurements and the effects of atropine and hcxamothonium
were determined using one-way analysis of variance (ANOVA) and Student's paired t test where
appropriate. P < 0 05 was taken as significant.
RESULTS
The bronchoconstrictor effects of intravenous substance P (SP) and neurokinin A (NKA)
were examined in anaesthetized sheep. There was no significant different between baseline
values of Rh and Cdyn prior to SP or NKA administration. SP and NKA caused a dose-
dependent reduction in Cdyn with a maximal change of 79±7% with SP and of 34+10%
with NKA (Fig. 1). While both peptides had a similar effect on Cdyn, SP was more potent
than NKA at all dose levels except 10-7, 3 x 10-7 and 7 x 10-7 mol kg-1 (P < 0-01). In direct
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Fig. 2. Percentage increase (means+ S.E.M.) in respiratory resistance after intravenous administration of substance
P (□; n = 10) and neurokinin A (♦; n = 7). Significance of difference between SP and NKA, * P < 0-05,
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Fig. 3. Percentage decrease (means+ S.E.M.) in respiratory rate after intravenous administration of substance P
(□; n = 10) and neurokinin A (♦ ; n = 7). * P < 0-05, ** P < 0-01.
contrast, SP had a marked effect on Rh, while the effect of NKA on R, was minimal and
only significantly different from baseline at the highest dose of 5 x 10~6 mol kg-1 (Fig. 2).
The difference between the effect of SP and NKA on Rh was statistically significant at
doses of 5 x 10~7 mol kg"1 or greater (P < 0-05).
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Fig. 4. Percentage change (means + s.E.M.) in mean blood pressure after intravenous administration of





Fig. 5. The effect of intravenous pretreatment with atropine (1 mg kg"1) on percentage change (means + s.E.M.)
in dynamic compliance (filled columns) and respiratory resistance (hatched columns) after intravenous
administration of substance P (n = 6). Control and Test represent the SP response before and after atropine,
respectively. Significance of difference between control and test, * P < 0-05, ** P < 0 01.
There was a dose-dependent reduction in respiratory rate with SP and NKA and this was
significantly different from baseline values at doses of 7 x 10"7 mol kg-1 or greater (P <
0-05; Fig. 3). NKA had a more marked effect on respiratory rate, but the difference between
the two neuropeptides was not significant. SP caused a dose-dependent reduction in MBP
while NKA caused a marginal increase (Fig. 4). With both peptides, changes in MBP were
due to changes in the same direction in both systolic and diastolic pressures. The change
in MBP with SP was significantly different from baseline at doses of 10-6 mol (kg body
weight)-1 or greater.





Fig. 6. The effect of intravenous pretreatment with hexamethonium (20 mg kg-1) on percentage change
(mean + s.e.m.) in dynamic compliance (filled columns) and respiratory resistance (hatched columns) after
intravenous administration of substance P (n = 3). Control and Test represent the SP response before and after
hexamethonium, respectively. Significance of any difference, * P < 0-05.
Atropine (n = 6) had no significant effect on basal bronchomotor tone, but reduced the
effect of a submaximal dose of SP (Fig. 5). SP caused a mean fall in Cdyn of 57 ±9% and
an increase in Rh of 321 + 115 %. After atropine pretreatment the changes in Cdyn and R,
were —13 +11 and +15 +18% respectively (P < 0 05). Hexamethonium (n = 3) also
reduced the change in Cdyn and Rh to SP (Fig. 6) from a control value of —71 + —4 to
-43+10% for Cdyn (P < 0-05) and from 425+168 to 44 + 33% for Rh (P < 005).
Hexamethonium also markedly reduce mean blood pressure from 98+ 10 to 67 + 14 mmHg
(P < 0 05).
DISCUSSION
This study demonstrates that SP is a potent bronchoconstrictor agent in the sheep and has
a marked effect on both central (Rh) and peripheral (Cdyn) bronchomotor tone. NKA has
some effect on Cdyn but has little or no effect on Rh. This is an unusual finding, and while
NKA might preferentially constrict the peripheral airways, it is probable that the decrease
in Cdyn with NKA is due to pulmonary vascular congestion and subsequent alveolar
collapse. Our results compare with inhalation studies where SP, in allergic sheep pretreated
with the neutral endopeptidase inhibitor thiorphan, is a more potent bronchoconstrictor
than NKA (Abraham et al. 1991). However, the bronchoconstrictor effect of inhaled SP in
allergic sheep is only modest and is far less than that achieved with bradykinin. The effect
of injected SP and NKA in allergic sheep has not been reported. The bronchoconstrictor
order of potency for SP and NKA in sheep contrasts with that reported for other species.
NKA is more potent than SP in rats (Joos et al. 1988), in guinea-pigs (Hua et al. 1984;
Uchida, Nomura, Ohtsuka, Hasegawa, Goto, Kimura, Sugita & Uchiyama, 1987) and in
isolated airway tissue preparations in man (Advenier et al. 1987; Naline, Devillier,
Drapeau, Toty, Bakdach, Regoli & Advenier, 1989). This suggests that the NK-2 receptor
is the predominant tachykinin receptor in the airways of these species. In both asthmatic
and normal humans inhaled and infused SP (NK-1 receptor agonist) has little or no effect
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on bronchomotor tone (Joos, Pauwels & Van Der Straeten, 1987; Evans et al. 1988), while
NKA is an effective bronchoconstrictor agent in asthma patients (Joos et al. 1987). On the
basis of our results it would appear that the NK-1 receptor predominates in sheep airways.
The recent development of specific tachykinin receptor antagonists for NK-1 and NK-2
receptors will facilitate characterization of this division, but their present use is constrained
by cost. However, as with rabbits and rats, the bronchoconstrictor response to SP in the
sheep was largely inhibited by atropine pretreatment (Tanaka & Grunstein, 1984, 1986;
Joos et al. 1988), suggesting that SP acts indirectly causing bronchoconstriction by
prejunctional modulation of acetylcholine release from vagal cholinergic nerve endings. In
allergic sheep bradykinin-induced bronchoconstriction, which results from stimulation of
C fibre afferent endings, can also be inhibited by atropine. It is possible that several
bronchoactive neuropeptides, including SP, have a similar mechanism of action when
administered exogenously to sheep (Abrahams et al. 1991). In the guinea-pig atropine has
no effect on SP-induced bronchoconstriction (Shore & Drazen, 1989) and SP has a direct
effect on smooth muscle (Gerard, 1987). There is evidence that peptides associated with
non-adrenergic non-cholinergic neurotransmission in airways can act by a combination of
direct and indirect mechanisms. Vasoactive intestinal peptide (VIP) relaxes airway smooth
muscle by inhibiting excitatory neurotransmission prejunctionally and has a direct action
on smooth muscle (Hiroyuki & Ito, 1990). We have also found that SP causes contraction
of isolated sheep trachealis muscle in vitro suggesting an additional direct action for SP
(B. M. Corcoran & A. L. Haigh, unpublished observation).
The cardiovascular effects of SP and NKA could indirectly affect bronchomotor tone
through arterial baroreceptor and chemoreceptor reflexes. Baroreceptor activation results
in reflex inhibition of respiration and bronchodilatation (Grunstein, Derenne & Milic-
Emili, 1975). The marginal pressor response with NKA may have activated this reflex, but
this is unlikely. Chemoreceptor activation by arterial hypoxaemia will cause broncho¬
constriction and this could have augmented the bronchoconstriction caused by SP.
However, we did not monitor blood gases.
The reduction of the bronchoconstrictor response to SP by hexamethonium, although
not as marked as with atropine, contrasts with previous reports in other species.
Hexamethonium enhances the SP-induced bronchoconstriction in the rat (Joos et al. 1988)
and guinea-pig, and in the latter case this is due to inhibition of sympathetic innervation
to the airways (Stewart & Fennessy, 1986). Our results suggest that SP-induced
bronchoconstriction in the sheep involves ganglionic neurotransmission and might be of
reflex origin, involving activation of pulmonary vagal afferent nerves. The marked
vasdodilatation that occurred with hexamethonium was systemic evidence of ganglion
blockade, but we have not assessed the role, if any, of vasodilatation in the SP response.
The significant fall in respiratory rate with SP and NKA has not been reported
previously. The reduction in respiratory rate did not involve a reduction in tidal volume
suggesting the baroreceptor reflex was not activated. Furthermore, the bronchoconstriction
preceded or coincided with the reduction in respiratory rate suggesting pulmonary stretch
receptors or blood gas changes are not involved in the bronchomotor response. In man
slow infusion of SP results in an increase in ventilation and in the ventilatory response to
hypoxia, but with no change in the respiratory rate (Fuller, Maxwell, Dixon, McGregor,
Barnes, Bloom & Barnes, 1987; Maxwell, Fuller, Dixon, Cuss & Barnes, 1990). Intra-atrial
(pulmonary artery) injection of SP in rabbits increases the respiratory rate by activating C
fibre bronchopulmonary afferent nerve endings (Prabhakar, Runold, Yamamoto,
Lagercrantz, Cherniack & Von Euler, 1987). However, Green, Schmidt, Schultz, Roberts,
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Coleridge & Coleridge (1984) demonstrated that stimulation of bronchopulmonary C fibre
afferents by capsaicin, which releases neuropeptides from sensory nerve endings, can also
result in transient apnoea and have suggested co-existence of both depressant and stimulant
divisions of the pulmonary chemoreflex.
The reduction in mean blood pressure (MBP) with intravenous SP compares with
previous reports from other species including man (Hua et al. 1984; Fuller et al. 1987; Joos
et al. 1988) indicating that SP is a potent vasodilator. Joos et al. (1988) have speculated that
the reduction in Cayn with SP may be secondary to vasodilatation as SP can relax
precontracted pulmonary vessels. Flowever, we have shown that NKA causes mild
vasoconstriction and so can reduce Cdyn without causing a reduction in blood pressure.
Neither peptide had a significant or consistent effect on heart rate.
In summary, we have demonstrated that the tachykinin neuropeptides SP and NKA
cause a dose-dependent bronchoconstriction in sheep. SP is a more potent broncho-
constrictor than NKA. While the exact mode and site of action of SP and NKA is not
known the response to SP may be indirect, vagally mediated and possibly of reflex origin
involving prejunctional release of acetylcholine from postganglionic cholinergic nerve
endings.
B. M. Corcoran is a Wellcome Research Leave Fellow. This study was funded by a grant from the
Wellcome Trust. We thank Dr D. S. McQueen for his comments on the manuscript.
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Age-related respiratory responses to substance P in normal sheep
B. M. CORCORAN, Department of Veterinary Clinical Studies, A. L. HAIGH, Department of Preclinical
Veterinary Sciences, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Summerhall,
Edinburgh EH9 1QH
The in vivo effects of substance P (SP) on respiratory
parameters in four different age groups of sheep were
examined. Intravenous SP (10-8 to 5x1th6 mol kg-1
bodyweight) caused a dose-dependent reduction in
dynamic compliance and increase in respiratory resis¬
tance in all four groups. The bronchoconstrictor response
was age-related, with the greatest response occurring
in the youngest age group (four to six months). In the
oldest group (over four years) there was minimal bron-
chomotor response to SP, but a dose-dependent apnoea
was present. These findings indicate that there is an
age-related alteration in the respiratory response to SP
in sheep.
SUBSTANCE P (sp) is an undecapeptide member of
the tachykinin family ofneuropeptides which has been
identified in the respiratory tract of several mammalian
species and is present in sensory nerves including
unmyelinated C-fibre afferents (Lundberg et al 1984).
In most species sp is a potent bronchoconstrictor and
vasodilator (Corcoran and Haigh 1992), but in adult
humans its main effect is on ventilation (Fuller et al
1987, Maxwell et al 1990). sp has also been identified
in the carotid bodies and is believed to be a mediator
in the hypoxic ventilatory response (Scheibner et al
1988). The bronchomotor and ventilatory responses
to sp also appear to change with age (Tanaka and
Grunstein 1990) and the increase in the hypoxia
response coincides with an age-related increase in
carotid body glomus cell sp-like immunoreactivity
(Scheibner et al 1988). The present study was under¬
taken to investigate the bronchomotor response to sp
in normal sheep and also to determine if there is any
alteration in this response with age.
Experiments were carried out on 11 Suffolk-cross
and four Scottish Blackface female sheep obtained
from commercial sources. The sheep weighed 30 to
60 kg and were divided into four age groups: group
1, four to six months (n=3); group 2, six to 12 months
(n=4); group 3, approximately 18 months (n=4); group
4, approximately four years (n=4). Group 4 were
Scottish Blackface as these were the only aged sheep
available from commercial sources.
The sheep were anaesthetised with an intravenous
injection of 30 mg kg-' bodyweight and maintained
with a constant infusion of 0 54 per cent pentobarbi¬
tone in normal saline (0-15 M) and adjusted to deliver
2 mg kg~'h~' of pentobarbitone. The sheep were intu¬
bated with a cuffed endotracheal tube, placed in a
prone position with the head supported by a sling,
and allowed to breath room air. Dynamic compliance
(Cdyn) and respiratory resistance (rl) were calculated
graphically from transpulmonary pressure, respiratory
flow and tidal volume using methods described else¬
where (Corcoran and Haigh 1992). Periodic forced
lung inflation with 100 per cent oxygen was used to
reverse changes in Cdyn associated with anaesthesia.
The presence of hypoxia or hypercapnia, however,
was not assessed.
sp (Cambridge Research Biochemicals) was dis¬
solved in normal saline (0 15 M) and administered by
rapid intravenous injection via the right cephalic vein
in the dose range of 10 8 to 5x10-6 mol kg-' bodyweight.
An injection of 1 ml normal saline was used as control
and had no effect on basal bronchomotor tone. Dose-
response curves for sp were recorded within one hour
of the induction of anaesthesia.
Cdyn, rl and respiratory rate were measured 20 to
30 seconds after sp injection. The presence of apnoea
(seconds) was also noted and included periods of com¬
plete cessation of respiration and, or, concurrent
reduced pressure and flow. Typically apnoea appeared
25 to 30 seconds after injection.
Data are presented as the mean (±sem). The signif¬
icance of any difference between groups was deter¬
mined by one-way analysis of variance. P<0 05 was
taken as significant.
There was a dose-dependent decrease in Cdyn and
increase in rl with sp in all sheep which was most
pronounced in the youngest group (Fig 1). This group
also achieved a greater maximum bronchoconstriction,
as measured by Cdyn and rl, compared to the other
groups. The changes in rl and Cdyn in groups 1 and
2 were significantly different from those in groups 3
and 4, while the increase in rl in group 1 was signif¬
icantly different from those in group 2. Group 3 had
a significantly greater decline in Cdyn than group 4.
There was a dose-dependent reduction in respiratory
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FIG 1: Percentage change in dynamic compliance and respiratory resistance after intravenous injection of substance P (10-8 to 5x10-6
mol kg-1). Group 1, four to six months; group 2, six to 12 months; group 3, 12 to 18 months; group 4, more than four years. Values
are mean ± sem (vertical bars)
rate in all four groups (Fig 2a). Groups l to 4 had
mean (+sem) basal respiratory rates of 30, 35 (±2-9),
36-2 (±8) and 29 (±3-3) breaths per minutes, respec¬
tively. There was no statistically significant difference
in basal respiratory rates in groups. The decrease in
respiratory rate was similar in groups 1 and 4 and
was significantly different from group 3. Three sheep
in group 4 also had marked apnoeic periods (Fig 2b),
which were dose dependent (data not shown).
However, one sheep in group 4 did not develop apnoea,
but had the most pronounced bronchoconstrictor
response of that group. At no time did group 1 sheep
demonstrate apnoea and in groups 2 and 3 apnoeic
periods tended to be minor or inconsistent.
The authors have demonstrated that sp is a potent
bronchoconstrictor in sheep, that the response decreas¬
es with age and that in aged sheep sp causes apnoea.
They have not assessed the affect of breed differences
or possible subclinical respiratory disease in the aged
sheep on the results. sp is recognised as a potent bron¬
choconstrictor in a variety of species including sheep
(Corcoran and Haigh 1992), but has little effect on
bronchomotor tone in adult humans, where the pre¬
dominant effect is to increase ventilation and improve


















(b) Substance P and apnoea
FIG 2: (a) Percentage change in respiratory rate after intravenous injection of substance P (10-8 to 5x10"6 mol kg-1). Age groups as
for Fig 1. Error bars have been omitted for clarity, (b) Apnoea (seconds) after intravenous injection of substance P (5 x 10"6 mol kg-1)
in three different age groups. Values are mean ± sem (vertical bars)
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the hypoxic respiratory drive (Fuller et al 1987). While
the increased ventilatory response in man is due to
direct action of sp on peripheral chemoreceptors in
the carotid bodies (Maxwell et al 1990), sp is also
believed to be involved in the pulmonary chemoreflex
(rapid shallow breathing). Activation of pulmonary
C-fibre afferents by both sp and capsaicin stimulates
rapid shallow breathing (Green et al 1984, Prabhakar
et al 1987). Injection of capsaicin as a bolus into the
right atrium, but not the systemic arterial circulation,
can also result in apnoea (Green et al 1984) and there¬
fore the rapid injection of sp into the systemic venous
circulation may activate this apnoeic part of the pul¬
monary chemoreflex.
The change with age of the sheep response to sp
contrasts with other species and the reaction of sheep
to other spasmogenic agents. Sheep have been shown
to demonstrate an age-related increase in the bron-
chomotor response to both histamine and carbachol
(Saunders et al 1984). In rabbits, the neuromodulatory
action of sp on cholinergic neurotransmission and con¬
trol of bronchomotor tone increases with age (Tanaka
and Grunstein 1990), but this is due to an increase in
intrinsic bronchoreactivity rather than an increase in
the contractile response to sp. In the cat carotid body
there is an age-related increase in sp-like immunore-
activity coinciding with development of the hypoxic
ventilatory response (Scheibner et al 1988), while there
is an age-related decrease in sp-containing nerves in
normal human airways (Hislop et al 1990). The change
in human neuronal expression of peptides and the
sheep bronchomotor response to sp roughly coincides
with the onset of maturity.
The apnoeic response in aged sheep is probably due
to activation of pulmonary C-fibre afferent nerve end¬
ings and while the functional significance of the findings
is not known, these preliminary results suggest a limited
role for sp in the control of bronchomotor tone in
adult sheep.
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